Commonwealth of Australia

Gazette

No. GN 46, Wednesday, 23 November 1994

Published by the Australian Government Publishing Service, Canberra

GOVERNMENT NOTICES

CONTENTS

Variation of closing times	**2978**
General information	**2978**
Legislation	**2982**
Government departments	**2983**

Special Gazette Nos. S 397, S 398, S 399, S 400, S 401, S 402, S 403 and S 404 are herewith

The date of publication of this Gazette is 23 November 1994

THIS GAZETTE IS PRODUCED AS A CAMERA-READY PUBLICATION!

QUALITY OF YOUR PUBLICATION:

To maximise the quality of your notice, all copy must be type-written or typeset using a laser printer. Handwritten material will not be accepted. Other material may be accepted however, AGPS will take no responsibility for the quality of production of these notices.

ADVERTISING RATES:

A charge of $126.50 per/page will apply to the submission of camera-ready copy

CUSTOMER ACCOUNT NUMBERS and CUSTOMER REFERENCE CODES

must be clearly stated on the covering sheet and submitted with your notice. Any notice submitted without this information will not be published.

CLOSING TIMES:

Gazette copy will be accepted by the Gazette Office until 10.00 a.m. on Friday, the week prior to publication.

INQUIRIES:

Please direct all inquiries to (06) 295 4661.

54522 Cat. No. 94 0883 4
ISSN 0819-7105

9 780644 372473

Variation of closing times

CHRISTMAS/NEW YEAR PERIOD

Commonwealth of Australia Gazette

Government Notices

The last *Government Notices Gazette* for 1994 will be published on Wednesday, 21 December 1994 with normal closing times. There will be no issue of this *Gazette* on 28 December 1994 or 4 January 1995.

Departments are requested to note the dates upon which regular issues will not appear and to make every effort to avoid the need for Special Issues during the holiday period by making arrangements for all necessary administrative and executive material to be gazetted by Wednesday, 21 December 1994. Where possible, all other material should be held over until the first regular issue of 1995.

Issue of 11 January 1995

Friday, 6 January 1995 at 10.00 a.m.

CANBERRA DAY EARLY CLOSING

Monday, 20 March 1995 is a public holiday in the Australian Capital Territory thus affecting closing times for the following *Government Notices Gazette.*

Issue of 22 March 1995

Thursday, 16 March 1995 at 10.00 a.m.

General Information

GAZETTE INQUIRIES

Lodgment inquiries	(06) 295 4661
Subscriptions	(06) 295 4485
Accounts (Gazette Notices)	(06) 295 4864
Gazettal Forms	(06) 295 4613

Government Notices issues, published each Wednesday, contain all legislation, proclamations, special information and government departments notices and are sold at $5.95 each or on subscription of $295.00 (50 issues), $150.00 (25 issues).

NOTICES FOR PUBLICATION and related correspondence should be addressed to:

Gazette Officer, Australian Government Publishing Service, GPO Box 4007, Canberra ACT 2601. Telephone (06) 295 4661

or lodged at AGPS, Government Printing Office Building, Wentworth Avenue, Kingston. Notices are accepted for publication in the next available issue, unless otherwise specified.

Except where a standard form is used, all notices for publication must have a covering instruction setting out requirements. A typewritten original or good copies are to be provided, wherever possible double-spaced, with a margin surrounding the typewritten matter. Copy is to be confined to one side of the paper, sheets are to be of uniform size (preferably A4), numbered consecutively and fastened securely together. Dates, proper names and signatures particularly are to be shown clearly.

Copy will be returned unpublished if not submitted in accordance with these requirements.

CLOSING TIMES. Notices for publication should be lodged at AGPS, Government Printing Office Building, unless otherwise specified, by the following times (except at holiday periods for which special advice of earlier closing times will be given).

Government Notices Gazette all copy: Friday at 10.00 a.m. in the week before publication.

RATES for Government Notices are: $126.50 per camera-ready page.

For Special *Gazette* notices the rates are the same as for Government Notices plus $110.00 per page.

For Periodic *Gazette* notices the rates are $20.00 per camera-ready page plus $300.00 per issue plus 15% of total costs.

Late copy may be accepted on payment of a surcharge. For further information contact the Gazette Client Liaison Unit on (06) 295 4661.

SUBSCRIPTIONS are payable in advance and are accepted for a maximum period of one year. All subscriptions are on a firm basis and refunds for cancellations will not be given. Rates include surface postage in Australia and overseas. Other carriage rates are available on application.

AVAILABILITY. The *Gazette* may be purchased by mail from:

Mail Order Sales, Australian Government Publishing Service, GPO Box 84, Canberra ACT 2601

or over the counter from Commonwealth Government Bookshops at:

Adelaide:	Level 3, Myer Centre, Rundle Mall Tel. (08) 213 0144
Brisbane:	City Plaza, cnr Adelaide and George Sts, tel. (07) 229 6822
Canberra:	70 Alinga St, tel. (06) 247 7211
Hobart:	31 Criterion St, tel. (002) 34 1403
Melbourne:	347 Swanston St, tel. (03) 663 3010
Parramatta:	Horwood Pl, tel. (02) 893 8466
Perth:	469 Wellington St, tel. (09) 322 4737
Sydney:	32 York St, tel. (02) 299 6737
Townsville:	277 Flinders Mall, tel. (077) 21 5212

Agents:

Albury:	DAS Regional Office, 512 Swift St, tel. (060) 41 3788
Darwin:	Northern Territory Government Publishing, 13 Smith St, tel. (089) 89 7152

Commonwealth Acts and Statutory Rules, Australian Capital Territory Ordinances and Regulations, and other Commonwealth Government publications may also be purchased at these addresses.

ALL REMITTANCES should be made payable to;

Collector of Public Moneys, Australian Government Publishing Service.

OTHER ISSUES OF THE GAZETTE

Public Service issues contain notices concerning administrative matters, including examinations, vacancies, transfers and promotions within the Australian Public Service and the Services of the Australian Postal Corporation and Defence Force appointments etc. These issues are published weekly at 10.30 am on Thursday, and sold at $8.95 each or on subscription of $395.00 (50 issues), $206.00 (25 issues) or $103.00 (12 issues).

Business issues, published each Tuesday, containing Notices under the Corporations Law, Bankruptcy Act and Private Notices and sold at $4.95 each or on subscription of $220.00 (50 issues), $116.00 (25 issues).

Australian Securities Commission issues contain Notices under the Corporations Law and are published on the first Tuesday of each month and are sold at $14.95 each or on subscription of $132.00 (12 issues).

Special issues include notices which require urgent publication. All costs associated with producing Specials will be borne by the responsible department or authority. A limited number of Special Gazettes will be made available for sale from the Commonwealth Government Bookshop, Canberra, on the day of publication. General distribution of these notices will be by their inclusion in the next published issue of the Government Notices *Gazette* or Business *Gazette* as well as in the next published issue of the series of the Gazette in which the notice would normally have been published.

Tariff concessions issues contain notices of tariff concessions proposed, granted or revoked in accordance with the provisions of Part XVA of the *Customs Act 1901*. These issues are published each Wednesday and are sold at $2.95 or on subscription only at $115.00 for 50 issues including surface postage.

Periodic issues contain lengthy notices of a non-urgent nature, including the following: Australian Public Service conditions of entry and advancement; holders of import licences and tariff quotas; notification by Australian Securities Commission of intention to deregister defunct companies. Issues are made at irregular intervals as required, at individual prices according to size. Advice of availability is given in the Government Notices and Business issues immediately following the day of publication. Periodic issues are not available on subscription, but standing orders are accepted for all selected issues.

Purchasing and Disposals issues of the *Gazette* provide information on Commonwealth purchases and disposals and other matters of general interest to persons buying from or selling to the Commonwealth. These issues are published each Wednesday and sold at $3.95 or on subscription of $220.00 including postage for 50 issues.

Index issues contain references to entries in the Government Notices and the related Special and Periodic issues. Index issues are published quarterly, are available over the counter from Commonwealth Government Bookshops and are supplied without charge to annual subscribers to the Government Notices issues.

Chemicals issues of the *Gazette* provide information on the National Industrial Chemicals Notification and Assessment Scheme (NICNAS). These issues are published monthly and the cost is variable.

National Registration Authority issues of the *Gazette* contain details of the certificates for registration of chemical products issued by the National Registration Authority for Agricultural and Veterinary Chemicals. These issues are published monthly and the cost is variable.

ISSUE OF PERIODIC GAZETTES

The following Periodic issues of the *Gazette* have been published.

Copies may be purchased from Commonwealth Government Bookshops or by mail from the relevant address given on the front page of this *Gazette*.

Gazette number	*Date of Publication*	*Subject*
P1	12.1.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P2	17.1.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permits granted, refused, suspended or revoked for the period 1.9.93 to 30.11.93.
P3	10.2.94	Determination Under Section 66(2) of the *Civil Aviation Act 1988.*
P4	11.2.94	Tariff Quotas—Quota Transactions Processed in the Period 1 July 1993 to 31 December 1993.
P5	25.2.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permits granted, refused, suspended or revoked for the period 1.10.93 to 31.10.93.
P6	8.3.94	*Australian Heritage Commission Act 197.* Notice of intention to enter places in the register of the National Estate. Notice of decision not to enter places and parts of places in the register of the National Estate. Notice of intention to remove places and parts of places from the register of the National Estate.
P7	4.3.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P8	8.3.94	Money or Property Unclaimed by Dissenting Shareholders.
P9	9.3.94	National Food Authority—Amendment No. 19 to the Food Standards Code.
P10	28.3.94	Instruments made under Part VII of the *National Health Act 1953.*
P11	26.4.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P12	5.5.94	*Insurance (Agents and Brokers) Act 1984*
P13	11.5.94	National Food Authority—Amendment No. 20 to the Food Standards Code.
P14	25.5.94	Money or Property Unclaimed by Dissenting Shareholders.
P15	31.5.94	Conditions of Entry and Advancement in the Public Service Commission
P16	2.6.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P17	2.6.94	Commonwealth of Australia *Therapeutic Goods Act 1989*—Cancellations of Listings and Registrations from the Australian Register of Therapeutic Goods.
P18	29.6.94	National Health and Medical Research Council—An Invitation to Make Submissions About Draft Guidelines.
P19	28.6.94	Money or Property Unclaimed by Dissenting Shareholders.
P20	6.7.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P21	27.7.94	Money or Property Unclaimed by Dissenting Shareholders.
P22	27.7.94	National Food Authority—Amendment No. 21 to the Food Standards Code.
P23	29.7.94	Instruments made under Part VII of the *National Health Act 1953.*

Gazette number	*Date of Publication*	*Subject*
P24	5.8.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permits granted, refused, suspended or revoked for the period 1.1.94 to 31.3.94.
P25	5.8.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permissions granted, refused, suspended or revoked for the period 1.4.94 to 30.5.94 and not previously Gazetted and particulars of some permissions granted, refused, suspended or revoked for the following periods: 1.6.94 to 30.6.94; 1.7.94 to 31.7.94.
P26	31.8.94	Australian Customs Service, Tariff Cheese Quotas, Quota Holder Allocations—1 July 1994, Quota Holder Transactions—1 January 1994 to 30 June 1994
P27	5.9.94	General Recurrent Grants to Non-Government, Non-Systemic Schools.
P28	2.9.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
P29	16.9.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permissions granted, refused, suspended or revoked for the period 1.6.94 to 30.6.94 and not previously gazetted and particulars of some permissions granted, refused, suspended, reinstated or revoked for the following period 1.1.94 to 31.1.94 and not previously gazetted and particulars of some permissions granted, refused, suspended, reinstated or revoked for the period 1.8.94 to 31.8.94.
P30	22.9.94	Road Vehicle (National Standards) Determination No. 3 of 1994.
P31	14.10.94	National Food Authority—Amendment No. 22 to the Food Standards Code.
P32	20.10.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permissions granted, refused, suspended or revoked for the period 1.7.94 to 31.7.94 and not previously gazetted and particulars of some permissions granted, refused, suspended, reinstated or revoked for the following period 1.8.94 to 31.8.94.
P33	20.10.94	Road Vehicle (National Standards) Determination No. 2A of 1994.
P34	1.11.94	Notice by the Australian Securities Commission of intention to deregister defunct companies.
*P35	17.11.94	*Great Barrier Reef Marine Park Act 1975*. Particulars of permissions granted, refused, suspended, reinstated or revoked for the period 1.8.94 to 31.8.94 and not previously gazetted and particulars of permissions granted, refused, suspended, reinstated or revoked for the following period 1.7.94 to 31.7.94 and not previously gazetted.

*First time notified

N.N.—9403878

Legislation

Act of Parliament assented to

IT IS HEREBY NOTIFIED for general information that His Excellency the Governor-General, in the name of Her Majesty, assented on 15 November 1994 to the undermentioned Act passed by the Senate and the House of Representatives in Parliament assembled, viz:

No. 136 of 1994 - An Act to amend the *Migration Act 1958*, and for related purposes (*Migration Legislation Amendment Act (No. 4) 1994*).

HARRY EVANS
Clerk of the Senate

9403879

Government Departments

Administrative Services

COMMONWEALTH OF AUSTRALIA

Lands Acquisition Act 1989

DECLARATION

I hereby declare, pursuant to the provisions of section 41 of the *Lands Acquisition Act 1989*, that an easement in the terms set out in Schedule 1 of the Appendix hereto together with the rights set out in Schedule 2 of the said Appendix is acquired by the Pipeline Authority by compulsory process for the following public purpose:

> Construction of pipelines and associated equipment and structures for conveyance of ethane gas and other hydrocarbons from Moomba in South Australia to Botany in New South Wales and maintenance and operation of those pipelines and associated equipment and structures.

Dated this 9th day of NOVEMBER 1994

.....

Minister of State for Administrative Services

DESCRIPTION OF LAND

SEE ATTACHED APPENDIX

APPENDIX

In this Appendix "Authority" means the Pipeline Authority or its subsidiaries. "Petroleum" and "pipeline" have respectively the same meaning as those expressions have in the Pipeline Authority Act 1973 (hereinafter called "the Act").

SCHEDULE 1

An easement in favour of the Authority over the land described in Schedule 3 at all times and from time to time to construct, maintain and operate pipelines or parts thereof under the Act, together with the rights set out in Schedule 2 in, under, on, across, over and through the said land for the purpose of the construction, maintenance and operation of any such pipeline or part thereof and for any purpose incidental thereto.

SCHEDULE 2

The full and free right for the Authority by itself, its servants and agents and any person authorised by it at all times and from time to time:-

(a) to enter, go, return, pass, repass and remain with or without tools, implements, machinery and vehicles;

(b) to clear and remove any obstruction, timber, trees, undergrowth, crops and fences;

(c) to dig, break up and restore the surface;

(d) to make surveys, take levels, sink bores, dig pits and examine the soil;

(e) to lay down pipes together with any associated equipment and structures

(f) to construct, build and place any plant, machinery, equipment and goods;

(g) to take sand, clay, stone, earth, gravel, timber, wood and other materials and things;

(h) to make cuttings and excavations;

(i) to deposit sand, clay, stone, earth, gravel, timber, wood and other materials and things;

(j) to erect workshops, sheds and other buildings;

(k) to make roads;

(l) to manufacture and work materials of any kind;

(m) to demolish, destroy and remove any plant, machinery, equipment, goods, workshop, shed, buildings and road;

(n) to inspect, patrol (including aerial patrol), alter, renew, reconstruct, replace, repair, cleanse, maintain and change the size of any pipeline or part thereof;

(o) to remove any pipeline or part thereof;

(p) to have the right of support of any pipeline or part thereof;

(q) to convey through any such pipeline petroleum belonging to the Authority or to other persons; and

(r) to do all things necessary or convenient to be done in connection with or incidental to the exercise of the aforesaid rights.

SCHEDULE 3

All that piece of land in the Local Government Areas of Wollondilly, Campbelltown, Camden and Liverpool in the State of New South Wales being the land delineated "PIPELINE EASEMENT 6 WIDE, 10 WIDE AND 14 WIDE" in sheets 1 to 15 of a plan lodged for registration at the New South Wales Land Titles Office as Deposited Plan Number 499057 excepting thereout those parts of the easement delineated on the plan described above affecting the following land;

FIRSTLY: Part of Lot 1 in Deposited Plan 570000 in the Local Government Area of Wollondilly Parish of Wilton County of Camden being the land delineated "X PIPELINE EASEMENT 8 WIDE" on sheet 1 of the plan lodged for registration at the New South Wales Land Titles Office as Deposited Plan 499057

SECONDLY: Part of Lot 1 in Deposited Plan 913122 in the Local Government Area of Wollondilly Parish of Appin County of Cumberland being part of the land in Certificate of Title Volume 1101 Folio 23 Folio Identifier 1/913122.

THIRDLY: Part of Book 206 Conv No. 142 in the Local Government Area of Wollondilly Parish of Appin County of Cumberland.

FOURTHLY: Part of Lot 3004 in Deposited Plan 802845 in the Local Government Area of Campbelltown Parish of Menangle County of Cumberland being the land delineated "Y PIPELINE EASEMENT 4 WIDE" on sheet 8 of the plan lodged for registration at the New South Wales Land Titles Office as Deposited Plan 499057

FIFTHLY: Part of Lot 22 in Deposited Plan 499001 in the Local Government Area of Camden Parish of St Peter County of Cumberland being part of the land in Certificate of Title Folio Identifier 22/499001.

SIXTHLY: Part of an un-named road separating Raby Road from part of the common property in the strata scheme based on Strata Plan 37300 within the parcel shown in the title diagram in the Local Government Area of Camden Parish of Minto County of Cumberland being part of the land in Certificate of Title Folio Identifier CP/SP37300

SEVENTHLY: Part of the common property in the strata scheme based on Strata Plan 37300 within the parcel shown in the title diagram in the Local Government Area of Camden Parish of Minto County of Cumberland being the land delineated "Y PIPELINE EASEMENT 4 WIDE" on sheet 13 of the plan lodged for registration at the New South Wales Land Titles Office as Deposited Plan 499057

EIGHTHLY: Part of an un-named road within Lot 3 in Deposited Plan 88405 Certificate of Title Volume 7114 Folio 65 (Folio Identifier Auto Consol 7114-65) in the Local Government Area of Campbelltown Parish of Minto County of Cumberland

9403880

Defence

Department of Defence

DEFENCE (AREAS CONTROL) REGULATIONS - RAAF BASE SCHERGER - COMPENSATION CLAIMS

Amendments to the Defence (Areas Control) Regulations, made under the Defence Act, to enable the continued safety of aircraft operations at RAAF Base Scherger in Queensland, were gazetted on 6 September 1994. The Regulations, Statutory Rules 1994 No.321, provide a clear legal framework for the exercise of necessary safety-related controls. The Regulations limit the height of buildings and other objects in the vicinity of Defence airfields.

The plans set out in this notice identifies land affected by height restrictions imposed by regulations 6 and 7 of the Regulations. Regulation 6 prevents the construction of buildings higher than 45 metres without approval. Regulation 7 prevents the construction of buildings higher than 90 metres without approval. (There is no land affected by Regulation 5).

Any landholder affected by regulations 3 or 4 of the Regulations, which prevent construction either absolutely or above 7.5 metres without approval, will be given specific notice in writing.

Where the value of the land has been diminished by the effect of the Regulations compensation will be paid. Should you have had an interest in land at the time the land became affected by the Regulations and consider that you are entitled to compensation, and application for compensation must be lodged within six(6) months of this notification. Applications must be sent Security Post and addressed to:

Assistant Secretary Estate Management
(Attention: Mr B A Beasley)
Department of Defence
CP4-3-9
Campbell Park Offices
CANBERRA ACT 2600

Applications must be in accordance with subregulation 17(5) of the Regulations.

Subregulation 17(5) provides that an application for compensation for the diminution in the value of the land must set out:

(a) the name and address of the applicant; and

(b) the interest that the applicant claims to have had in that land on the relevant day (6 September 1994, the day on which the land became affected by the Regulations); and

(c) the facts on which the applicant relies to establish that the applicant had that interest on the relevant day; and

(d) the amount claimed by the applicant to be the total amount of compensation payable by the Commonwealth for the diminution in the value of the land; and

(e) the names and addresses of any other persons known to the applicant who had, on that day, an interest in that land and, if known to the applicant, the nature of each of those interests; and

(f) if the applicant does not claim the amount referred to in paragraph (d)-the amount of compensation claimed in respect of the applicant's interest in the land.

A copy of the Regulations may be obtained from the Commonwealth Government Bookshop.

RIGHT PAGE LEFT PAGE TOP TRIM LINE

TOP TRIM LINE RIGHT PAGE LEFT PAGE





PLAN No 1 - RAAF BASE SCHERGER - QLD

LEGEND

STRUCTURES HIGHER THAN 45 m REQUIRE APPROVAL

STRUCTURES HIGHER THAN 90 m REQUIRE APPROVAL

RIGHT PAGE LEFT PAGE BOTTOM TRIM LINE

BOTTOM TRIM LINE RIGHT PAGE LEFT PAGE

RIGHT PAGE LEFT PAGE TOP TRIM LINE

TOP TRIM LINE RIGHT PAGE LEFT PAGE



INDEX TO ADJOINING PLANS



PLAN No 2 - RAAF BASE SCHERGER - QLD

LEGEND

STRUCTURES HIGHER THAN 45 m REQUIRE APPROVAL

STRUCTURES HIGHER THAN 90 m REQUIRE APPROVAL

RIGHT PAGE LEFT PAGE BOTTOM TRIM LINE

BOTTOM TRIM LINE RIGHT PAGE LEFT PAGE

RIGHT PAGE LEFT PAGE TOP TRIM LINE

TOP TRIM LINE RIGHT PAGE LEFT PAGE





PLAN No 3 - RAAF BASE SCHERGER - QLD

LEGEND

STRUCTURES HIGHER THAN 45 m REQUIRE APPROVAL

STRUCTURES HIGHER THAN 90 m REQUIRE APPROVAL

RIGHT PAGE LEFT PAGE BOTTOM TRIM LINE

BOTTOM TRIM LINE PAGE PAGE

RIGHT PAGE LEFT PAGE TOP TRIM LINE

TOP TRIM LINE RIGHT PAGE LEFT PAGE





PLAN No 4 - RAAF BASE SCHERGER - QLD

LEGEND

STRUCTURES HIGHER THAN 45 m REQUIRE APPROVAL

STRUCTURES HIGHER THAN 90 m REQUIRE APPROVAL

9403881

RIGHT PAGE LEFT PAGE BOTTOM TRIM LINE

BOTTOM TRIM LINE RIGHT PAGE LEFT PAGE

COMMONWEALTH OF AUSTRALIA

Defence Force Regulations

DECLARATION OF DEFENCE PRACTICE AREAS

Pursuant to sub-regulation 49(1) of the Defence Regulations, I, Robert Ray, Minister for Defence, hereby revoke the declaration dated 16 July 1987, published in Gazette No. GN16 dated 19 August 1987, and declare the areas of land, sea or air in or adjacent to Australia described in the schedule hereto, in which it is necessary or expedient in the interests of the safety or defence of Australia to carry out Royal Australian Air Force operations and practices of the kind specified in the schedule opposite the description of each area of land, sea or air, to be Defence Practice Areas.

Declared this 17 day of October 1994

ROBERT RAY
Minister for Defence

SCHEDULE
The areas of land, sea or air

Item and map no.	Area	Description of area	Kind of practice
1.	Cartier Island	All that area of land and sea being as to the land Cartier Island and as to the sea part of the Indian Ocean bounded by the circumference of a circle radius 10 kilometres the centre of which is situated on Cartier island by latitude 12°32'S and longitude 123°32'30"E	Air to surface weapons firing
2.	AD/R224 Darwin	Lateral limits: 12°15'S 131°35'E, 11°59'S 132°33'E, 11°38'S 132°27'E, 11°52'S 131°36'E, 11°57'S 131°35'E, 12°15'S 131°35'E. Vertical limits: NOTAM Hours of Activity: NOTAM	Air to air weapons firing
3.	AD/R225 Darwin	Lateral limits: 13°40'S 128°20'E, 14°00'S 129°10'E, 12°30'S 129°50'E, 12°10'S 129°00'E, 13°40'S 128°20'E. Vertical limits: NOTAM Hours of activity: NOTAM	Air to air weapons firing
4.	AD/R228 Darwin	Lateral limits: 12°00'S 130°28'E, thence the minor arc of a circle 35NM radius centred on Darwin Airport to 12°26'30"S 130°17'E, 12°39'30"S 130°17'E, 12°50'30"S 129°24'30"E, thence the minor arc of a circle 90NM radius centred on Darwin Airport to 12°00'S 129°24'30"E. 12°00'S 130°28'E Vertical limits: 0-FL290 Hours of activity: NOTAM	Air to air weapons firing
5.	Devil's Tower	All that area of land and water in Bass Strait, Tasmania enclosed within the circumference of a circle of radius 5500 metres, the centre of which circle is the centre of an island known as Devil's Tower situated at latitude 39°22'36"S and longitude 146°44'30"S.	

6.	Dutson	All that area of land and water being as to the land situated in the parishes of Dulungalong and of Glencoe, County of Buln Buln and in the Parish of Sale, County of Tanjil, all in the State of Victoria bounded by lines commencing at a point distant 405 metres on a bearing of 77°20' from the south-west corner of crown allotment 24, Section "C", Parish of Glencoe, thence bearing 00°24' for a distance of 366 metres, thence bearing 330° 24' for a distance of 7421 metres, thence by an arc of a circle of which the radius is 8518 metres and of which the length is 8920 metres the chord of which arc bears 90° 24' and is 8518 metres in length thence bearing 210° 24', for a distance of 4169 metres, thence by part of a circumference of a circle radius 1829 metres the centre of which circle is a point distant 1875 metres on a bearing of 39° 30' from an angle on the north side of a 40 metres road, which road forms the southern boundary of Crown Allotment 6, Section "C", in the Parish of Glencoe the said angle being formed by the junction of one line for bearing 90° 30' and another line bearing 124° 09'. to a point of the circumference of the said circle distant 736 metres on a bearing of 325° 15' from the said angle in the road described above, thence by a line bearing 210° 24' for a distance of 180 metres, thence by a line bearing 180°24' for a distance of 366 metres, thence by a line bearing 270° 24' for a distance of 1097 metres to the point of commencement.	Air to surface weapons firing and Small arms practice
7.	Evans Head	All that area of sea being part of the South Pacific ocean bounded by a line commencing at a point situated in Latitude 29°18'52"S and longitude 153°23'03"E, thence proceeding north-north-east to a point situated in Latitude 28°56'21"S and longitude 153°32'30'E, thence proceeding east-north-east to a point situated in latitude 28°55'05"S and longitude 153°37'12"E, thence proceeding south to a point situated in Latitude 29°10'53"S and Longitude 153°37'45"E, thence proceeding south-west to a point situated in latitude 29°22'29"S and Longitude 153°25'42"E, thence north-north-east to the point of commencement.	Air to air weapons firing
8.	Evans Head	Firstly- All that area of land in the parish of Evans, County of Richmond in the State of New South Wales, and all that area of sea being part of the South Pacific Ocean which together are bounded by the circumference of a circle of 1850 metres radius the centre of which circle is at a point distant 2347 metres on a bearing of 107°15' from the south-eastern corner of Portion 24 in the parish of Evans. Secondly- All that area of land in the Parishes of Evans and Esk, County of Richmond, in the State of New South Wales, and all that area of sea being part of the South Pacific Ocean which together are bounded by a line commencing at a point distant 838 metres on a bearing of 149°15' from the north eastern corner of water Reserve 1977 notified 14th July 1886 in the said Parish of Esk, thence bearing 124°15' for a distance of 457 metres, thence bearing 94°15' to a point situated in Latitude 29°12'56"S and Longitude 153° 29'49"E, thence to a point situated in Latitude 29°14'46"S and Longitude 153°29'18'E, thence to a point situated in Latitude 29°16'44"S and Longitude 153°27'04"E, to a point situated in Latitude 29°17'10"S, and Longitude 153°25'E, thence bearing 334°15' for a distance of 10 272 metres, thence bearing 304°15' for a distance of 457 metres, thence bearing 34°15' for a distance of 914 metres to the point of commencement.	Air to surface and surface to surface weapons firing
9.	Flat Rock	All that area of land and sea enclosed by the circumference of a circle of radius 4500 metres, the centre of which circle is located on an island known as Flat Rock at Latitude 30°45'10"S and Longitude 115°09'45"E, the land portion being part of 1503 the whole of a camping reserve 10 986 and crown 93 land all in the Melbourne Location, Perth land Office, also the island known as Flat Rock the sea, portion being part of the Indian Ocean adjoining.	Air to surface weapons firing
10.	Halifax Bay	The area of sea and land in Halifax Bay, Queensland bounded by an imaginary line commencing at the intersection of the parallel 19°08'55"S Latitude with the meridian 146°38'32"E longitude, thence generally in a north-western direction to the intersection of the parallel 19°01'28"S Latitude with the meridian 146°27'52"E longitude, thence generally in a north-north-westerly direction to the intersection of the parallel 18°55'43"S latitude with the meridian 146° 23'49"E Longitude, thence generally in a north-easterly direction to the inter-section of parallel 18°54'01"S Latitude with the meridian 146°25'16"E Longitude, thence in a generally easterly direction to the intersection of the parallel 18°53'45"S Latitude with the meridian 146°40'11"E Longitude, thence generally in a south-easterly direction to the intersection of the parallel 18°57'05"S Latitude with the meridian 146°44'30"E Longitude, thence, generally in a southerly direction to the intersection of the parallel 19°05'27"S Latitude with the meridian 146°45'27"E Longitude, and thence generally in a south-westerly direction to the point of commencement.	Air to surface weapon firing

11.	Lake Wellington	All that area of land and water being, as to the land, parts of Crown Allotment 30 of B in the Parish of Dulungalong, County of Buln Buln, and part of Crown Allotment 30 in the Parish of Booran, County of Buln Buln, and, as to the water, part of Lake Wellington in the County of Tanjil, which area is bounded by a line commencing at a point distant 1 308 metres on a bearing of 270°39' (magnetic) from the south-western corner of Crown Allotment 30 in the Parish of Dulungalong, County of Buln Buln, thence on a bearing of 344° (magnetic) for a distance of 6 437 metres, thence on a bearing of 74° (magnetic) for a distance of 9 656 metres, thence on a bearing of 164° (magnetic) for a distance of 6 437 metres, thence on a bearing of 254° (magnetic) for a distance of 9 656 metres to the point of commencement.	Air to surface weapons firing
12.	Lancelin (Land)	All that piece of land in the State of Western Australia, known as Lancelin Training Area, being all that piece of land in the District of Melbourne north of and within the vicinity of the townsite of Lancelin and shown on the Department of Lands and Surveys lithographs 30/80 and 59/80 and National topographic 1:25000 maps 1936-1-SW, 1936-1-SE, 1936-11-NW, 1936-11 -NE, 1936-11-SW and shown diagrammatically in the subtended locality plan and more particularly bounded by lines commencing at the north-west corner of Location 3 909, thence proceeding south along the western boundary of that location and its southern prolongations, the western boundaries of Locations 3910, 3911, 3912, 3913 and their southern prolongation to its intersection with a forth class road at AMG co-ordinates 344000E 6570320N, thence generally westerly along that road to an intersection at AMG co-ordinates 340080E 6572040N, thence generally northerly along that road to its intersection with the southern boundary of Location 3 988 at AMG co-ordinates 338500E 6576970N, thence north-easterly, north, north westerly and west along boundaries of that location to their intersection with the aforementioned forth class road at AMG co-ordinates 336360E 6590580N, thence north-westerly along that road to the south-west corner of location 3379, thence east and northerly along boundaries of that location to its north-east corner, thence east to a point on the western boundary of location 3821, thence south along the western boundary of location 2821 and its southern prolongation to the northern boundaries of location 942, thence west and south along boundaries of location 942, thence west and south along boundaries of location 2392, thence west and south along boundaries of location 2040, thence south along the southern prolongation of the western boundary of location 2046 to the northern boundary of location 3909, thence west along that boundary to the point of commencement.	Air to surface weapons firing
13.	Lancelin (Sea)	An area of sea off the coast of Western Australia bounded by a line commencing at a position at Latitude 30°45'30"S Longitude 115°17'30"E, thence proceeding in a straight line to a position at Latitude 30°55'S Longitude 115°24'E, thence proceeding in a straight line to a position at Latitude 31°07'30"S longitude 115°05'E, thence proceeding in a straight line to a position at latitude 30°54'S longitude 114°56'E, thence proceeding in a straight line to the point of commencement. Vertical limits: 0-FL-500 Hours of activity: NOTAM	Air to surface weapons firing
14.	Learmonth	Lateral limits: 20°36'S 113°05'E, 21°03'S 113°50'E, 22° 27'S 112°52'E, 22°00'S 112°07'E, 20°36'S 113°05'E. Vertical limits 0-FL310 Hours of activity: NOTAM	Air to air weapons firing
15.	Learmonth	All that piece of land in the State of Western Australia containing an area of 18 781 hectares or thereabouts, being Lyndon, Location 97	Air to surface and surface to surface weapons firing
16.	N.N.E Rock	All that area of land and water in Spencer Gulf, South Australia, enclosed within the circumference of a circle of radius 1 150 metres, the centre of which circle is the centre of a rock known as "N.N.E. Rock" in approximate Latitude 35°04'30"S and approximate longitude 136°29'40"E	Air to air and air to surface weapons firing
17.	Orchard Hills	All that area of land in the County of Claremont, New South Wales, enclosed within a circle of radius 1400 metres the centre of which is located at Latitude 33°49'S and longitude 150°43'49"E	Explosives demolition

18.	Pearce	All that area of land situated in the Swan District in the State of Western Australia, bounded by lines commencing at the south-west corner of Crown grant 2231, thence easterly along portion of the southern boundary of Crown Grant 2231 to the north-western corner of Crown Grant 2010, thence southerly and easterly along the western and southern boundaries of Crown Grant 2010 to its south-eastern corner, thence southerly along portion of the western boundary of Crown Grant 2010 and the western boundary of Location 2480, thence easterly along the southern boundary of Location 2480 to its south-eastern corner, thence southerly along portion of western boundary of Crown Grant 1505 and the western boundary of Location 2941, thence easterly along portion of the southern boundary of Location 2941 to the north-west corner of Crown Grant 2766, thence southerly along the western boundary of Crown Grant 2766 to its south-west corner, thence southerly along western boundary of Crown Grant 1810 to a point on the north boundary of Crown Grant 1500, thence westerly by portion of the northern boundary of Crown Grant 1500 to its north-west corner, thence southerly by the western boundary of Crown Grant 1500 to its south-west corner, thence westerly along the north side of a 20 metre road, thence southerly across the 20 metre road to the north-west corner of Location 2844, thence southerly along the western boundary of location 2844 to its south-west corner, thence easterly along portion of the southern boundary of Location 2844 to the north-west corner of Crown Grant 2233, thence southerly along the western boundary of Crown Grant 2233 to its south-west corner, thence easterly along southern boundary of Crown Grant 2233 to the point of intersection of the northern extention of the western boundary of Location 1907, thence southerly along the extention and the western boundary of Location 1907 to the south-west corner of location 1907, thence easterly along portion of southern boundary of location 1907 and the whole of the northern boundary of Location 2210 to the north-west corner of Crown Grant 1924, thence southerly along the western boundary and easterly along the southern boundary of Crown Grant 1924 to its south-east corner and the north-east corner of Location 1941, thence southerly by the eastern boundary of Location 1941, thence easterly by portion of the northern boundary of Location 1953 to the north-west corner of Location 2667, thence southerly by the western boundary of Location 2667 and easterly by part of the southern boundary of Location 2667 to the north-west corner of Crown Grant 2895, thence southerly along the western boundary of Crown Grant 2895 to the northern boundary of Crown Grant 1458, thence westerly along portion of its northern boundary and the southern boundary of Location 2278 to the north-west corner of the Crown Grant 1458, thence southerly along its western boundary to its south-west corner, thence easterly by portion of the southern boundary of Crown Grant 1458 to a point of intersection of the northern extention of the western boundary of Crown Grant 1773, thence southerly along the extention to the north-west corner of Crown Grant 1773, thence southerly by portion of the western boundary of Crown Grant 1773 to a point of intersection of the eastern extention of the northern boundary of Crown Grant 2064, thence westerly along extention to the north-east corner of Location 2064, thence westerly by the northern boundary of location 2064 to its north-west corner, thence southerly along the western boundary of Location 2064 to a point on the northern boundary of Location 2478, thence westerly along portion of the northern boundary of Location 2478 to its north-west corner, thence southerly along the western boundary of Location 2478 and portion of the western boundary of Location 2154 to the northern boundary of Crown Grant 1432, thence westerly along portion of the northern boundary of Crown Grant 1432 to the eastern boundary of Crown Grant 1548, thence northerly by portion of the eastern boundary of Crown Grant 1548 to its north-east corner, thence westerly by portion of the northern boundary of Crown Grant 1548 to the south-east corner of Crown Grant 2890, thence northerly along the eastern boundary of Crown Grant 2890 to its north-east corner, thence westerly along its northern boundary to its north-west corner, thence southerly along the western boundary to its south-west corner, thence westerly along portion of the northern boundary of Crown Grant 1548 to its north-west corner, thence southerly along the western boundary of Crown Grant 1548 and a western boundary of Crown Grant 2289, thence westerly along the north side of a 20 metre road to the south-east corner of Location 2356, thence northerly along the eastern boundary of the location 2356 to its north-east corner, thence westerly along the northern boundary of Location 2356, thence southerly along the western boundary of Location 2356 to its south-west corner thence southerly across a 20 metre road thence easterly along the south side of the 20 metre road to the north-west corner of Crown Grant 6865, thence southerly along the western boundary of Crown Grant 6865 and Crown Grant 1949 to its south-west corner, thence southerly across a 20 metre road to point on the northern boundary of Crown Grant 2284, thence westerly along northern boundary of Crown Grant 2284 to its north-west corner, thence along part of the north-east boundary of location 5607 being part of State Forest Number 65 to a point on the southern boundary of Location 3414, thence westerly along southern boundary of Location 3414 to its south-west corner, thence northerly along portion of the western boundary of Location 3414 to the point of intersection of the eastern extention of the southern boundary of Location 3415, thence westerly across a 20 metre road to the south-east corner of Location 3415, thence westerly along southern boundaries of Locations 3415 and 3416 to the south-west corner of Location 3416, thence westerly along north side of 20 metre road to the south-east corner of Location 1965, thence northerly along the eastern boundaries of Locations 1965, 1964, 1963, 4134 and 5607 to the south-east corner of Location 5608 being part of State forest Number 65, thence north-easterly to the point of commencement.	Air to surface weapons firing and small arms practice

19.	Point Cook	All that area of land and water, as to the land Parts of Crown allotment 23A, 23B and Lot 2 LP85746, lot 2 LP123270 in the Parish of Deutgam, County of Bourke, and as to the water, Part of Port Phillip Bay in the County of Bourke, which area is bounded by a line commencing at a point in RAAF Point Cook, latitude 37°56'25"S, longitude 144°44'37"E, thence by a straight line to a point Latitude 37°56'56"S Longitude 144°44'41"E, thence by a straight line to a point Latitude 37°57'41"S Longitude 144°44'33"E, thence by a straight line to a point latitude 37°57'37"S longitude 144°43'57"E, thence by a straight line to a point latitude 37°56'52"S Longitude 144°44' 04"E, thence by a straight line to a point Latitude 37°56'23"S longitude 144°44'20"E situated in Lot 2 LP123270 Parish of Deutgam, County of Bourke, thence to a point in RAAF Point Cook Latitude 37°56'16"S Longitude 144°44'26"E, thence by a straight line to a point Latitude 37°56'17"S Longitude 144°44'33"E, thence in a straight line to the point of commencement.	Small arms practice
20.	Purga	All that area of land being in the Parish of Ipswich County of Stanley comprising Lot 1 Portion of Lot 205 210, 220, 4, 3, 411 and 2 commencing at a point distant 226.327 metres on a bearing of 74°52'15", the said bearing and distance on the north boundary to 76.05 metres on a bearing of 90°06'50", thence 774.342 metres on 90°06', 1805.77 metres on 90°06' being the prolongation of the north boundary, thence bearing of 180°17'20" for a distance of 1869.121 metres being the prolongation of the east boundary thence bearing of 270°17'20" for a distance of 1086.662 metres, thence bearing of 290°47' for a distance of 113.987 metres, thence bearing of 259°35' for a distance of 114.58 metres, thence bearing of 89°58' for a distance of 428.097 metres, thence bearing of 89°58' for a distance of 779.947 metres, thence bearing of 359°41" for a distance of 460.812 metres and 75.237 metres, thence bearing of 45°00' for a distance of 28.445 metres, thence bearing of 270°23' for a distance of 272.094 metres being the prolongation of the south boundary, thence bearing of 354°12'20" for a distance of 931.156 metres being the prolongation of the east boundary to the point of commencement.	Small arms practice
21.	Pyramid Rock	All that area of land and water in Bass Strait, Tasmania enclosed within the circumference of a circle of radius 5500 metres the centre of which circle is the centre of a rock known as Pyramid Rock situated at Latitude 39°49'15"S and longitude 147°14'45"E.	Air to surface weapons firing
22.	Quail Island	All that area of land and water being as to the land the Islands known as Quail Island, Little Quail Island, Bare Sand Island and the northern tip of Grose Island and as to the water, being part of the Timor Sea adjoining, bounded by the circumference of a circle of radius 5500 metres the centre of which circle is the centre point of Quail Island which point is located at latitude 12°31'19"S and Longitude 130°25'18"E.	Air to Surface weapons firing
23.	Salt Ash	All that area of land situated in the Parishes of Stowell and Sutton, County of Gloucester, in the State of New South Wales, bounded by a line commencing at a point in Crown Reserve in the Parish of Stowell, distant 596 metres on a bearing of 343°43' from a point on the northern boundary of Lot 1 DP578547 in the Parish of Stowell, distant 171 metres on a bearing of 90° from the north-western corner of tho Lot 1 DP578547, thence bearing 73°43' for a distance of 274 metres, thence 343°43' for a distance of 366 metres, thence by a straight Line in a north-north-east direction to the western corner of Portion 114, Parish of Sutton, thence by a straight line in a northerly direction to the north-western corner of Portion 152, Parish of Sutton, thence along the southern side of a road in a north-westerly direction to a point on the northern boundary of Portion 157, Parish of Sutton, thence in a westerly direction along the southern side of the said road and the northern boundary of Portion 157, Parish of Sutton, to the north-western corner of Portion 157, thence by a straight line in a west-south-west direction to the north-western corner of Portion 7, Parish of Sutton, thence south along the western boundary of Portion 7, Parish of Sutton, to the southern bank of Twelve Mile Creek to its intersection with Pipeclay Creek, thence in a westerly direction along the southern bank of Pipeclay Creek to the north-western corner of Portion 78, Parish of Sutton, thence south along the western boundaries of portions 78, 136, 98, Parish of Sutton to the south-western corner of Portion 98, Parish of Sutton, thence easterly along the north side of a road and the southern boundary of Portion 98 to the south-western corner of portion 98, Parish of Sutton, thence by a straight line across the said road in a south-easterly direction to a point in Crown Reserve, Parish of Stowell, thence by a line bearing 163°43' for a distance of 366 metres, thence by a line bearing 73°43' for a distance of 274 metres to the point of commencement.	Air to surface weapons firing
24.	AT/R722 Saumarez Reef	Lateral limits: A circle 5NM radius centred on 21°51'18"S 153°38'47"E. Vertical limits: 0-10000' Hours of activity: HJ	Air to surface weapons firing
25.	Townshend Island	All that area of land situated in the Parish of Townshend, County of Palmerston, in the State of Queensland, and all that area of sea being part of the South Pacific Ocean which together are bounded by a line commencing at a position of latitude 22°25'S and longitude 150°25'E, thence proceeding in a straight line to a position at Latitude 22°25'S and Longitude 150°37'E, thence proceeding in a straight line to a position at Latitude 22°09'S and Longitude 150°37'E, thence proceeding in a straight line to a position at Latitude 22°09'S and Longitude 150°25'E, thence proceeding in a straight line to the point of commencement.	Air to surface weapons firing

26.	R-780 Townsville	Lateral limits: 17°20'S 147°30'E, 19°00'S 147°30'E, 19°00'S 148°25'E, 17°20'S 148°25'E, 17°20'S 147°30'E Vertical limits: NOTAM Hours of activity: NOTAM	Air to air weapons firing
27.	AS/R 585(A) Williamtown	Lateral limits: 33°09'S 152°06'E, thence the minor arc of a circle of 25NM radius centred on Williamtown Aerodrome (32°48'S 151°50'E) to 32°44'30'S 152°19'30'E, 32°36'S 153°24'15"E, thence the minor arc of a circle of 80NM radius centred on Williamtown Aerodrome (32°48'S 151°50'E) to 32°42'30"S 153°25'E 33°20'30"S 152°15'E, 33°09'S 152°06'E. Vertical limits: NOTAM Hours of activity: NOTAM	Air to air and air to surface weapons firing
28.	AS/R 585(B) Williamtown	33°20'30"S 152°15'E, to 32°42'30"S 153°25'E, thence the minor arc of a circle of 80NM radius centred on Williamtown Aerodrome (32°48'S 151°50'E) to 33°03S 153°23'E, 33°17'S 153°11'E, 33°25'S 152°18'40"E, 33°20'30"S 152°15'E Vertical limits: NOTAM Hours of activity: NOTAM	Air to air and air to surface weapons firing

MAP NO. 1


TN
123°32'30" E
OCEAN
10 km Rad.
12°32'00" S
CARTIER ISLAND
INDIAN
KILOMETRES
0 5 10 15 20

MAP NO. 2



MAP NO. 3



MAP NO 4



MAP NO 5


WILSONS PROMONTORY
STRAIT
Rodondo Is.
146° 44' 30" E
Hogan Group
DEVIL'S TOWER
39° 22' 36" S
N
BASS
Curtis Group
KILOMETRES
0 5 10 15 20

MAP NO 6


COUNTY OF TANJIL
LAKE WELLINGTON
N
PARISH OF SALE
LATROBE RIVER
POODY BAY
PARISH OF GLENCOE
PARISH OF
LAKE COLEMAN
DULUNGALONG
COUNTY OF
BULN BULN
KILOMETRES
0 1 2 3 4 5

MAP NO 7


BALLINA
28° 35' 08" S
153° 37' 12" E
28° 56' 21" S
153° 32' 30" E
N
OCEAN
PACIFIC
SOUTH
Richmond River
EVANS HEAD
Evans River
Snapper Point (Evans Head)
29° 10' 53" S
153° 37' 45" E
29° 18' 52" S
153° 23' 03" E
29° 22' 29" S
153° 25' 42" E
Woody Head
Freshwater Creek
ILUKA
YAMBA
KILOMETRES
0
15

MAP NO 8


N
OCEAN
PACIFIC
SOUTH
A
B
29° 12' 56"S
153° 29' 48"E
29° 14' 46"S
153° 29' 18"E
29° 16' 44"S
153° 27' 04"E
29° 17' 10"S
153° 25' 00"E
DGAW - A1
A1

MAP NO 9


1138
93
30° 45' 40" S
FLAT ROCK
115° 09' 45" E
1503
93
N
10986
Camping
Reserve
Track
Track
INDIAN OCEAN
WEDGE ISLAND
KILOMETRES
0 1 2 3 4 5

MAP NO 10


18° 54' 01" S
146° 25' 16" E
18° 33' 48" S
146° 40' 11" E
18° 38' 43" S
146° 23' 49" E
18° 37' 05" S
146° 44' 30" E
ACHERON Is.
Corbette Reefs
CORAL
SEA
HALIFAX
19° 01' 28" S
146° 27' 52" E
RATTLESNAKE Is.
HERALD Is.
19° 05' 27" S
146° 45' 27" E
BAY
MAGNETIC Is.
N
19° 06' 55" S
146° 36' 32" E
TOWNSVILLE
0 5 0 5 10 15 20
KILOMETRES

MAP NO 11


COUNTY OF TANJIL
N
LAKE WELLINGTON
74° 00'
9436
124° 00'
344° 00'
6437
6437
344° 00'
9436
270° 38'
1308
PARISH OF SEACOMBE
PARISH OF BOORAN
COUNTY OF BULN BULN
PARISH OF DULUNGALONG
KILOMETRES
0 1 2 3 4 5

MAP NO 12


3821
3379
3822
3980
WEDGE ISLAND
942
Road
2046
2392
INDIAN
3988
Island
3909
3910
3911
3912
3913
OCEAN
Lancelin
LANCELIN TRAINING AREA
Km. 0 5 10 Km.
1 : 250,000

MAP NO 13


INDIAN
OCEAN
WESTERN
AUSTRALIA
Fremantle
114°
115°
116°
117°
118°
119°
31°
32°
33°

MAP NO 14



MAP NO 15


N
OCEAN
INDIAN
LYNDON LOCATION 97
18 781 ha
SHIRE OF EXMOUTH
394
1248
STATION
3114
996
EXMOUTH
3114
436
NINGALOO
STATION
EXMOUTH
398
501
STATION
3114
623
1 0 1 2 3 4 5 KILOMETRES
SCALE

MAP NO 16


GULF
THISTLE IS.
SPENCER
Waterhouse Pt.
N.N.E. ROCK
WARD ROCK
GAMBIER ISLANDS
THE WEDGE
SOUTHERN
OCEAN
N
KILOMETRES
0
5
10
15
20
25


MAP NO 17
CLAREMONT

MAP NO 18


N
STATE FOREST No. 68
SHANGARA WATER RESERVE
MUCHEA
BRISLAND
RAILWAY
STATE FOREST No. 69
BULLSBROOK
KILOMETRES

MAP NO 19


ROAD
AVIATION
RAAF BASE
POINT COOK
37° 36' 16" S
144° 44' 25" E
37° 36' 17" S
144° 44' 33" E
37° 36' 23" S
144° 44' 20" E
37° 36' 29" S
144° 44' 37" E
37° 36' 52" S
144° 45' 04" E
37° 36' 56" S
144° 44' 41" E
BAY
PHILLIP
37° 37' 37" S
144° 43' 37" E
37° 37' 41" S
144° 44' 33" E
PORT
N
METRES
0
400
800
1200


MAP NO 20
GN
Road
20·117
Wide
Lot 1
Area 428·9 ha
(Acquired 24 July 1981)
AMB Attached Property N° 90
Lot 2 (RP 810599)
Parish of Ipswich
County of Stanley

MAP NO 21


KENT GROUP
N
BASS
STRAIT
147° 14' 45" E
PYRAMID ROCK
39° 49' 15" S
FLINDERS
ISLAND
KILOMETRES
0 5 10 20 30

MAP NO 22


130° 25' 48" E
LITTLE QUAIL IS.
12° 31' 19" S
QUAIL ISLAND
BARE SAND IS.
REEF
REEF
SIMMS
REEF
GROSE IS.
REEF
N
KILOMETRES
0 1 2 3 4 5

MAP NO 23



MAP NO 24


215
153E
R 724
225
R 695
(A,B&C)
R 695 A
R 694
R 02 B
TOWNSVILLE FIR
BRISBANE FIR
R 702 A
R 702 C
R 709
D 705
D 707
D 704
R 693
DRANGOOL
235
245

MAP NO 25


150°23'E
22°09'S
150°37'E
22°09'S
CORAL
SEA
TN
MASTER QUADRANT HUT
LEICESTER ISLAND
TOWNSHEND ISLAND
SHOALWATER BAY
MOUNT WESTALL
TRIANGULAR ISLAND
PENINSULA
RANGE
150°25'E
22°25'S
150°37'E
22°25'S
KILOMETRES
0 2 4 6 8 10


MAP NO 26
145E
149E
14S
15S
16S
17S
144E
147E
205
R 793
COOKTOWN
QLN
R 796
D 786
D 783
D 784 B
D 784 A
R 780
D 776
INGHAM
R 750
EWAN
R 751
D 752
R 757
D 784
ATR
CHARTERS TOWERS
148E
D 761

MAP NO 27



MAP NO. 28



Employment, Education and Training

Commonwealth of Australia

Training Guarantee (Administration) Act 1990

Training Guarantee (Entry-level Training) Guidelines No. 1 of 1994

ELT 1994/1

I, ROSS FREE, Minister for Schools, Vocational Education and Training, make the following Guidelines under subsection 30 (2) of the *Training Guarantee (Administration) Act 1990*.

Dated 10 October 1994.

Minister for Schools, Vocational Education and Training

Citation

1. These Guidelines may be cited as Training Guarantee (Entry-level Training) Guidelines No. 1 of 1994.

Interpretation

2. In these Guidelines:

"the Act" means the *Training Guarantee (Administration) Act 1990*.

Approved entry-level training arrangement: the Australian Vocational Certificate

3. (1) A training arrangement:

(a) that is a project approved by the Minister for the purposes of Part VII of the *Employment, Education and Training Act 1988*; and

(b) that forms part of the educational program known as the "Australian Vocational Certificate"; and

(c) entered into on or after 1 December 1992;

is an approved entry-level training arrangement to which section 29 of the Act applies.

(2) Employees who participate in the training arrangement for the purpose of receiving training in employment related skills are employees to whom the arrangement applies.

(3) The approved amount applicable to the training arrangement is the minimum allowable apprentice or trainee amount.

Approved entry-level training arrangements: the Career Start Traineeship

4. (1) A training arrangement:

(a) that is a project approved by the Minister for the purposes of Part VII of the *Employment, Education and Training Act 1988*; and

(b) that forms part of the educational program known as the "Career Start Traineeship"; and

(c) entered into on or after 1 December 1992;

is an approved entry-level training arrangement to which section 29 of the Act applies.

(2) Employees who participate in the training arrangement for the purpose of receiving training in employment related skills are employees to whom the arrangement applies.

(3) The approved amount applicable to the training arrangement is the minimum allowable apprentice or trainee amount.

Environment, Sport and Territories

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 11

DECLARATION OF AN APPROVED INSTITUTION

I, JAMES G WESTON, the Designated Authority under sub-section 20(1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of sub-section 11(1) of that Act, hereby declare the organisation specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved institution in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this seventeenth day of November 1994

DESIGNATED AUTHORITY

SCHEDULE

Column 1 Item	Column 2 Name and Country of Approved Institution	Column 3 Approved class, or classes, of specimens
1	Nagano Chausuyama Zoological Park 570 Utabi Shinonoi NAGANO CITY NAGANO 380 JAPAN	*Vombatus ursinus*

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 12

DECLARATION OF AN APPROVED ZOOLOGICAL ORGANIZATION

I, JAMES G WESTON, the Designated Authority under sub-section 20(1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of sub-section 12(1) of that Act, hereby declare the zoological organization specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved zoological organization in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this seventeenth daty of November 1994

James G. Weston

DESIGNATED AUTHORITY

SCHEDULE

Column 1 Item	Column 2 Name and Country of Zoo	Column 3 Approved class, or classes, of specimens
1	Nagano Chausuyama Zoological Park 570 Utabi Shinonoi NAGANO CITY NAGANO 380 JAPAN	*Vombatus ursinus*

9403884

NOTICE OF A PERMIT GRANTED UNDER THE ENVIRONMENT PROTECTION (SEA DUMPING) ACT 1981

Pursuant to section 25 of the Environment Protection (Sea Dumping) Act 1981, notice is given that a permit was granted on 8 November 1994 that allows DIVCON Australia Pty Ltd of 4/125 Melville Parade, Como, PERTH WA 6125 to dump further out to sea the already sunken tug "Provincial Trader", which currently lies in 40 metres of water within Twofold Bay, Eden NSW.

Copies of the application and the permit may be obtained from the Commonwealth Environment Protection Agency, 40 Blackall Street BARTON ACT 2600, or may be inspected by appointment at the offices of DIVCON at the above address.

Mark Hyman
Assistant Secretary
Waste Management Branch

8 November 1994

9403885

Human Services and Health

COMMONWEALTH OF AUSTRALIA
NATIONAL HEALTH ACT 1953

DETERMINATION OF PRINCIPLES UNDER SECTION 73BC

I, CARMEN MARY LAWRENCE, Minister for Human Services and Health, in pursuance of subsection 73BC(5B) of the National Health Act 1953 (the Act), hereby revoke the principles determined by me on 31 July 1994 under subsection 73BC(5B) of the Act, and determine with effect from 1 January 1995 the principles set out in the attached Schedule as principles relating to the operation of the Health Benefits Reinsurance Trust Fund established under subsection 73BC(2) of the Act as set out hereunder:

Dated this Nineth day of ~~October~~ November 1994

CARMEN MARY LAWRENCE
Minister for Human Services and Health

SCHEDULE

COMMONWEALTH OF AUSTRALIA
NATIONAL HEALTH ACT 1953 (THE ACT)

DETERMINATION OF PRINCIPLES FOR THE PURPOSES OF SUBSECTION 73BC(5B)

DEBIT OF BENEFITS

1. Organisations may debit to their Reinsurance Accounts benefits paid from a basic private table ('basic benefits') or a supplementary hospital table ('supplementary benefits'), which meet the eligibility criteria set out in a determination made under subsection 73BB(9) of the Act, on the following basis:

(a) where in any 12 months period patient days of a contributor, in respect of any person covered by the contributor membership who is under the age of 65 years, exceed 35 days. Each claim should be examined to determine whether each accommodation day on the claim represents a day in excess of 35 days during the previous 12 months period up to that day; and

(b) for all patient days in respect of any person within a contributor membership who has reached the age of 65 years.

ACCOUNTS AND RECORDS TO BE MAINTAINED

2. Organisations are required under subsection 73BB(1) of the Act to maintain a Reinsurance Account in respect of each fund operated.

3. The specific recording and reporting requirements of the Private Health Insurance Administration Council ('the Council') are notified separately to organisations.

MEMBERSHIP RECORDS

4. Organisations are required to maintain accurate membership records in a format which allows the Council to arrange for the audit of the records and reconcile the membership details on the quarterly returns. It is important that membership records contain dates of birth of contributors and dependants.

5. The Council reserves the right to make adjustments to membership figures or amounts payable into or out of the Trust Fund where it becomes aware of discrepancies in membership figures notified or amounts debited or credited by organisations to their Reinsurance Accounts.

PROCEDURES TO BE FOLLOWED BY ORGANISATIONS

6. Within one month after the end of a quarter, each organisation shall forward a statement or statements, certified as being true and correct by the Public Officer, to the Council setting out the following details:

(a) fund benefits paid during the quarter in respect of Reinsurance Account contributors (including number of patient days). Separate details for basic and supplementary benefits and persons under the age of 65 years and 65 years and over are required;

(b) adjustments to membership, benefits and patient days relating to previous periods; and

(c) details of the number of single and family contributors enrolled in the basic table and supplementary table(s) at the end of the quarter.

7. For the purposes of paragraph 6, in the case of an organisation which is a restricted membership organisation and has members who reside in more than one State, a separate statement setting out the above details in respect of each State where members reside will be necessary. However, where the number of members (expressed as basic table single equivalent units) in any State is less than 5 per cent of the total membership of the organisation, the members in that State(s) shall be included with the State where the majority, or in the absence of a majority, the largest number of members reside.

ACTION BY THE COUNCIL

8. As soon as possible after the end of each settlement period, the Council will determine the net amounts payable by or to each organisation in respect of that period and notify them accordingly.

9. Subject to paragraph 10 below, the amounts will be determined on the following basis:

(a) in respect of the Reinsurance Account deficit for each organisation's health benefits fund(s) ascertain separately the amounts of basic table benefits and supplementary table benefits. Calculate separately amounts which equal 85% of the basic benefits and 85 % of the supplementary benefits;

(b) calculate the average numbers of contributors enrolled in the basic table and in any supplementary table(s) of each organisation's health benefits fund(s). For this purpose, contributors at the family rate will count as two and those at the single rate as one.

(c) determine separate totals of the amounts calculated under (a), in respect of basic and supplementary benefits, for all health benefits funds in each State, respectively;

(d) determine the average amount in respect of basic benefits per contributor to basic tables and the average amount in respect of supplementary benefits per contributor to supplementary tables for each State [i.e. the total amounts calculated in (c) in respect of basic and supplementary benefits divided by the total number of basic and supplementary contributors, repsectively];

(e) determine the amount that would have applied to each health benefits fund if it had had average experience [i.e. the number of basic and supplementary contributors for each health benefits fund under (b) multiplied by the rates in respect of basic and supplementary benefits calculated under (d)];

(f) calculate the difference between (a) and (e) for each health benefits fund. Where (e) exceeds (a) each organisation is to be notified that an amount equal to the difference is payable to the Trust Fund. Where (a) exceeds (e) an amount equal to the difference is payable from the Trust Fund to each organisation;

10. In relation to an organisation which is a restricted membership organisation which submits separate statements as required by paragraph 7, the determination of amounts on the basis outlined in paragraph 9 shall assume for reinsurance purposes that those organisations operate a separate fund in each of the States in respect of which such a statement is submitted.

11. After receiving advice from the Council, organisations will be required, where payments are due to the Trust Fund, to make such payments within 14 days of the date of the advice. Payments not made by the due date may attract a penalty calculated at a daily rate of 15 per cent per annum.

12. Payments from the Trust Fund may, if the Council so determines, be made in two or more instalments. For each instalment, the Council shall distribute the total available moneys between organisations in proportion to the net amounts, if any, due to them.

CLAIMS LAG FOR HOSPITAL BENEFITS

13. The determination of the eligibility of benefits payments for transfer of transactions to Reinsurance Accounts must be based on the dates on which the treatment or services in respect of the contributor and his dependants are provided. However, the situation may arise, because of late claims, that benefits may be paid for a period which, had the claims been received within a reasonable time of the treatment or service, may have resulted in the determination of a different commencing date of the 12 months eligibility period. If this occurs, it may be necessary for the organisation to adjust the amount of benefits debited to its Reinsurance Account.

INCOME FROM INTEREST AND PENALTIES

14. Where the Council receives bank interest from the operation of the reinsurance arrangements or income from penalties imposed because of late payments, such amounts shall be applied by the Council to offset levies imposed on organisations under section 82G(h)(i) of the Act.

INTERPRETATION

"Contributors" for the purposes of the calculations set out in these principles shall be deemed by an organisation to include all such persons who pay contributions or on whose behalf contributions are paid to the organisation, including those persons who may be in arrears in the payment of such contributions for any period, with the exception of the following persons:

(a) where persons normally make individual payments to the organisation, or to any agent of the organisation, those persons may be deemed to be no longer contributors if contribution payments are more than two months in arrears as provided for in Paragraph (g) of the Schedule to the Act, or such longer period as may be provided by the Rules of the organisation; and

(b) where persons normally make contribution payments through a group arrangement, those persons may be deemed to be no longer contributors if:

(i) contribution payments are more than two months in arrears as provided for in Paragraph (g) of the Schedule to the Act, or such longer period as may be provided by the Rules of the organisation, of the contribution payments for the group generally; and

(ii) the contributors have been advised in writing by the organisation that they are no longer contributors.

"State" or "States". For the purposes of paragraphs 7 to 10 inclusive of these principles, the Northern Territory shall be regarded as a State in the following circumstances:

(a) where an organisation (not being a restricted membership organisation) has, under its rules, established a separate fund in the Northern Territory, as permitted by subsection 68(3)(a)(ii) of the Act; or

(b) where a restricted membership organisation has not less that 5% of the total membership of the organisation resident in the Northern Territory and in accordance with paragraph 10 is deemed to operate a separate fund in respect of the Northern Territory.

9403886

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DECLARATION UNDER SUBSECTION 85 (2)

No. PB 17 of 1994

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, pursuant to subsection 85 (2) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into operation on 1 December 1994.

2. Declaration No. PB 10 of 1994 under subsection 85 (2) of the Act made on 15 July 1994 with effect from 1 August 1994, as amended by Declaration No. PB 13 of 1994 under subsection 85 (2) of the Act made on 14 September 1994 with effect from 1 October 1994 and by Declaration No. PB 15 of 1994 under subsection 85 (2) of the Act made on 6 October 1994 with effect from 12 October 1994, is hereby revoked.

3. In this Declaration:

   "the Act" means the *National Health Act 1953*;

   "the Regulations" means the National Health (Pharmaceutical Benefits) Regulations made under the Act;

   "the Managing Director" means the Managing Director of the Health Insurance Commission;

   "approved pharmacist" has the same meaning as in subsection 84 (1) of the Act;

   "ready-prepared pharmaceutical benefit" means a drug or medicinal preparation in respect of which there is in force a determination under subsection 85 (6) of the Act;

   "extemporaneously-prepared pharmaceutical benefit" means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit.

4. Part VII of the Act applies in relation to each of the drugs and medicinal preparations the name of which is specified in Schedule 1.

5. A medicinal preparation composed of a compound that includes a pharmaceutical benefit the name of which is specified in column 1 of Schedule 2, other than a compound the name of which is specified in column 2 of that Schedule opposite the name of that pharmaceutical benefit, is not a medicinal preparation to which Part VII of the Act applies, unless the name of that pharmaceutical benefit is also specified in Schedule 3, in which case the provisions of paragraphs 7 and 8 apply.

6. Part VII of the Act does not apply in relation to a medicinal preparation composed of a compound that includes a ready-prepared pharmaceutical benefit, other than sterilised Water for Injections or a pharmaceutical benefit the name of which is specified in column 1 of Schedule 2.

7. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations the names of which are specified in Schedule 3.

8. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations the names of which are specified in Schedule 3 with the addition of one or more of the substances the names of which are specified in Schedule 4.

9. The substances the names of which are specified in Schedule 4 are additives for the purposes of paragraph 85 (2) (b) of the Act.

10. Part VII of the Act applies in relation to each of the drugs and medicinal preparations the name of which is specified in Schedule 5.

11. The drugs and medicinal preparations the names of which are specified in Schedule 5 are additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act.

12. Where circumstances are specified in column 2 of Schedule 1 or Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of either of those Schedules, that pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.

13. Where circumstances are specified in column 2 of Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of that Schedule, those circumstances are also specified in relation to any medicinal preparation containing that pharmaceutical benefit.

14. Subject to paragraph 17, the following circumstances are specified in relation to each relevant pharmaceutical benefit for the purposes of section 88A of the Act:

(a) Where a class of persons is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;

(b) Where a disease or condition is specified in column 2 of Schedule 1 or Schedule 3—

(i) if subsubparagraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or

(ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;

(c) Where a purpose is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for that purpose;

(d) Where it is specified in column 2 of Schedule 1 or Schedule 3 that compliance with authority procedures set out in subparagraph 14 (d) is required—that an application for the authority of the Managing Director in relation to the supply of the pharmaceutical benefit has been prepared by a medical practitioner:

(i) by writing in ink on a form approved by the Managing Director; or

(ii) by means of a computer on the form referred to in subparagraph (i); or

(iii) by means of a computer on a form approved for the purpose by the Managing Director, in the format approved by the Managing Director; or

(iv) by another method approved in writing by the Managing Director;

and that:

(v) (A) the application has been forwarded to the Managing Director by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist; and

(B) the Managing Director has approved the application; or

(vi) (A) the details of the application have been telephoned to the Managing Director by the medical practitioner; and

(B) the Managing Director has informed the medical practitioner that the application has been approved and has informed the medical practitioner of the telephone approval number that applies to that application; and

(C) the medical practitioner has endorsed on the form the telephone approval number referred to in subsubparagraph (B); and

(D) the medical practitioner has forwarded the Health Insurance Commission copy of the form to reach the Managing Director within 7 days after the date on which the details of the application were telephoned.

15. Where a medical practitioner makes an application under subsubparagraph 14 (d) (iv) and the Managing Director approves the application, the Managing Director shall record the approval on a numbered authority and—

(a) where, in the approval, the Managing Director requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or

(b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person for whom the pharmaceutical benefit is to be supplied.

16. The following circumstances, additional to those specified in paragraph 14, are specified in relation to the pharmaceutical benefits gemfibrozil, pravastatin sodium and simvastatin, each of which is a relevant pharmaceutical benefit for the purposes of section 88A of the Act:

(a) where the circumstance "dyslipidaemia" is specified in column 2 of Schedule 1—that the patient, except in the case of a patient who is at risk of pancreatitis, or who has had coronary artery by-pass surgery or coronary angioplasty, or who has a definite history of coronary heart disease, has had at least 6 months' intensive dietary therapy and qualifies for the supply of the benefit in accordance with the following table:

Category of patient	Lipid level
(1) patients with 1 or more of the following: prior cardiovascular disease; peripheral vascular disease; family history of cardiovascular disease (first degree relative less than 60 years of age); familial hypercholesterolaemia; diabetes mellitus	cholesterol greater than 6.5 mmol per L; or cholesterol greater than 5.5 mmol per L and high density lipoprotein less than 1 mmol per L
(2) patients, not in category (1), with hypertension or high density lipoprotein level less than 1 mmol per L	cholesterol greater than 6.5 mmol per L

4

(3) patients, not in category (1) or (2), being men over 34 but less than 76 years of age or postmenopausal women less than 76 years of age	cholesterol greater than 7.5 mmol per L; or triglyceride greater than 4 mmol per L
(4) patients, not in category (1), (2) or (3)	cholesterol greater than 9 mmol per L; or triglyceride greater than 8 mmol per L

(b) where the circumstance "dyslipidaemia in patients established on therapy with this drug prior to 1 December 1994" is specified in column 2 of Schedule 1—that the patient has been supplied with that pharmaceutical benefit prior to 1 December 1994 and that at that time the patient had:

(i) in respect of the pharmaceutical benefit gemfibrozil, an initial fasting serum triglyceride level in excess of 4 mmol per L following, except in the case of a patient who was at risk of pancreatitis, at least 6 months' intensive dietary therapy; or

(ii) in respect of the pharmaceutical benefit pravastatin sodium or simvastatin, an initial serum cholesterol level of at least:

(A) 6.5 mmol per L in the case of a patient who exhibited at least 1 risk factor; or

(B) 7.5 mmol per L in the case of a patient who did not exhibit a risk factor;

following, except in the case of a patient who had undergone coronary artery by-pass surgery or coronary angioplasty or who had a definite history of coronary heart disease, at least 6 months' intensive dietary therapy, where "risk factor" means:

(C) hypertension; or

(D) history of cardiovascular disease in a first degree relative less than 60 years of age; or

(E) diabetes mellitus; or

(F) cigarette smoking; or

(G) definite history of coronary heart disease.

SCHEDULE 1 — Ready-prepared pharmaceutical benefits

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Acetazolamide	—
Acetazolamide Sodium	—
Acetylcysteine Sodium	Bronchiectasis Cystic fibrosis (mucoviscidosis)
Acyclovir	In respect of the eye ointment: Eye infections caused by herpes simplex virus In respect of the tablet 200 mg: In compliance with authority procedures set out in subparagraph 14 (d): Moderate or severe initial genital herpes In respect of the tablets 200 mg, 90: In compliance with authority procedures set out in subparagraph 14 (d): Moderate or severe recurrent genital herpes, confirmed by appropriate microbiological technique Suppression of genital herpes in severely immunocompromised patients In respect of the tablets 400 mg, 70 and the tablets 800 mg, 35: In compliance with authority procedures set out in subparagraph 14 (d): Treatment of patients with herpes zoster in whom the duration of rash is less than 72 hours
Adrenaline	—
Adrenaline Acid Tartrate	—
Adrenaline Hydrochloride	—
"Albumaid XPXT"	Tyrosinaemia
"Alfaré"	In compliance with authority procedures set out in subparagraph 14 (d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Proven combined intolerance to cows' milk protein and soy protein formulae Severe diarrhoea of greater than 2 weeks duration in infants under the age of 4 months Severe intestinal malabsorption including short bowel syndrome
Allopurinol	—
Alprazolam	In compliance with authority procedures set out in subparagraph 14 (d): Panic disorder or agoraphobia with panic attacks where other treatments have failed or are inappropriate
Alprenolol Hydrochloride	—
Alteplase	In compliance with authority procedures set out in subparagraph 14 (d): Treatment, in a hospital, of acute myocardial infarction within 6 hours of onset of attack where the patient has received parenteral streptokinase within the preceding 12 months
Aluminium Hydroxide, Dried	—
Aluminium Hydroxide, Dried with Light Kaolin or Light Kaolin (Natural)	—
Aluminium Hydroxide, Dried with Magnesium Hydroxide	—
Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine	—
Aluminium Hydroxide, Dried with Magnesium Trisilicate and Magnesium Hydroxide	—
Amantadine Hydrochloride	The treatment of Parkinson's disease caused otherwise than by treatment with a drug
Amiloride Hydrochloride	—
Aminacrine Hydrochloride	—
Aminoglutethimide	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
"Aminogran Food Supplement"	Phenylketonuria
"Aminogran Mineral Mixture"	Metabolic disorders
Aminophylline	—
Amiodarone Hydrochloride	For the continuing treatment of severe refractory cardiac arrhythmias where treatment with amiodarone hydrochloride was initiated in a hospital (in-patient or out-patient)
Amitriptyline Hydrochloride	—
Amlodipine Besylate	—
Ammonium Chloride	—
Amoxycillin Trihydrate	—
Amoxycillin Trihydrate with Potassium Clavulanate	Infections where resistance to amoxycillin is suspected or proven
Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.	Infections where resistance to amoxycillin is suspected or proven
Amoxycillin Trihydrate with Purified Water B.P.	—
Amphotericin	—
Ampicillin Sodium	—
Ampicillin Trihydrate	—
Antazoline Phosphate with Naphazoline Hydrochloride	—
Antazoline Sulfate with Naphazoline Nitrate	—
Aspirin	—
Atenolol	—
Atropine Sulfate	—
Auranofin	—
Aurothioglucose	—
Azathioprine	—
Baclofen	—
"BCG Immunotherapeutic" (Bacillus Calmette-Guérin/ Connaught strain)	Treatment of carcinoma in situ of the urinary bladder
"BCG-Tice" (Bacillus Calmette-Guérin/ Tice strain)	Primary and relapsing superficial urothelial carcinoma of the bladder
Beclomethasone Dipropionate	In respect of the aqueous nasal spray (pump pack) 50 micrograms per dose, 200 doses, the aqueous nasal spray refill 50 micrograms per dose, 200 doses and the aqueous nasal spray 50 micrograms per dose, 400 doses set containing 1 pump pack, 200 doses and 1 refill, 200 doses: In compliance with authority procedures set out in subparagraph 14 (d): Severe intractable rhinitis In respect of the other forms: —
Bendrofluazide	—
Benzathine Penicillin	—
Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium	—
Benzhexol Hydrochloride	—
Benztropine Mesylate	—
Benzydamine Hydrochloride	Treatment of radiation induced mucositis
Benzyl Benzoate	—
Benzylpenicillin Sodium	—
Betamethasone	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Betamethasone Acetate with Betamethasone Sodium Phosphate	In respect of a prescription written by a medical practitioner: Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Uveitis In respect of a prescription written by a participating dental practitioner: For local intra-articular or peri-articular infiltration Keloid Lichen planus hypertrophic
Betamethasone Dipropionate	—
Betamethasone Valerate	—
Betaxolol Hydrochloride	—
Bethanechol Chloride	—
Biperiden Hydrochloride	—
Bisacodyl	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function Patients who are receiving long-term nursing care in hospitals or nursing homes Patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved Patients receiving palliative care Terminal malignant neoplasia Anorectal congenital abnormalities Megacolon
Bismuth Subcitrate	—
Bleomycin Sulfate	Germ cell neoplasms Lymphoma
Bromocriptine Mesylate	In respect of the capsules: In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution In respect of the tablet: Urgent suppression of physiological lactation In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Budesonide	In respect of the aqueous nasal spray: In compliance with authority procedures set out in subparagraph 14 (d): Severe intractable rhinitis In respect of the nebuliser suspensions: In compliance with authority procedures set out in subparagraph 14 (d): Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy In respect of the other forms: —
Bumetanide	—
Busulfan	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Calcitonin (Human)—Synthetic	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone, or hypercalcaemia, in patients unable to tolerate both pork and salmon calcitonin or who are resistant to treatment with either pork or salmon calcitonin
Calcitonin (Pork)	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia
Calcitriol	In compliance with authority procedures set out in subparagraph 14 (d): Established post-menopausal osteoporosis in patients with fracture due to minimal trauma Hypocalcaemia due to renal disease Hypoparathyroidism Hypophosphataemic rickets Vitamin D-resistant rickets
Calcium Carbonate	Hyperphosphataemia in chronic renal failure Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Carbonate with Calcium Lactate-Gluconate	Hyperphosphataemia in chronic renal failure Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Folinate	Antidote to folic acid antagonists
Captopril	Cardiac failure Hypertension
Carbachol	—
Carbamazepine	—
Carbimazole	—
Carboplatin	—
Carmellose Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Severe dry eye syndrome where less costly alternative preparations are inappropriate
Cefaclor Monohydrate	—
Cefaclor Monohydrate with Purified Water B.P.	—
Cefotaxime Sodium	In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that cefotaxime sodium is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that cefotaxime sodium is an appropriate therapeutic agent
Cefotetan Disodium	In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that cefotetan disodium is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that cefotetan disodium is an appropriate therapeutic agent
Ceftriaxone Sodium	In respect of the injection equivalent to 250 mg ceftriaxone, vial (with required solvent): In respect of a prescription written by a medical practitioner: Gonorrhoea Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent In respect of the other injections: In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent
Cephalexin	—
Cephalexin with Purified Water B.P.	—
Cephalothin Sodium	—
Cephazolin Sodium	In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that cephazolin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that cephazolin sodium is an appropriate therapeutic agent
Charcoal, Activated	Ileostomy or colostomy conditions
Chlorambucil	—
Chloramphenicol	In respect of the capsule: Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic In respect of the ear drops, the eye drops and the eye ointment: —
Chloramphenicol Sodium Succinate	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol with Polymyxin B Sulfate	—
Chlorhexidine Gluconate	—
Chloroquine Phosphate	—
Chlorothiazide	—
Chlorpromazine Hydrochloride	—
Chlorpropamide	—
Chlorthalidone	—
Cholestyramine	—
Choline Theophyllinate	—
Chorionic Gonadotrophin	In respect of the injection set containing 1 ampoule powder for injection 5,000 units and 1 ampoule solvent 1 mL: For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	In respect of the other injection sets: For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism For the treatment of infertility in males associated with isolated luteinising hormone deficiency For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation For the treatment, for a period not exceeding 6 months, of males over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty
Cimetidine	Initial and maintenance treatment of peptic ulcer Reflux oesophagitis Scleroderma oesophagus Zollinger-Ellison syndrome
Cimetidine Hydrochloride	Initial and maintenance treatment of peptic ulcer Reflux oesophagitis Scleroderma oesophagus Zollinger-Ellison syndrome
Ciprofloxacin Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Serious infections for which no other antimicrobial agent is appropriate
Cisapride Monohydrate	Gastroparesis Reflux oesophagitis
Cisplatin	—
Cladribine	In compliance with authority procedures set out in subparagraph 14 (d): Hairy cell leukaemia
Clindamycin Hydrochloride	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clioquinol	—
Clofibrate	Hypertriglyceridaemia in patients with a triglyceride level greater than 8.5 mmol per L in whom the response to intensive dietary therapy and to other lipid-lowering drugs is inadequate
Clomiphene Citrate	Anovulatory infertility Patients undergoing in-vitro fertilisation
Clomipramine Hydrochloride	Cataplexy associated with narcolepsy Obsessive compulsive disorders Phobic disorders in adults
Clonazepam	Epilepsy
Clonidine Hydrochloride	—
Clotrimazole	—
Cloxacillin Sodium	—
Codeine Phosphate	—
Codeine Phosphate with Aspirin	—
Codeine Phosphate with Paracetamol	—
Colchicine	—
Colestipol Hydrochloride	—
Colistin Sulfomethate Sodium	—
Copper Sulfate	—
Cortisone Acetate	—
Cyclophosphamide	—
Cyproheptadine Hydrochloride	Prevention of migraine

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Cyproterone Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Idiopathic precocious puberty Advanced carcinoma of the prostate Moderate to severe androgenisation, of which acne alone is not a sufficient indication, in non-pregnant women Reduction of drive in sexual deviations of males
Cytarabine	—
Dalteparin Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Major hip surgery
Danazol	In compliance with authority procedures set out in subparagraph 14 (d): Endometriosis, proven by visual means Hereditary angio-oedema Treatment, for up to 6 months, of intractable primary menorrhagia Treatment, for up to 6 months, of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments
Dantrolene Sodium	Treatment of chronic spasticity
"De-Lact Infant"	Acute lactose intolerance in patients up to the age of 12 months, where the age of the patient is shown on the prescription
Demeclocycline Hydrochloride	Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug
Desipramine Hydrochloride	—
Desmopressin	In compliance with authority procedures set out in subparagraph 14 (d): Diabetes insipidus
Dexamethasone	—
Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin	—
Dexamethasone Sodium Phosphate	In respect of the injection equivalent to 120 mg dexamethasone phosphate in 5 mL vial: For use in a hospital In respect of the other injections: —
Dexamethasone with Framycetin Sulfate and Gramicidin	—
Dexamphetamine Sulfate	In compliance with authority procedures set out in subparagraph 14 (d): Use in attention deficit hyperactivity disorder, in accordance with State/Territory law Narcolepsy
Dextran 40 with Glucose	—
Dextran 40 with Sodium Chloride	—
Dextran 70 with Sodium Chloride	—
Diazepam	—
Dichlorphenamide	—
Diclofenac Potassium	—
Diclofenac Sodium	In respect of the tablet 25 mg (enteric coated) and the tablet 50 mg (enteric coated): Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the tablets 50 mg (enteric coated), 20 and the suppository 100 mg: —
Dienoestrol	—
Diflunisal	Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease
"Digestelact"	Acute lactose intolerance in children over 1 year of age
Digoxin	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Dihydroergotamine Mesylate	—
Dihydrotachysterol	In compliance with authority procedures set out in subparagraph 14 (d): Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Diltiazem Hydrochloride	In respect of the capsule 90 mg (sustained release) and the capsule 120 mg (sustained release): In compliance with authority procedures set out in subparagraph 14 (d): Hypertension where other calcium channel blocking drugs are inappropriate In respect of the tablet 60 mg, the capsule 180 mg (controlled delivery) and the capsule 240 mg (controlled delivery): —
Diphenoxylate Hydrochloride with Atropine Sulfate	—
Diphtheria and Tetanus Vaccine, Adsorbed	—
Diphtheria and Tetanus Vaccine, Adsorbed, Diluted	—
Diphtheria Antitoxin	—
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed	—
Diphtheria Vaccine, Adsorbed	—
Diphtheria Vaccine, Adsorbed, Diluted	—
Dipivefrine Hydrochloride	—
Disodium Etidronate	In compliance with authority procedures set out in subparagraph 14 (d): Active Paget's disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy or unacceptable side effects Heterotopic ossification
Disopyramide	—
Disopyramide Phosphate	—
Docusate Sodium with Bisacodyl	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function Patients who are receiving long-term nursing care in hospitals or nursing homes Patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved Patients receiving palliative care Terminal malignant neoplasia Anorectal congenital abnormalities Megacolon
Domperidone	—
Dothiepin Hydrochloride	—
Doxepin Hydrochloride	—
Doxorubicin Hydrochloride	—
Doxycycline Hydrochloride	In respect of the capsule equivalent to 50 mg doxycycline (containing enteric coated pellets) and the tablet equivalent to 50 mg doxycycline: Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne In respect of the other capsule and the other tablet: —
"Duocal"	Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae
Dydrogesterone	In compliance with authority procedures set out in subparagraph 14 (d): Endometriosis, proven by visual means
Econazole Nitrate	—
Ecothiopate Iodide	—
Enalapril Maleate	Cardiac failure Hypertension

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Enoxacin	In compliance with authority procedures set out in subparagraph 14 (d): Complicated urinary tract infection
Enoxaparin Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Major hip surgery
Epirubicin Hydrochloride	—
Ergocalciferol	Hypocalcaemia Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Ergometrine Maleate	—
Ergotamine Tartrate	—
Ergotamine Tartrate with Caffeine	—
Erythromycin	—
Erythromycin Estolate	—
Erythromycin Ethyl Succinate	—
Erythromycin Ethyl Succinate with Purified Water B.P.	—
Erythromycin Lactobionate	—
Erythromycin Stearate	—
Ethacrynic Acid	Patients who are hypersensitive to other oral diuretics
Ethinyloestradiol	—
Ethosuximide	—
Ethynodiol Diacetate with Ethinyloestradiol	—
Etoposide	—
Etretinate	In compliance with authority procedures set out in subparagraph 14 (d): Acantholytic dermatosis Darier's disease Erythrokeratoderma Pityriasis rubra pilaris Severe congenital ichthyosis (lamellar, bullous and sex linked) Severe intractable psoriasis Severe lichen planus Severe palmo-plantar keratoderma
Famotidine	Initial and maintenance treatment of duodenal ulcer Treatment of gastric ulcer Reflux oesophagitis Zollinger-Ellison syndrome
Felodipine	—
Ferrous Gluconate	—
Ferrous Sulfate, Dried	—
Ferrous Sulfate, Dried with Folic Acid	—
Flecainide Acetate	Treatment of serious cardiac arrhythmias where treatment was initiated in a hospital (in-patient or out-patient)
Fluclorolone Acetonide	—
Flucloxacillin Magnesium with Purified Water B.P.	Serious staphylococcal infections
Flucloxacillin Sodium	In respect of the capsule equivalent to 250 mg flucloxacillin and the capsule equivalent to 500 mg flucloxacillin: Serious staphylococcal infections In respect of the injections: —

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Fluconazole	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of cryptococcal meningitis in patients unable to take or tolerate amphotericin Maintenance therapy in patients with cryptococcal meningitis and immunosuppression Treatment of oropharyngeal and oesophageal candidiasis in immunosuppressed patients Secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients Treatment of serious and life-threatening candida infections in patients unable to tolerate amphotericin
Fludrocortisone Acetate	—
Flumethasone Pivalate with Clioquinol	—
Fluocortolone Pivalate with Fluocortolone Hexanoate	—
Fluorometholone	—
Fluorometholone Acetate	—
Fluorouracil Sodium	—
Fluoxetine Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of major depressive disorders where other therapy is inappropriate
Fluoxymesterone	In compliance with authority procedures set out in subparagraph 14 (d): Aplastic anaemias, proven Carcinoma of the breast Male hypogonadism Osteoporosis
Flupenthixol Decanoate	—
Fluphenazine Decanoate	—
Fluphenazine Hydrochloride	—
Flutamide	In compliance with authority procedures set out in subparagraph 14 (d): For use in conjunction with luteinising hormone-releasing hormone agonists for the treatment of advanced prostatic carcinoma
Folic Acid	—
Fosfestrol Sodium	Carcinoma of the prostate
Fosinopril Sodium	Mild to moderate hypertension
Framycetin Sulfate	—
Frusemide	—
Frusemide Sodium	—
Fusidic Acid	For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections
Gabapentin	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs
Gas-gangrene Antitoxin, Mixed	—
Gemfibrozil	Dyslipidaemia Dyslipidaemia in patients established on therapy with this drug prior to 1 December 1994
Gentamicin Sulfate	In respect of the eye drops: Invasive ocular infection Perioperative use Suspected pseudomonal eye infection In respect of the injections: —
Glibenclamide	—
Gliclazide	—
Glipizide	—
Glucagon Hydrochloride	—
Glucose	—
Glucose and Ketone Indicator—Urine	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Glucose Indicator—Blood	—
Glucose Indicator—Urine	—
Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate	—
Glycerol	Paraplegic or quadriplegic patients and others with severe neurogenic impairment of bowel function Patients who are receiving long-term nursing care in hospitals or nursing homes Patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved Patients receiving palliative care Terminal malignant neoplasia Anorectal congenital abnormalities Megacolon
Glyceryl Trinitrate	—
Goserelin Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Advanced carcinoma of the prostate Treatment of premenopausal women with advanced breast cancer Treatment, for up to 6 months, of visually proven endometriosis in a patient who has not previously been issued with an authority prescription for this drug for this purpose
Griseofulvin	—
Haloperidol	—
Haloperidol Decanoate	—
Heparin Calcium	—
Heparin Sodium	In respect of the injection (preservative-free) 5,000 I.U. in 5 mL ampoule: For use in home dialysis In respect of the injection 5,000 units in 0.2 mL ampoule, the injection 5,000 units in 1 mL ampoule, the injection 20,000 units in 20 mL ampoule, the injection 25,000 units in 5 mL ampoule and the injection 35,000 units in 35 mL vial: —
Hexamine Hippurate	—
Homatropine Hydrobromide	—
Hydralazine Hydrochloride	—
Hydrochlorothiazide	—
Hydrochlorothiazide with Amiloride Hydrochloride	—
Hydrochlorothiazide with Triamterene	—
Hydrocortisone	—
Hydrocortisone Acetate	In respect of the rectal foam: Proctitis Ulcerative colitis In respect of the creams, the eye ointments and the ointments: —
Hydrocortisone with Cinchocaine Hydrochloride	Anal and perianal conditions
Hydrocortisone Sodium Succinate	In respect of a prescription written by a medical practitioner: In respect of the injection equivalent to 500 mg hydrocortisone with 4 mL solvent: Any disease or condition in a patient receiving treatment in a hospital In respect of the other injections: — In respect of a prescription written by a participating dental practitioner: Any disease or condition in a patient receiving treatment in a hospital
Hydroxocobalamin	Pernicious anaemia Other proven vitamin B_{12} deficiencies
Hydroxychloroquine Sulfate	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Hydroxypropylcellulose	Severe dry eye syndrome unresponsive to artificial tear solutions
Hydroxyurea	—
Hyoscyamine Hydrobromide with Atropine Sulfate and Hyoscine Hydrobromide	—
Hyoscyamine Sulfate with Atropine Sulfate and Hyoscine Hydrobromide	—
Hypromellose 4500	—
Hypromellose 4500 with Dextran 70	—
Ibuprofen	In respect of the tablet 200 mg and the tablet 400 mg: Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the tablets 200 mg, 20 and the tablets 400 mg, 20: —
Idarubicin Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Acute myelogenous leukaemia
Idoxuridine	—
Imipramine Hydrochloride	—
Indapamide Hemihydrate	—
Indomethacin	In respect of the capsule 25 mg: Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the capsules 25 mg, 20, the ophthalmic suspension 10 mg per mL, 5 mL and the suppository 100 mg: —
Influenza Vaccine (Split Virion), Inactivated	For prophylaxis of persons at special risk of adverse consequences from infections of the lower respiratory tract
Insect Allergen Extract—Honey Bee Venom	—
Insect Allergen Extract—Paper Wasp Venom	—
Insect Allergen Extract—Yellow Jacket Venom	—
Insulin, Acid	—
Insulin, Isophane	—
Insulin, Neutral	—
Insulin, Neutral with Insulin, Isophane	—
Insulin, Protamine Zinc	—
Insulin Zinc Suspension	—
Insulin Zinc Suspension (Crystalline)	—
Interferon Alfa-2a	In compliance with authority procedures set out in subparagraph 14 (d): Hairy cell leukaemia
Interferon Alfa-2b	In respect of the injection set containing 5 vials powder for injection 3,000,000 I.U. and 5 ampoules solvent 2 mL: In compliance with authority procedures set out in subparagraph 14 (d): Hairy cell leukaemia In respect of the injection set containing 1 vial powder for injection 10,000,000 I.U. and 1 vial solvent 5 mL: In compliance with authority procedures set out in subparagraph 14 (d): Basal cell carcinoma when more efficacious treatments are considered inappropriate

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Ipratropium Bromide	In respect of the pressurised nasal spray 20 micrograms per dose, 200 doses: In compliance with authority procedures set out in subparagraph 14 (d): Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids In respect of the nebuliser solution 250 micrograms per mL, 20 mL, the nebuliser solution 250 micrograms in 1 mL single dose units, 30, the nebuliser solution 250 micrograms in 2 mL single dose units, 30 and the pressurised inhalation 20 micrograms per dose, 200 doses: —
Iron Polymaltose Complex	—
Isoniazid	—
Isosorbide Dinitrate	—
Isosorbide Mononitrate	—
Isotretinoin	In compliance with authority procedures set out in subparagraph 14 (d): Severe cystic acne not responsive to other therapy
Ketoconazole	In compliance with authority procedures set out in subparagraph 14 (d): Oral candidiasis in severely immunocompromised persons where other forms of therapy have failed Systemic or deep mycoses where other forms of therapy have failed Symptomatic vaginal candidiasis recurring after treatment of at least 2 episodes with topical therapy
Ketoprofen	In respect of the capsule 50 mg, the capsule 100 mg, the capsule 100 mg (sustained release) and the capsule 200 mg (sustained release): Chronic arthropathies (including osteoarthritis) with an inflammatory component In respect of the capsules 100 mg (sustained release), 10, the capsules 200 mg (sustained release), 7 and the suppository 100 mg: —
Labetalol Hydrochloride	—
Lactulose	Hepatic coma or precoma (chronic porto-systemic encephalopathy) Malignant neoplasia
Lamotrigine	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs
Lansoprazole	In compliance with authority procedures set out in subparagraph 14 (d): Refractory duodenal ulcer or refractory gastric ulcer, with proven failure to heal despite 8 weeks of continuous therapy with other ulcer healing drugs Severe refractory ulcerating oesophagitis Scleroderma oesophagus proven by endoscopy and unresponsive to other measures
Leuprorelin Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Advanced carcinoma of the prostate
Levobunolol Hydrochloride	—
Levodopa with Benserazide Hydrochloride	In respect of the capsule 100 mg-25 mg (benserazide) (sustained release): In compliance with authority procedures set out in subparagraph 14 (d): Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor In respect of the other capsules and the tablets: —
Levodopa with Carbidopa	In respect of the tablet 200 mg-50 mg (anhydrous) (modified release): In compliance with authority procedures set out in subparagraph 14 (d): Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor In respect of the other tablets: —

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Levonorgestrel	—
Levonorgestrel with Ethinyloestradiol	—
Lignocaine Hydrochloride	—
Lincomycin Hydrochloride	—
Liothyronine Sodium	—
Lisinopril	Cardiac failure Mild to moderate hypertension
Lithium Carbonate	—
"Locasol"	In compliance with authority procedures set out in subparagraph 14 (d): Hypercalcaemia in children under the age of 2 years
"Lofenalac"	Phenylketonuria
Loperamide Hydrochloride	—
Medroxyprogesterone Acetate	In respect of the injections 50 mg in 1 mL vial and 500 mg in 2.5 mL vial and the tablets 100 mg, 200 mg and 250 mg: Breast cancer Endometrial cancer In respect of the injection 150 mg in 1 mL vial: Breast cancer Endometrial cancer Endometriosis In respect of the tablet 500 mg: Advanced breast cancer In respect of the tablet 5 mg and the tablet 10 mg: —
Medrysone	—
Mefenamic Acid	Dysmenorrhoea Menorrhagia
Megestrol Acetate	Advanced breast cancer
Melphalan	—
Menotrophin	For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with chorionic gonadotrophin to achieve adequate spermatogenesis
Menotrophin standardised using Chorionic Gonadotrophin	For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with chorionic gonadotrophin to achieve adequate spermatogenesis
Mercaptopurine	—
Mesalazine	In compliance with authority procedures set out in subparagraph 14 (d): Colitis where hypersensitivity to sulfonamides or sustained intolerance to sulfasalazine exists
Metformin Hydrochloride	—
Methacycline Hydrochloride	—
Methadone Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Methdilazine Hydrochloride	Prevention of migraine
Methenolone Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Osteoporosis Patients on long-term treatment with corticosteroids
"Methionine, Threonine, Valine-free and Isoleucine low Amino Acid Mix"	Methylmalonic acidaemia Propionic acidaemia
Methotrexate	—
Methotrexate Sodium	—
Methyclothiazide	—
Methyldopa	—
Methylphenobarbitone	Epilepsy
Methylprednisolone Acetate	For local intra-articular or peri-articular infiltration
Methylprednisolone Sodium Succinate	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Methyl Salicylate	—
Methysergide Maleate	—
Metoclopramide Hydrochloride	—
Metolazone	—
Metoprolol Tartrate	—
Metronidazole	In respect of the intravenous infusion: In respect of a prescription written by a medical practitioner: Prophylaxis in large bowel surgery Treatment, in a hospital, of acute anaerobic sepsis In respect of a prescription written by a participating dental practitioner: Treatment, in a hospital, of acute anaerobic sepsis In respect of the suppositories and the tablets: —
Metronidazole Benzoate	—
Mexiletine Hydrochloride	—
Mianserin Hydrochloride	Severe depression
Miconazole Nitrate	—
Minocycline Hydrochloride	In respect of the tablet: Severe acne not responding to other tetracyclines In respect of the capsule: —
Minoxidil	In compliance with authority procedures set out in subparagraph 14 (d): For the continuing treatment of severe refractory hypertensive disease where treatment with minoxidil was initiated in a hospital (in-patient or out-patient)
Misoprostol	In compliance with authority procedures set out in subparagraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years
Mitozantrone Hydrochloride	—
Moclobemide	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of depressive disorders where other therapy is inappropriate
Morphine Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Morphine Sulfate	In respect of the tablet 30 mg: Severe disabling pain not responding to non-narcotic analgesics In respect of the capsule 20 mg (containing sustained release pellets), the capsule 50 mg (containing sustained release pellets), the capsule 100 mg (containing sustained release pellets), the tablet 10 mg (controlled release), the tablet 30 mg (controlled release), the tablet 60 mg (controlled release) and the tablet 100 mg (controlled release): Chronic severe disabling pain not responding to non-narcotic analgesics In respect of the injections: —
Morphine Tartrate	—
"M.S.U.D. AID"	Maple syrup urine disease
"M.S.U.D. Maxamaid"	Maple syrup urine disease
Nafarelin Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Treatment, for up to 6 months, of visually proven endometriosis in a patient who has not previously been issued with an authority prescription for this drug for this purpose
Nalidixic Acid	For use as a urinary antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is an appropriate therapeutic agent
Naloxone Hydrochloride	—
Nandrolone Decanoate	In compliance with authority procedures set out in subparagraph 14 (d): Osteoporosis where other therapy is inappropriate Patients on long-term treatment with corticosteroids

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Naphazoline Hydrochloride	—
Naproxen	In respect of the tablet 250 mg, the tablet 250 mg (enteric coated), the tablet 500 mg, the tablet 500 mg (enteric coated), the tablet 750 mg (sustained release), the tablet 1 g (sustained release) and the oral suspension: Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the tablets 250 mg, 20, the tablets 500 mg, 10, the tablets 750 mg (sustained release), 7, the tablets 1 g (sustained release), 7 and the suppository 500 mg: —
Naproxen Sodium	In respect of the tablet 550 mg: Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the tablets 550 mg, 10: —
"Neocate"	Proven combined intolerance to cows' milk protein, soy protein, and protein hydrolysate formulae of both whey and casein Severe intestinal malabsorption including short bowel syndrome
Neomycin Sulfate	—
Neomycin Undecenoate with Bacitracin Zinc	—
Neostigmine Bromide	—
Niclosamide	—
Nicotinic Acid	—
Nifedipine	In respect of the capsules: Angina In respect of the tablets: —
Nitrazepam	—
Nitrofurantoin	—
Nizatidine	Initial and maintenance treatment of duodenal ulcer Treatment of gastric ulcer Reflux oesophagitis
Norethisterone	—
Norethisterone with Ethinyloestradiol	—
Norethisterone with Mestranol	—
Norfloxacin	In compliance with authority procedures set out in subparagraph 14 (d): Acute bacterial enterocolitis Complicated urinary tract infection
Nortriptyline Hydrochloride	—
"Nutramigen"	In compliance with authority procedures set out in subparagraph 14 (d): Allergy to both cows' milk and soy protein in children under the age of 2 years Cystic fibrosis Galactosaemia Glycogen storage disease due to glucose-6-phosphatase deficiency in children Severe intestinal malabsorption including short bowel syndrome
Nystatin	—
Oestradiol	In respect of the transdermal patches: For use for post-menopausal symptoms where a trial of peri- or post-menopausal low-dose oestrogen therapy has demonstrated intolerance to oral oestrogens In respect of the vaginal tablets: —

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Oestradiol and Medroxyprogesterone Acetate	For use for post-menopausal symptoms where a trial of peri- or post-menopausal low-dose oestrogen therapy has demonstrated intolerance to oral oestrogens
Oestradiol Valerate	—
Oestradiol with Norethisterone Acetate	—
Oestriol	—
Oestrogens—Conjugated	—
Oestrogens—Conjugated and Medroxyprogesterone Acetate	—
Oestrone	—
Olsalazine Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Colitis where hypersensitivity to sulfonamides or intolerance to sulfasalazine exists
Omeprazole	In compliance with authority procedures set out in subparagraph 14 (d): Refractory duodenal ulcer or refractory gastric ulcer, with proven failure to heal despite 8 weeks of continuous therapy with other ulcer healing drugs Scleroderma oesophagus, proven by endoscopy and unresponsive to other measures Severe refractory ulcerating oesophagitis Zollinger-Ellison syndrome
Ondansetron Hydrochloride Dihydrate	In compliance with authority procedures set out in subparagraph 14 (d): Management of nausea and vomiting associated with cytotoxic chemotherapy or radiotherapy
Orphenadrine Hydrochloride	Parkinsonism
Oxandrolone	In compliance with authority procedures set out in subparagraph 14 (d): Promotion of growth in girls with Turner syndrome Promotion of growth in boys of short stature with delayed bone maturation
Oxazepam	—
Oxprenolol Hydrochloride	—
Oxycodone Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Oxycodone Pectinate	Severe disabling pain not responding to non-narcotic analgesics
Oxymetholone	In compliance with authority procedures set out in subparagraph 14 (d): Aplastic anaemias, proven Myelosclerosis
Paclitaxel	In compliance with authority procedures set out in subparagraph 14 (d): Advanced metastatic ovarian carcinoma after failure of standard therapy which includes a platinum compound
Pancreatin	—
Pancrelipase	—
Paracetamol	—
Paraffin, Soft White with Liquid Paraffin	—
Paroxetine Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of major depressive disorders where other therapy is inappropriate
Penicillamine	—
Pergolide Mesylate	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of Parkinson's disease as adjunctive therapy in combination with levodopa—decarboxylase inhibitor combinations
Pericyazine	—
Perindopril Erbumine	Cardiac failure Mild to moderate hypertension
Pethidine Hydrochloride	—
Phenelzine Sulfate	—
Phenobarbitone	Epilepsy
Phenobarbitone Sodium	Epilepsy
Phenoxybenzamine Hydrochloride	Neurogenic urinary retention Phaeochromocytoma

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Phenoxymethylpenicillin Benzathine	—
Phenoxymethylpenicillin Potassium	—
Phenylephrine Hydrochloride	—
Phenytoin	—
Phenytoin Sodium	—
Pilocarpine	Chronic glaucoma when other miotics are not tolerated
Pilocarpine Hydrochloride	—
Pindolol	—
Piperazine Oestrone Sulfate	—
Piroxicam	Chronic arthropathies (including osteoarthritis) with an inflammatory component
Pizotifen Malate	—
"PK AID II"	Phenylketonuria
Pneumococcal Vaccine, Polyvalent	Splenectomised persons over the age of 2 years Persons with Hodgkin's disease Persons at high risk of pneumococcal infections
Polygeline	—
Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate	—
Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin	—
Polyvinyl Alcohol	—
Polyvinyl Alcohol with Povidone	—
"Portagen"	In compliance with authority procedures set out in subparagraph 14 (d): Chronic liver failure with fat malabsorption Chyloascites Chylothorax Patients requiring a ketogenic diet for intractable childhood epilepsy Proven fat malabsorption
Potassium Chloride	—
Potassium Chloride with Potassium Bicarbonate	—
Pravastatin Sodium	Dyslipidaemia Dyslipidaemia in patients established on therapy with this drug prior to 1 December 1994
Prazosin Hydrochloride	—
Prednisolone	—
Prednisolone Acetate	—
Prednisolone Acetate with Phenylephrine Hydrochloride	Corneal grafts Uveitis
Prednisolone Sodium Phosphate	In respect of the suppositories: Proctitis Ulcerative colitis In respect of the eye/ear drops and the retention enema: —
Prednisone	—
"Pregestimil"	In compliance with authority procedures set out in subparagraph 14 (d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Galactosaemia Proven combined intolerance to cows' milk protein and soy protein formulae Severe diarrhoea of greater than 2 weeks duration in infants under the age of 4 months Severe intestinal malabsorption including short bowel syndrome
Primidone	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Probenecid	—
Probucol	In compliance with authority procedures set out in subparagraph 14 (d): Hypercholesterolaemia in patients with a cholesterol level greater than 8.0 mmol per L in whom the response to intensive dietary therapy and to other lipid-lowering drugs is inadequate
Procainamide Hydrochloride	—
Procaine Penicillin	—
Prochlorperazine	—
Prochlorperazine Edisylate	—
Prochlorperazine Maleate	—
Prochlorperazine Mesylate	—
Procyclidine Hydrochloride	—
Promethazine Hydrochloride	—
Promethazine Theoclate	—
Propantheline Bromide	Chronic neurogenic incontinence of urine
Propranolol Hydrochloride	—
Propylthiouracil	—
Protamine Sulfate	—
Pyrantel Embonate	—
Pyridostigmine Bromide	—
Pyridoxine Hydrochloride	In respect of the tablet: Anaemia proved to be responsive to pyridoxine hydrochloride Convulsions responsive to pyridoxine hydrochloride Homocystinuria Primary hyperoxaluria Radiation sickness Sideroblastic (refractory) anaemia Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy In respect of the injection: —
Pyrimethamine	—
Quinapril Hydrochloride	Mild to moderate hypertension
Quinidine Bisulfate	—
Quinine Bisulfate	—
Quinine Sulfate	—
Ramipril	Mild to moderate hypertension
Ranitidine Hydrochloride	Initial and maintenance treatment of peptic ulcer Reflux oesophagitis Scleroderma oesophagus Zollinger-Ellison syndrome
Red-back Spider Antivenom	—
Rifampicin	Prophylactic treatment of contacts of patients with *Haemophilus influenzae* type B Prophylaxis of meningococcal disease in close contacts and carriers In compliance with authority procedures set out in subparagraph 14 (d): Leprosy in adults
Roxithromycin	—
"RVHB Maxamaid"	Pyridoxine non-responsive homocystinuria
Salbutamol	—
Salbutamol Sulfate	In respect of the pressurised inhalation in breath actuated device equivalent to 100 micrograms salbutamol per dose, 400 doses: Patients unable to achieve co-ordinated use of other metered dose inhalers containing salbutamol or salbutamol sulfate In respect of the tablet, the capsule, the nebuliser solutions and the pressurised inhalations: —

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Salcatonin	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia
Selegiline Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Adjunctive therapy in late stage Parkinson's disease in patients being treated with levodopa with benserazide hydrochloride or levodopa with carbidopa
Sertraline Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of major depressive disorders where other therapy is inappropriate
Silver Sulfadiazine with Chlorhexidine Gluconate	For the prevention and treatment of infection in partial or full skin thickness loss due to burns or epidermolysis bullosa Stasis ulcers
Simvastatin	Dyslipidaemia Dyslipidaemia in patients established on therapy with this drug prior to 1 December 1994
Sodium Acid Phosphate	In compliance with authority procedures set out in subparagraph 14 (d): Familial hypophosphataemia Hypercalcaemia Hypophosphataemic rickets Vitamin D-resistant rickets
Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate	—
Sodium Aurothiomalate	—
Sodium Cellulose Phosphate	In compliance with authority procedures set out in subparagraph 14 (d): Hypercalciuria (urine calcium in excess of 8 millimoles per 24 hours within the last 3 years) in the presence of documented sarcoidosis Treatment of recurrent renal calculi in patients with urine calcium in excess of 8 millimoles per 24 hours who are unresponsive to dietary measures and thiazides
Sodium Chloride	—
Sodium Chloride with Glucose	—
Sodium Chloride with Potassium Chloride and Calcium Chloride	—
Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride	—
Sodium Citro-Tartrate	—
Sodium Cromoglycate	In respect of the eye drops: In compliance with authority procedures set out in subparagraph 14 (d): Vernal kerato-conjunctivitis In respect of the insufflation, the nebuliser solution and the pressurised inhalations: —
Sodium Fusidate	For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections
Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride	—
Sodium Nitroprusside	—
Sodium Valproate	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function Patients who are receiving long-term nursing care in hospitals or nursing homes Patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved Patients receiving palliative care Terminal malignant neoplasia Anorectal congenital abnormalities Megacolon
Sotalol Hydrochloride	Treatment of severe refractory cardiac arrhythmias
Spectinomycin Hydrochloride	—
Spironolactone	Female hirsutism Hyperaldosteronism, including refractory cardiac failure
Sterculia with Frangula Bark	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function Patients who are receiving long-term nursing care in hospitals or nursing homes Patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved Patients receiving palliative care Terminal malignant neoplasia Anorectal congenital abnormalities Megacolon
Streptokinase	Treatment, in a hospital, of acute myocardial infarction within 6 hours of onset of attack
Sucralfate	—
Sulfacetamide Sodium	—
Sulfamethizole	—
Sulfamethoxazole with Trimethoprim	—
Sulfasalazine	Crohn's disease Rheumatoid arthritis Ulcerative colitis
Sulfinpyrazone	Glomerulonephritis Gout Renal transplantation
Sulindac	In respect of the tablet 100 mg and the tablet 200 mg: Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease In respect of the tablets 100 mg, 20 and the tablets 200 mg, 10: —
Sulthiame	—
Surgical Cement	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances
Surgical Cement Solvent	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances
Tamoxifen Citrate	Breast cancer
Temazepam	—
Tenoxicam	Chronic arthropathies (including osteoarthritis) with an inflammatory component Bone pain due to malignant disease
Terbinafine Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Microbiologically proven onychomycosis due to dermatophyte fungi
Terbutaline Sulfate	—
Testosterone Enanthate	In compliance with authority procedures set out in subparagraph 14 (d): Klinefelter's syndrome (seminiferous tubule dysgenesis) Male hypogonadism

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate	In compliance with authority procedures set out in subparagraph 14 (d): Klinefelter's syndrome (seminiferous tubule dysgenesis) Male hypogonadism
Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate	In compliance with authority procedures set out in subparagraph 14 (d): Klinefelter's syndrome (seminiferous tubule dysgenesis) Male hypogonadism
Testosterone Undecanoate	In compliance with authority procedures set out in subparagraph 14 (d): Klinefelter's syndrome (seminiferous tubule dysgenesis) Male hypogonadism
Tetanus Vaccine, Adsorbed	—
Tetrabenazine	—
Tetracosactrin	—
Tetracycline Hydrochloride	—
Tetracycline Hydrochloride with a buffering agent	—
Theophylline	—
Thiabendazole	—
Thiamine Hydrochloride	—
Thioguanine	In respect of the tablet 200 mg and the tablet 300 mg: Inflammatory arthropathies requiring long-term therapy In respect of the tablets 200 mg, 20 and the tablets 300 mg, 10 —
Thioridazine	—
Thioridazine Hydrochloride	—
Thiotepa	—
Thyroxine Sodium	—
Tiaprofenic Acid	In respect of the tablet 200 mg and the tablet 300 mg: Chronic arthropathies (including osteoarthritis) with an inflammatory component In respect of the tablets 200 mg, 20 and the tablets 300 mg, 10: —
Ticarcillin Sodium	In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that ticarcillin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that ticarcillin sodium is an appropriate therapeutic agent
Ticarcillin Sodium with Potassium Clavulanate	In respect of a prescription written by a medical practitioner: Infections where positive bacteriological evidence confirms that ticarcillin sodium with potassium clavulanate is an appropriate therapeutic agent Septicaemia, suspected or proven In respect of a prescription written by a participating dental practitioner: Infections where positive bacteriological evidence confirms that ticarcillin sodium with potassium clavulanate is an appropriate therapeutic agent
Ticlopidine Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Patients at high risk of thrombo-embolic stroke following ischaemic cerebrovascular disturbances who are proven intolerant of low-dose aspirin, or who have further ischaemic cerebrovascular disturbances while on low-dose aspirin treatment
Timolol Maleate	—
Timolol Maleate with Pilocarpine Hydrochloride	—
Tinidazole	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Tobramycin	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Tobramycin Sulfate	Infections where positive bacteriological evidence confirms that tobramycin sulfate is an appropriate antibiotic Septicaemia, suspected or proven
Tolbutamide	—
Tranexamic Acid	Hereditary angio-oedema
Tranylcypromine Sulfate	—
Triamcinolone Acetonide	In respect of the injection: In respect of a prescription written by a medical practitioner: Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Psoriasis In respect of a prescription written by a participating dental practitioner: For local intra-articular or peri-articular infiltration Keloid Lichen planus hypertrophic In respect of the creams and the ointments: —
Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin	—
Trifluoperazine Hydrochloride	—
Triglycerides Oil, Medium Chain	In compliance with authority procedures set out in subparagraph 14 (d): Abetalipoproteinaemia Chyloascites Chylothorax Intestinal lymphangiectasia Intractable childhood epilepsy requiring a ketogenic diet Long chain fat oxidation disorders Short-term nutritional support in severe steatorrhoea Steatorrhoea due to distal small bowel resection
Trimethoprim	—
Trimipramine Maleate	—
Tropisetron Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Management of nausea and vomiting associated with cytotoxic chemotherapy
Urea	—
Urofollitrophin	For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union
Vancomycin Hydrochloride	In respect of the capsules: Antibiotic associated colitis In respect of the injection: Prophylaxis of endocarditis in patients hypersensitive to penicillin
Verapamil Hydrochloride	—
Vidarabine	Eye infections caused by herpes simplex virus
Vigabatrin	In compliance with authority procedures set out in subparagraph 14 (d): Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs
Vinblastine Sulfate	—
Vincristine Sulfate	—
Warfarin Sodium	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Water for Injections, sterilised	—
Wool Alcohols	—
"XP Albumaid"	Phenylketonuria
"XP Analog"	Phenylketonuria
"XPhen, Tyr Maxamum"	Tyrosinaemia
"XP Maxamaid"	Phenylketonuria
"XP Maxamum"	Phenylketonuria
Zinc Oxide	—
Zinc Sulfate with Phenylephrine Hydrochloride	—

SCHEDULE 2 — Allowable compounds of ready-prepared pharmaceutical benefits

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Allowable compounds*
Aluminium Hydroxide, Dried	Aluminium Hydroxide, Dried with Light Kaolin or Light Kaolin (Natural)
	Aluminium Hydroxide, Dried with Magnesium Hydroxide
	Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine
	Aluminium Hydroxide, Dried with Magnesium Trisilicate and Magnesium Hydroxide
Amiloride Hydrochloride	Hydrochlorothiazide with Amiloride Hydrochloride
Amoxycillin Trihydrate	Amoxycillin Trihydrate with Potassium Clavulanate
	Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.
	Amoxycillin Trihydrate with Purified Water B.P.
Antazoline Phosphate	Antazoline Phosphate with Naphazoline Hydrochloride
Antazoline Sulfate	Antazoline Sulfate with Naphazoline Nitrate
Aspirin	Codeine Phosphate with Aspirin
Atropine Sulfate	Diphenoxylate Hydrochloride with Atropine Sulfate
	Hyoscyamine Hydrobromide with Atropine Sulfate and Hyoscine Hydrobromide
	Hyoscyamine Sulfate with Atropine Sulfate and Hyoscine Hydrobromide
Bacitracin Zinc	Neomycin Undecenoate with Bacitracin Zinc
	Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate
Benserazide Hydrochloride	Levodopa with Benserazide Hydrochloride
Benzathine Penicillin	Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium
Benzylpenicillin Potassium	Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium
Betamethasone Acetate	Betamethasone Acetate with Betamethasone Sodium Phosphate
Betamethasone Sodium Phosphate	Betamethasone Acetate with Betamethasone Sodium Phosphate
Bisacodyl	Docusate Sodium with Bisacodyl
Caffeine	Ergotamine Tartrate with Caffeine
Calcium Carbonate	Calcium Carbonate with Calcium Lactate-Gluconate
	Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate
Calcium Chloride	Sodium Chloride with Potassium Chloride and Calcium Chloride
	Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride
Calcium Lactate-Gluconate	Calcium Carbonate with Calcium Lactate-Gluconate
Carbidopa	Levodopa with Carbidopa
Cefaclor Monohydrate	Cefaclor Monohydrate with Purified Water B.P.
Cephalexin	Cephalexin with Purified Water B.P.
Chloramphenicol	Chloramphenicol with Polymyxin B Sulfate
Chlorhexidine Gluconate	Silver Sulfadiazine with Chlorhexidine Gluconate
Cinchocaine Hydrochloride	Hydrocortisone with Cinchocaine Hydrochloride
Clindamycin Palmitate Hydrochloride	Clindamycin Palmitate Hydrochloride with Purified Water B.P.
Clioquinol	Flumethasone Pivalate with Clioquinol
Codeine Phosphate	Codeine Phosphate with Aspirin
	Codeine Phosphate with Paracetamol
Dexamethasone	Dexamethasone with Framycetin Sulfate and Gramicidin
Dexamethasone Sodium Metasulfobenzoate	Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin
Dextran 40	Dextran 40 with Glucose
	Dextran 40 with Sodium Chloride
Dextran 70	Dextran 70 with Sodium Chloride
	Hypromellose 4500 with Dextran 70
Diphenoxylate Hydrochloride	Diphenoxylate Hydrochloride with Atropine Sulfate
Docusate Sodium	Docusate Sodium with Bisacodyl
Ergotamine Tartrate	Ergotamine Tartrate with Caffeine
Erythromycin Ethyl Succinate	Erythromycin Ethyl Succinate with Purified Water B.P.
Ethinyloestradiol	Ethynodiol Diacetate with Ethinyloestradiol
	Levonorgestrel with Ethinyloestradiol
	Norethisterone with Ethinyloestradiol

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Allowable compounds*
Ethynodiol Diacetate	Ethynodiol Diacetate with Ethinyloestradiol
Ferrous Sulfate, Dried	Ferrous Sulfate, Dried with Folic Acid
Flucloxacillin Magnesium	Flucloxacillin Magnesium with Purified Water B.P.
Flumethasone Pivalate	Flumethasone Pivalate with Clioquinol
Fluocortolone Hexanoate	Fluocortolone Pivalate with Fluocortolone Hexanoate
Fluocortolone Pivalate	Fluocortolone Pivalate with Fluocortolone Hexanoate
Folic Acid	Ferrous Sulfate, Dried with Folic Acid
Framycetin Sulfate	Dexamethasone with Framycetin Sulfate and Gramicidin
	Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin
Frangula Bark	Sterculia with Frangula Bark
Glucose	Dextran 40 with Glucose
	Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate
	Sodium Chloride with Glucose
Gramicidin	Dexamethasone with Framycetin Sulfate and Gramicidin
	Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin
	Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin
	Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin
Hydrochlorothiazide	Hydrochlorothiazide with Amiloride Hydrochloride
	Hydrochlorothiazide with Triamterene
Hydrocortisone	Hydrocortisone with Cinchocaine Hydrochloride
Hyoscine Hydrobromide	Hyoscyamine Hydrobromide with Atropine Sulfate and Hyoscine Hydrobromide
	Hyoscyamine Sulfate with Atropine Sulfate and Hyoscine Hydrobromide
Hyoscyamine Hydrobromide	Hyoscyamine Hydrobromide with Atropine Sulfate and Hyoscine Hydrobromide
Hyoscyamine Sulfate	Hyoscyamine Sulfate with Atropine Sulfate and Hyoscine Hydrobromide
Hypromellose 4500	Hypromellose 4500 with Dextran 70
Insulin, Isophane	Insulin, Neutral with Insulin, Isophane
Insulin, Neutral	Insulin, Neutral with Insulin, Isophane
Kaolin, Light or Light Kaolin (Natural)	Aluminium Hydroxide, Dried with Light Kaolin or Light Kaolin (Natural)
Levodopa	Levodopa with Benserazide Hydrochloride
	Levodopa with Carbidopa
Levonorgestrel	Levonorgestrel with Ethinyloestradiol
Magnesium Chloride	Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride
Magnesium Hydroxide	Aluminium Hydroxide, Dried with Magnesium Hydroxide
	Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine
	Aluminium Hydroxide, Dried with Magnesium Trisilicate and Magnesium Hydroxide
Magnesium Trisilicate	Aluminium Hydroxide, Dried with Magnesium Trisilicate and Magnesium Hydroxide
Mestranol	Norethisterone with Mestranol
Naphazoline Hydrochloride	Antazoline Phosphate with Naphazoline Hydrochloride
Naphazoline Nitrate	Antazoline Sulfate with Naphazoline Nitrate
Neomycin Sulfate	Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate
	Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin
	Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin
Neomycin Undecenoate	Neomycin Undecenoate with Bacitracin Zinc
Norethisterone	Norethisterone with Ethinyloestradiol
	Norethisterone with Mestranol
Norethisterone Acetate	Oestradiol with Norethisterone Acetate

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Allowable compounds*
Nystatin	Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin
Oestradiol	Oestradiol with Norethisterone Acetate
Oxethazaine	Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine
Paracetamol	Codeine Phosphate with Paracetamol
Paraffin, Liquid	Paraffin, Soft White with Liquid Paraffin
Paraffin, Soft White	Paraffin, Soft White with Liquid Paraffin
Phenylephrine Hydrochloride	Prednisolone Acetate with Phenylephrine Hydrochloride
	Zinc Sulfate with Phenylephrine Hydrochloride
Pilocarpine Hydrochloride	Timolol Maleate with Pilocarpine Hydrochloride
Polymyxin B Sulfate	Chloramphenicol with Polymyxin B Sulfate
	Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate
	Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin
Polyvinyl Alcohol	Polyvinyl Alcohol with Povidone
Potassium Bicarbonate	Potassium Chloride with Potassium Bicarbonate
Potassium Chloride	Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate
	Potassium Chloride with Potassium Bicarbonate
	Sodium Chloride with Potassium Chloride and Calcium Chloride
	Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride
	Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride
Potassium Clavulanate	Amoxycillin Trihydrate with Potassium Clavulanate
	Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.
	Ticarcillin Sodium with Potassium Clavulanate
Povidone	Polyvinyl Alcohol with Povidone
Prednisolone Acetate	Prednisolone Acetate with Phenylephrine Hydrochloride
Procaine Penicillin	Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium
Silver Sulfadiazine	Silver Sulfadiazine with Chlorhexidine Gluconate
Sodium Acetate	Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride
Sodium Acid Citrate	Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate
Sodium Alginate	Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate
Sodium Bicarbonate	Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate
Sodium Chloride	Dextran 40 with Sodium Chloride
	Dextran 70 with Sodium Chloride
	Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate
	Sodium Chloride with Glucose
	Sodium Chloride with Potassium Chloride and Calcium Chloride
	Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride
	Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride
Sodium Citrate	Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
Sodium Gluconate	Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride
Sodium Lactate	Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride
Sodium Lauryl Sulfoacetate	Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
Sorbitol	Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
Sterculia	Sterculia with Frangula Bark
Sulfamethoxazole	Sulfamethoxazole with Trimethoprim
Testosterone Decanoate	Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Allowable compounds*
Testosterone Isocaproate	Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate
Testosterone Phenylpropionate	Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate
Testosterone Propionate	Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate
Tetracycline Hydrochloride	Tetracycline Hydrochloride with a buffering agent
Ticarcillin Sodium	Ticarcillin Sodium with Potassium Clavulanate
Timolol Maleate	Timolol Maleate with Pilocarpine Hydrochloride
Triamcinolone Acetonide	Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin
Triamterene	Hydrochlorothiazide with Triamterene
Trimethoprim	Sulfamethoxazole with Trimethoprim
Water, Purified B.P.	Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate with Purified Water B.P. Cefaclor Monohydrate with Purified Water B.P. Cephalexin with Purified Water B.P. Clindamycin Palmitate Hydrochloride with Purified Water B.P. Erythromycin Ethyl Succinate with Purified Water B.P. Flucloxacillin Magnesium with Purified Water B.P.
Zinc Sulfate	Zinc Sulfate with Phenylephrine Hydrochloride

SCHEDULE 3 — Drugs or medicinal preparations which may be used as ingredients of extemporaneously-prepared pharmaceutical benefits

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Acacia, Powdered B.P.	—
Acetic Acid (33 per cent) B.P.	—
Alum B.P.	—
Aluminium Acetate Solution B.P.	—
Aminophylline B.P.	—
Ammonia Spirit, Aromatic B.P.	—
Ammoniated Mercury B.P. 1973	—
Ascorbic Acid B.P.	Use as ingredient of Ferrous Sulfate Mixture A.P.F. and Ferrous Sulfate Mixture C.F. A.P.F. 13
Aspirin B.P.	—
Beeswax, White B.P.	—
Belladonna Tincture B.P.	—
Benzocaine B.P.	—
Benzoic Acid B.P.	—
Benzoin Tincture, Compound B.P.	—
Cade Oil B.P.C. 1973	—
Calamine B.P.	—
Calcium Hydroxide B.P.	—
Camphor Spirit, Compound A.P.F.	—
Cetomacrogol Emulsifying Wax B.P.	—
Cetostearyl Alcohol B.P.	—
Cetrimide B.P.	—
Chlorbutol B.P.	—
Chlorhexidine Cream, Aqueous A.P.F.	—
Chlorinated Lime B.P.	—
Citric Acid Monohydrate B.P.	—
Coal Tar B.P.	—
Coal Tar Solution B.P.	—
Cocaine Hydrochloride B.P.	—
Coconut Oil B.P.	—
Codeine Phosphate B.P.	—
Collodion, Flexible B.P.	—
Dithranol B.P.	—
Emulsifying Wax B.P.	—
Ephedrine Hydrochloride B.P.	May only be prescribed in nasal instillations
Ferrous Sulfate B.P.	—
Formaldehyde Solution B.P.	—
Gentian Infusion, Compound, Concentrated B.P.	—
Glycerol B.P.	—
Hydrochloric Acid, Dilute B.P.	—
Ichthammol B.P.	—
Iodine B.P.	—
Ipecacuanha Tincture B.P.	—
Kaolin, Light B.P.	—
Kaolin, Light (Natural) B.P.	—
Lactic Acid B.P.	—
Lavender Oil, Spike B.P.C. 1968	—
Lemon Syrup B.P.	—
Levomenthol B.P.	—
Liquorice Liquid Extract B.P.	—
Lobelia Tincture, Ethereal B.P.C. 1973	—
Magnesium Carbonate, Light B.P.	—
Magnesium Sulfate B.P.	May only be prescribed for other than oral use
Magnesium Trisilicate B.P.	—
Menthol, Racemic B.P.	—
Methyl Hydroxybenzoate B.P.	—

Column 1 *Name of pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Methyl Salicylate B.P.	—
Methyl Salicylate Ointment, Compound A.P.F. 1934	—
Morphine Hydrochloride B.P.	—
Oleic Acid B.P.	—
Opium Tincture B.P.	—
Orange Tincture B.P.	—
Paraffin, Hard B.P.	—
Paraffin, Light Liquid B.P.	—
Paraffin, Liquid B.P.	May only be prescribed for other than oral use
Paraffin, Soft White B.P.	—
Paraffin, Soft Yellow B.P.	—
Phenobarbitone Sodium B.P.	May only be prescribed for the treatment of epilepsy
Phenol B.P.	May not be prescribed in ear drops
Podophyllum Resin B.P.	—
Potassium Citrate B.P.	—
Potassium Iodide B.P.	—
Potassium Permanganate B.P.	—
Propylene Glycol B.P.	—
Propyl Hydroxybenzoate B.P.	—
Pumilio Pine Oil B.P. 1980	—
Red Syrup A.P.F.	—
Resorcinol B.P.	—
Salicylic Acid B.P.	—
Siberian Fir Oil B.P.C. 1949	—
Silver Nitrate B.P.	—
Soap, Soft B.P.	—
Sodium Bicarbonate B.P.	—
Sodium Chloride B.P.	—
Sodium Citrate B.P.	—
Starches B.P.	—
Stramonium Tincture B.P. 1980	—
Sulfur, Precipitated B.P. 1980	—
Syrup B.P.	—
Talc, Purified B.P., sterilised	—
Thymol B.P.	—
Thymol Mouth Wash, Compound A.P.F.	—
Tolu Syrup B.P.	—
Tragacanth, Powdered B.P.	—
Tragacanth Powder, Compound B.P. 1980	—
Trichloroacetic Acid B.P. 1980	—
Triethanolamine B.P.	—
Turpentine Liniment B.P.	—
Water for Injections, sterilised B.P.	May only be prescribed in eye drops and eye lotions
Water, Purified B.P.	—
Wool Alcohols B.P.	—
Wool Fat B.P.	—
Wool Fat, Hydrous B.P.	—
Zinc Oxide B.P.	—
Zinc Sulfate B.P.	—

SCHEDULE 4 — Additives

Acetone B.P.
Anise Water, Concentrated B.P.
Arachis Oil B.P.
Borax B.P.
Boric Acid B.P.
Castor Oil B.P.
Chlorhexidine Acetate B.P.
Chloroform B.P.
Ethanol (96 per cent) B.P.
Ethanols, Dilute B.P.
Ether, Solvent B.P.
Eucalyptus Oil B.P.
Glucose B.P.
Honey, Purified B.P.
Industrial Methylated Spirit B.P.
Olive Oil B.P.
Peppermint Oil B.P.
Peppermint Water, Concentrated A.P.F.
Pholcodine Citrate Syrup B.P.C. 1959
Sodium Thiosulfate B.P.
Turpentine Oil B.P.

SCHEDULE 5 — Additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act

Anti-Haemophilic Factor of Animal Origin
Botulinum Toxin Type A Purified Neurotoxin Complex
Clozapine
Cyclosporin
Desferrioxamine Mesylate
Didanosine
Erythropoietin, Recombinant Human
Filgrastim
Foscarnet Sodium
Ganciclovir Sodium
Lenograstim
Methadone Hydrochloride B.P.
Somatropin
Zalcitabine
Zidovudine

Dated this sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DECLARATION UNDER SUBSECTION 85 (2AA)

No. PB 18 of 1994

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, having in accordance with subsection 85 (2AB) of the *National Health Act 1953* obtained the advice of the Pharmaceutical Benefits Advisory Committee, pursuant to subsection 85 (2AA) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into operation on 1 December 1994.

2. The drugs and medicinal preparations specified in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the *National Health Act 1953* applies.

THE SCHEDULE

Amylobarbitone Sodium
Chlormethiazole Edisylate
Cyclopenthiazide
Dextran 70 with Glucose
Diazoxide
Methsuximide
Phensuximide
"PK AID I"
Sodium Lactate with Sodium Chloride, Potassium Chloride, Calcium Chloride and Anhydrous Glucose

---

Dated this Sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATIONS UNDER SECTIONS 85, 85A AND 88

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, pursuant to sections 85, 85A and 88 of the *National Health Act 1953*, hereby make the following Determinations:

1. These Determinations shall come into operation on 1 December 1994.

2. The Determinations under sections 85, 85A and 88 of the Act made on 15 July 1994 with effect from 1 August 1994, as amended on 14 September 1994 with effect from 1 October 1994 and on 6 October 1994 with effect from 12 October 1994, are hereby revoked.

3. In these Determinations:
'CFU' means colony forming unit;
'g' means gram;
'I.M.' means intramuscular;
'I.U.' means international unit;
'I.V.' means intravenous;
'kg' means kilogram;
'L' means litre;
'm' means metre;
'mg' means milligram;
'mL' means millilitre;
'mm' means millimetre;
'mmol' means millimole;
'Sch. 3' means the Third Schedule to these Determinations;
'the Act' means the *National Health Act 1953*;
'the Regulations' means the National Health (Pharmaceutical Benefits) Regulations made under the Act;
'the Managing Director' means the Managing Director of the Health Insurance Commission.

4. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the First Schedule to these Determinations in relation to a drug or medicinal preparation referred to in subsection 85 (2) of the Act the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of the Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit when prescribed by a medical practitioner.

5. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the Second Schedule to these Determinations in relation to a drug or medicinal preparation referred to in subsection 85 (2) of the Act the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of the Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a

pharmaceutical benefit referred to in subsection 88 (1A) of the Act for the supply of which a participating dental practitioner is authorized to write a prescription.

6. The purposes set out in the column headed 'Purposes' in Part 2 of the First Schedule to these Determinations are the only purposes for which a medical practitioner may prescribe the maximum quantities and numbers of repeats specified in that Part in relation to those pharmaceutical benefits specified in that same Part.

7. The purposes set out in the column headed 'Purposes' in Part 2 of the Third Schedule to these Determinations are the only purposes for which a participating dental practitioner may prescribe the maximum quantities specified in that Part in relation to those pharmaceutical benefits specified in that same Part.

8. The manner of administration, if any, set out in the column headed 'Manner of administration' in relation to a pharmaceutical benefit, the name of which is specified in:

   (a) the First Schedule to these Determinations, is the only manner in which a medical practitioner may, in a prescription, direct the pharmaceutical benefit to be administered; or

   (b) the Second Schedule to these Determinations, is the only manner in which a participating dental practitioner may, in a prescription, direct the pharmaceutical benefit to be administered.

9. The maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion is:

   (a) where the name of the pharmaceutical benefit is specified—

      (i) in Part 1 of the First Schedule to these Determinations—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

      (ii) in Part 2 of the First Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

      (iii) in Part 1 of the Second Schedule to these Determinations—the quantity or number, if any, specified in that Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

      (iv) in Part 2 of the Second Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

      (v) if reference is made to the Third Schedule to these Determinations in the column headed 'Maximum quantity' in the First Schedule to these Determinations—the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Third Schedule to these Determinations in relation to the form of the pharmaceutical benefit; or

   (b) in any other case—the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Third Schedule to these Determinations in relation to the form of the pharmaceutical benefit.

10. The maximum number of occasions, if any, on which the supply of a pharmaceutical benefit may, in one prescription, be directed by a medical practitioner to be repeated is:

(a) where the name of the pharmaceutical benefit is specified—

(i) in Part 1 of the First Schedule to these Determinations—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum number of repeats' in relation to the pharmaceutical benefit; or

(ii) in Part 2 of the First Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Maximum number of repeats' in relation to the pharmaceutical benefit; or

(iii) if reference is made to the Third Schedule to these Determinations in the column headed 'Maximum number of repeats' in the First Schedule to these Determinations—the quantity or number, if any, specified in the column headed 'Maximum number of repeats' in the Third Schedule to these Determinations in relation to the form of the pharmaceutical benefit; or

(b) in any other case—the number, if any, specified in the column headed 'Maximum number of repeats' in the Third Schedule to these Determinations in relation to the form of the pharmaceutical benefit.

11. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the First Schedule to these Determinations:

(a) Where a class of persons is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;

(b) Where a disease or condition is specified in the column headed 'Purposes'—

(i) if subsubparagraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or

(ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;

(c) Where a purpose is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for that purpose;

(d) Where it is specified in column headed 'Purposes' that compliance with authority procedures set out in subparagraph 11 (d) is required—that an application for the authority of the Managing Director in relation to the supply of the pharmaceutical benefit has been prepared by a medical practitioner:

(i) by writing in ink on a form approved by the Managing Director; or

(ii) by means of a computer on the form referred to in subparagraph (i); or

(iii) by means of a computer on a form approved for the purpose by the Managing Director, in the format approved by the Managing Director; or

(iv) by another method approved in writing by the Managing Director;

and that:

4

(v) (A) the application has been forwarded to the Managing Director by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist; and

(B) the Managing Director has approved the application; or

(vi) (A) the details of the application have been telephoned to the Managing Director by the medical practitioner; and

(B) the Managing Director has informed the medical practitioner that the application has been approved and has informed the medical practitioner of the telephone approval number that applies to that application; and

(C) the medical practitioner has endorsed on the form the telephone approval number referred to in subsubparagraph (B); and

(D) the medical practitioner has forwarded the Health Insurance Commission copy of the form to reach the Managing Director within 7 days after the date on which the details of the application were telephoned.

12. Where a medical practitioner makes an application under subsubparagraph 10 (d) (iv) and the Managing Director approves the application, the Managing Director shall record the approval on a numbered authority and—

(a) where, in the approval, the Managing Director requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or

(b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person for whom the pharmaceutical benefit is to be supplied.

13. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the Third Schedule to these Determinations:

(a) Where a class of persons is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;

(b) Where a disease or condition is specified in the column headed 'Purposes'—

(i) if subsubparagraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or

(ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;

(c) Where a purpose is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for that purpose.

14. The name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed 'Brand' in the First or Second Schedule to these Determinations in relation to a drug or medicinal preparation the name of which is specified in that Schedule is or are the brand or brands under which the drug or medicinal preparation may be supplied under Part VII of the Act as a pharmaceutical benefit:

5

Letters	*Manufacturer's Name*
AA	ASTA Medica, Degussa Australia Pty Limited
AB	Abbott Australasia Pty Ltd
AD	Amrad Pharmaceuticals Pty Ltd
AF	Alphapharm Pty Limited
AG	Allergan Australia Pty Ltd
AM	Ames Product Group, Division of Bayer Diagnostics Aust. Pty Limited
AP	Astra Pharmaceuticals Pty Ltd
AQ	Alcon Laboratories (Australia) Pty Ltd
AY	Ayerst Laboratories Pty Ltd, Division of Wyeth Australia Pty Limited
BA	Boots Pharmaceuticals, A Division of The Boots Company (Australia) Pty Ltd
BC	Bristol Laboratories, A Division of Bristol-Myers Squibb Pharmaceuticals Pty Ltd
BF	Pilkington Barnes Hind Pty Limited
BL	David Bull Laboratories Pty Ltd
BN	Bayer Australia Limited
BO	Boehringer Mannheim Australia Pty Limited
BQ	Bristol–Myers Squibb Pharmaceuticals Pty Ltd
BT	The Boots Company (Australia) Pty Ltd
BW	Wellcome Australia Limited
BX	Baxter Healthcare Pty Ltd
BY	Boehringer Ingelheim Pty Limited
BZ	Boucher & Muir Pty Limited
CC	ConvaTec
CG	Ciba-Geigy Australia Limited
CL	Cilag Pty Limited
CS	Commonwealth Serum Laboratories Limited
DL	Dista Products (Australia) & Company
DP	Douglas Pharmaceuticals Aust. Ltd
DW	Delta West Pty Ltd
EG	Eagle Pharmaceuticals Pty Ltd
EO	Ego Pharmaceuticals Pty Ltd
EX	Essex Laboratories
FA	Faulding Pharmaceuticals, A Division of F. H. Faulding & Co. Limited
FC	Fisons Pty Ltd
FM	Fawns and McAllan Pty Ltd
FR	Charles E. Frosst, Division of Merck Sharp & Dohme (Australia) Pty Ltd
GA	Galderma Australia Pty Ltd
GL	Glaxo Australia Pty Ltd
GP	GP Laboratories, A Division of Pfizer Pty Limited
HA	Hamilton Laboratories Pty Ltd
HG	Hypoguard (Exports) Ltd, U.K.
HP	Hoechst Australia Limited
IC	ICI Australia Operations Pty Ltd
IQ	The Ioquin Company
JC	Janssen-Cilag Pty Ltd
JP	Janssen Pharmaceutica Pty Ltd
JT	Johnson & Johnson Pacific Pty Limited
KN	Knoll AG, Germany
KR	Kenral Division of Upjohn Pty Limited
LE	Lederle Laboratories Division, Cyanamid Australia Pty Ltd
LH	Lipha Pharmaceuticals, London, U.K.
LY	Eli Lilly Australia Pty Limited
MB	May & Baker, Division of Rhône-Poulenc Rorer Australia Pty Ltd
MD	Macarthur Research, A Division of Syntex Australia Limited
MG	J. McGloin Pty Ltd
MJ	Mead Johnson
MK	Merck Sharp & Dohme (Australia) Pty Ltd
ML	Marion Merrell Dow Australia Pty Ltd
MM	3M Pharmaceuticals Australia Pty Ltd
MS	MediSense Australia Pty Ltd
NA	National Diagnostic Products (Australia) Pty Ltd
NE	Norgine Pty Limited
NN	Nelson Laboratories, Division of Laboratories Pharm-a-care Pty Ltd
NO	Novo Nordisk Pharmaceuticals Pty Ltd
NR	Nordia, Denmark
NS	Nicholas Products Pty Limited
NT	Nestlé Australia Ltd
NU	Nutricia
OL	Owen Laboratories, Division of Galderma Australia Pty Ltd
OP	Organon Pharmaceuticals, A division of Organon (Australia) Pty Limited
OR	Organon (Australia) Pty Limited
OT	Organon Teknika Pty Ltd
PD	Parke Davis Pty Ltd
PF	Pfizer Pty Limited
PP	Petrus Pharmaceuticals
PS	Pharmacia (Australia) Pty Ltd
PV	Pasteur Mérieux Sérums & Vaccins, Division of Rhône-Poulenc Rorer Australia Pty Ltd
PY	Procter & Gamble Pharmaceuticals Australia Pty Ltd
QM	Qualimed, A Division of Cassenne Pty Limited
RC	Reckitt & Colman Pharmaceuticals
RL	Roussel Uclaf Australia Pty Limited
RO	Roche Products Pty Ltd
RR	Rorer Consumer, Division of Rhône-Poulenc Rorer Australia Pty Ltd
SB	Scientific Hospital Supplies (Australia) Pty Ltd
SC	Schering Pty Ltd, Australian subsidiary of Schering AG, Berlin
SD	Syntex Australia Limited
SE	Servier Laboratories (Aust.) Pty Ltd
SG	Serono Australia Pty Ltd
SH	Schering-Plough Pty Ltd
SI	Sigma Company Limited
SJ	Sharpe Laboratories Pty Ltd
SK	SmithKline Beecham (Australia) Pty Ltd
SN	Smith & Nephew (Aust.) Pty Ltd
SR	Searle Australia Pty Ltd
SU	Sauter Laboratories (Aust.) Pty Ltd
SV	Stafford-Miller Limited
SW	Sanofi Winthrop
SY	Schering AG
SZ	Sandoz Australia Pty Ltd
UP	Upjohn Pty Limited
UW	United Works of Pharmaceutical and Dietetic Products, Hungary
WE	Wille Laboratories Pty Ltd
WT	Whitehall Laboratories Pty Limited
WW	Wm R. Warner
WY	Wyeth Australia Pty Limited

FIRST SCHEDULE — PART 1

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Acetazolamide	Tablet 250 mg	Oral	100	3	LE
Acetazolamide Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg acetazolamide, vial (with required solvent)	Injection	1	..	LE
Acetylcysteine Sodium	Solution for inhalation equivalent to 200 mg acetylcysteine per mL, 10 mL	Inhalation	5	3	BQ
Acyclovir	Eye ointment 30 mg per g, 4.5 g	Application to the eye	1	..	BW
	Tablet 200 mg	Oral	50	..	AD, BW
	Tablets 200 mg, 90	Oral	1	2	AD, BW
	Tablets 400 mg, 70	Oral	1	..	BW
	Tablets 800 mg, 35	Oral	1	..	AD, BW
Adrenaline	Eye drops 5 mg per mL, 7.5 mL	Application to the eye	1	5	BF
Adrenaline Acid Tartrate	Injection equivalent to adrenaline 1 in 1,000, 1 mL	Injection	5	1	AP
Adrenaline Hydrochloride	Eye drops equivalent to 10 mg adrenaline per mL, 10 mL	Application to the eye	1	5	AG
	Eye drops equivalent to 20 mg adrenaline per mL, 10 mL	Application to the eye	1	5	AG
"Albumaid XPXT"	Oral powder 200 g	Oral	20	5	SB
"Alfaré"	Oral powder 400 g	Oral	8	5	NT
Allopurinol	Capsule 100 mg	Oral	200	2	FM
	Capsule 300 mg	Oral	60	2	FM
	Tablet 100 mg	Oral	200	2	AF, BW
	Tablet 300 mg	Oral	60	2	AF, BW
Alprazolam	Tablet 250 micrograms	Oral	50	..	AF, KR, UP
	Tablet 500 micrograms	Oral	50	..	AF, KR, UP
	Tablet 1 mg	Oral	50	2	AF, KR, UP
Alprenolol Hydrochloride	Tablet 100 mg	Oral	100	5	AP
Alteplase	Injection set containing 1 vial 50 mg in 2.333 g dry powder, 1 vial sterile water for injection 50 mL and 1 transfer cannula	Injection	2	..	BY
Aluminium Hydroxide, Dried	Oral suspension 321 mg per 5 mL, 500 mL	Oral	2	5	WT
Aluminium Hydroxide, Dried with Light Kaolin or Light Kaolin (Natural)	Oral suspension 137 mg-1 g per 5 mL, 500 mL	Oral	1	2	WT
Aluminium Hydroxide, Dried with Magnesium Hydroxide	Oral suspension 200 mg-200 mg per 5 mL, 500 mL	Oral	2	5	PD, WW
	Oral suspension 215 mg-80 mg per 5 mL, 500 mL	Oral	2	5	WT
	Tablet 200 mg-200 mg	Oral	200	5	PD, WW
Aluminium Hydroxide, Dried with Magnesium Hydroxide and Oxethazaine	Oral suspension 306 mg-97.5 mg-10 mg per 5 mL, 500 mL	Oral	2	5	WT
Aluminium Hydroxide, Dried with Magnesium Trisilicate and Magnesium Hydroxide	Oral suspension 250 mg-120 mg-120 mg per 5 mL, 500 mL	Oral	2	5	FM
	Tablet 250 mg-120 mg-120 mg	Oral	200	5	FM
Amantadine Hydrochloride	Capsule 100 mg	Oral	100	5	BT, CG
Amiloride Hydrochloride	Tablet 5 mg	Oral	100	1	AF, MK
Aminacrine Hydrochloride	Eye drops 3 mg in 15 mL	Application to the eye	1	2	SI
Aminoglutethimide	Tablet 250 mg	Oral	100	5	CG

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
"Aminogran Food Supplement"	Oral powder 500 g	Oral	4	5	GL
"Aminogran Mineral Mixture"	Oral powder 250 g	Oral	1	5	GL
Aminophylline	Injection 250 mg in 10 mL ampoule	I.V. injection	5	..	SI
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Amiodarone Hydrochloride	Tablet 100 mg	Oral	30	5	AF, SW
	Tablet 200 mg	Oral	30	5	AF, SW
Amitriptyline Hydrochloride	Tablet 10 mg	Oral	50	2	AF, MK
	Tablet 25 mg	Oral	50	2	AF, MK
	Tablet 50 mg	Oral	50	2	AF
Amlodipine Besylate	Tablet equivalent to 5 mg amlodipine	Oral	30	5	PF
	Tablet equivalent to 10 mg amlodipine	Oral	30	5	PF
Ammonium Chloride	Tablet 500 mg	Oral	100	5	FM
Amoxycillin Trihydrate	Capsule equivalent to 250 mg amoxycillin	Oral	20	1	AF, CS, FC, SI, SK
	Capsule equivalent to 500 mg amoxycillin	Oral	20	1	AF, CS, FC, SI, SK
	Sachet containing oral powder equivalent to 3 g amoxycillin	Oral	1	..	CS, SK
	Tablet, chewable, equivalent to 250 mg amoxycillin	Oral	20	1	CS, SK
Amoxycillin Trihydrate with Potassium Clavulanate	Tablet equivalent to 250 mg amoxycillin-125 mg clavulanic acid	Oral	15	1	CS, SK
	Tablet equivalent to 500 mg amoxycillin-125 mg clavulanic acid	Oral	15	1	CS, SK
Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL, 75 mL	Oral	1	1	SK
	Powder for oral suspension equivalent to 250 mg amoxycillin-62.5 mg clavulanic acid per 5 mL, 75 mL	Oral	1	..	SK
Amoxycillin Trihydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL	Oral	1	1	AF, CS, FC, SI, SK
	Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL	Oral	1	..	AF, CS, FC, SI, SK
	Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL, 20 mL	Oral	1	1	SK
Amphotericin	Lozenge 10 mg	Oral	20	1	BQ
Amphotericin with any determined brand of sterilised Water for Injections or other solvent	Injection 50 mg vial (with required solvent)	Injection	1	..	BQ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Ampicillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg ampicillin, vial (with required solvent)	Injection	5	1	CS, FC
	Injection equivalent to 1 g ampicillin, vial (with required solvent)	Injection	5	1	CS, FC
Ampicillin Trihydrate	Capsule equivalent to 250 mg ampicillin	Oral	24	1	AF, SK
	Capsule equivalent to 500 mg ampicillin	Oral	24	..	AF, SK
Antazoline Phosphate with Naphazoline Hydrochloride	Eye drops 5 mg-500 micrograms per mL, 15 mL	Application to the eye	1	5	AG
Antazoline Sulfate with Naphazoline Nitrate	Eye drops 5 mg-250 micrograms per mL, 10 mL	Application to the eye	1	5	CG
Aspirin	Tablet 300 mg	Oral	100	1	SI
	Tablet 325 mg (buffered)	Oral	100	1	MJ
	Tablet 650 mg (enteric coated)	Oral	100	2	SK
	Tablet, dispersible, 300 mg	Oral	100	1	RC
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Atenolol	Tablet 50 mg	Oral	30	5	AF, IC
Atropine Sulfate	Eye drops 5 mg per mL, 15 mL	Application to the eye	1	2	SI
	Eye drops 10 mg per mL, 15 mL	Application to the eye	1	2	SI
	Injection 600 micrograms in 1 mL ampoule	Injection	5	1	AP
	Injection 1.2 mg in 1 mL ampoule	Injection	5	1	AP
	Tablet 600 micrograms	Oral	100	2	FM
Auranofin	Tablet 3 mg	Oral	60	5	SK
Aurothioglucose	Injection 50 mg per mL, 10 mL	Injection	1	..	SH
Azathioprine	Tablet 25 mg	Oral	100	2	BW
	Tablet 50 mg	Oral	100	2	AF, BW
Baclofen	Tablet 10 mg	Oral	100	5	AF, CG
	Tablet 25 mg	Oral	100	5	AF, CG
"BCG Immunotherapeutic" (Bacillus Calmette-Guérin/ Connaught strain)	Single dose set comprising 3 vials powder for intravesical administration containing 2.2 to 6.4 x 10^8 CFU per vial and 3 vials diluent 1 mL	Intravesical administration	3	1	RR
"BCG-Tice" (Bacillus Calmette-Guérin/ Tice strain)	Ampoule containing powder for intravesical administration approximately 5 x 10^8 CFU	Intravesical administration	3	1	OT
Beclomethasone Dipropionate	Aqueous nasal spray (pump pack) 50 micrograms per dose, 200 doses	Nasal	1	1	GL, SH
	Aqueous nasal spray refill 50 micrograms per dose, 200 doses	Nasal	1	1	SH
	Aqueous nasal spray 50 micrograms per dose, 400 doses set containing 1 pump pack, 200 doses and 1 refill, 200 doses	Nasal	1	..	SH
	Capsule 100 micrograms	Inhalation by mouth	200	5	GL

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Pressurised inhalation 50 micrograms per dose, 200 doses	Inhalation by mouth	1	5	GL, SH
	Pressurised inhalation 100 micrograms per dose, 200 doses	Inhalation by mouth	1	5	GL
	Pressurised inhalation 250 micrograms per dose, 200 doses	Inhalation by mouth	1	5	GL
Bendrofluazide	Tablet 5 mg	Oral	100	1	BT
Benzathine Penicillin	Injection 1.8 g in 4 mL disposable syringe	Injection	1	..	WY
Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium	Injection set containing 1 vial powder for injection 450 mg-300 mg-187 mg and 2 mL sterilised water for injections	Injection	1	..	WY
Benzhexol Hydrochloride	Tablet 2 mg	Oral	200	2	LE
	Tablet 5 mg	Oral	200	1	LE
Benztropine Mesylate	Injection 2 mg in 2 mL ampoule	Injection	5	..	MK
	Tablet 2 mg	Oral	60	2	MK
Benzydamine Hydrochloride	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	Topical	1	1	MM
Benzyl Benzoate	Application 50 g in 200 mL	Application	1	2	MG
Benzylpenicillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 600 mg benzylpenicillin, vial (with required solvent)	Injection	10	1	CS
	Injection equivalent to 3 g benzylpenicillin, vial (with required solvent)	Injection	10	..	CS
Betamethasone	Tablet 500 micrograms	Oral	30	4	SH
Betamethasone Acetate with Betamethasone Sodium Phosphate	Injection 3 mg-3.9 mg in 1 mL ampoule	Injection	5	..	SH
Betamethasone Dipropionate	Cream equivalent to 500 micrograms betamethasone per g, 15 g	Application	1	1	EX, SH
	Ointment equivalent to 500 micrograms betamethasone per g, 15 g	Application	1	1	EX, SH
	Scalp lotion equivalent to 500 micrograms betamethasone per g, 30 mL	Application to the scalp	1	..	EX, SH
Betamethasone Valerate	Cream equivalent to 200 micrograms betamethasone per g, 100 g	Application	2	..	GL, SH
	Cream equivalent to 500 micrograms betamethasone per g, 15 g	Application	1	1	GL, SH
	Gel equivalent to 500 micrograms betamethasone per g, 15 g	Application	1	1	GL
	Ointment equivalent to 200 micrograms betamethasone per g, 100 g	Application	2	..	SH
	Ointment equivalent to 500 micrograms betamethasone per g, 15 g	Application	1	1	GL, SH

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Betaxolol Hydrochloride	Eye drops, solution, equivalent to 5 mg betaxolol per mL, 5 mL	Application to the eye	1	5	AQ
	Eye drops, suspension, equivalent to 2.5 mg betaxolol per mL, 5 mL	Application to the eye	1	5	AQ
Bethanechol Chloride	Injection 5 mg in 1 mL ampoule	Injection	2	..	MK
	Tablet 10 mg	Oral	100	2	HA, MK
Biperiden Hydrochloride	Tablet 2 mg	Oral	200	2	KN
Bisacodyl	Enemas 10 mg in 5 mL, 25	Enema	1	2	FC
	Suppositories 10 mg, 10		3	5	BY
	Suppositories 10 mg, 12		3	4	PP
	Tablet 5 mg	Oral	200	2	FC
Bismuth Subcitrate	Tablet equivalent to 107.7 mg bismuth	Oral	112	2	PD
Bleomycin Sulfate with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 15 units bleomycin activity (with required solvent)	Injection	10	..	BQ
Bromocriptine Mesylate	Capsule equivalent to 5 mg bromocriptine	Oral	60	5	SZ
	Capsule equivalent to 10 mg bromocriptine	Oral	100	5	SZ
	Tablet equivalent to 2.5 mg bromocriptine	Oral	30	..	SZ
Budesonide	Aqueous nasal spray (pump pack) 100 micrograms per dose, 200 doses	Nasal	1	..	AP
	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	1	5	AP
	Nebuliser suspension 1 mg in 2 mL single dose units, 30	Inhalation	1	5	AP
	Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Pressurised inhalation 50 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Pressurised inhalation 100 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Pressurised inhalation 200 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
Bumetanide	Tablet 1 mg	Oral	100	1	AP
Busulfan	Tablet 2 mg	Oral	100	..	BW
Calcitonin (Human)—Synthetic	Injection 0.5 mg with 1 mL ampoule solvent	Injection	15	5	CG
Calcitonin (Pork)	Injection 160 I.U. vial with 2 mL vial gelatin solvent	Injection	20	5	MB

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Calcitriol	Capsule 0.25 microgram	Oral	100	5	RO
Calcium Carbonate	Tablet 1.5 g (equivalent to 600 mg calcium)	Oral	120	1	LE
	Tablet, chewable, 1.25 g (equivalent to 500 mg calcium)	Oral	120	1	MM
Calcium Carbonate with Calcium Lactate-Gluconate	Tablet, compound effervescent, 800 mg-5.23 g (equivalent to 1 g calcium)	Oral	60	1	SZ
Calcium Folinate	Injection equivalent to 3 mg folinic acid in 1 mL ampoule	Injection	5	..	BL
	Tablet equivalent to 15 mg folinic acid	Oral	10	..	BL, LE
Captopril	Tablet 12.5 mg	Oral	90	5	BQ
	Tablet 25 mg	Oral	90	5	BQ
	Tablet 50 mg	Oral	90	5	BQ
Carbachol	Eye drops 15 mg per mL, 15 mL	Application to the eye	1	5	AQ
	Eye drops 30 mg per mL, 15 mL	Application to the eye	1	5	AQ
Carbamazepine	Oral suspension 100 mg per 5 mL, 300 mL	Oral	1	5	CG
	Tablet 100 mg	Oral	200	2	CG
	Tablet 200 mg	Oral	200	2	AF, CG
	Tablet 200 mg (controlled release)	Oral	200	2	CG
Carbimazole	Tablet 5 mg	Oral	200	2	NS
Carboplatin	Solution for I.V. injection 50 mg in 5 mL vial	Injection	2	..	BL, DW
	Solution for I.V. injection 150 mg in 15 mL vial	Injection	6	..	BL, DW
	Solution for I.V. injection 450 mg in 45 mL vial	Injection	2	..	BL, DW
Carmellose Sodium	Eye drops 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	4	5	AG
Cefaclor Monohydrate	Capsule equivalent to 250 mg cefaclor	Oral	15	1	LY
Cefaclor Monohydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL	Oral	1	1	LY
	Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL, 75 mL	Oral	1	..	LY
Cefotaxime Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cefotaxime, vial (with required solvent)	Injection	5	..	RL
	Injection equivalent to 2 g cefotaxime, vial (with required solvent)	Injection	5	..	RL
Cefotetan Disodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cefotetan, vial (with required solvent)	Injection	10	..	LE
	Injection equivalent to 2 g cefotetan, vial (with required solvent)	Injection	10	..	LE

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Ceftriaxone Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 250 mg ceftriaxone, vial (with required solvent)	Injection	1	..	RO
	Injection equivalent to 500 mg ceftriaxone, vial (with required solvent)	Injection	5	..	RO
	Injection equivalent to 1 g ceftriaxone, vial (with required solvent)	Injection	5	..	RO
	Injection equivalent to 2 g ceftriaxone, vial (with required solvent)	Injection	5	..	RO
Cephalexin	Capsule 250 mg (anhydrous)	Oral	20	1	AF, GL, LY
	Capsule 500 mg (anhydrous)	Oral	20	1	AF, GL, LY
Cephalexin with Purified Water B.P.	Granules for oral suspension 125 mg per 5 mL, 100 mL	Oral	1	1	AF, GL, LY
	Granules for oral suspension 250 mg per 5 mL, 100 mL	Oral	1	..	AF, GL, LY
Cephalothin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cephalothin, vial (with required solvent)	Injection	10	1	LY
Cephazolin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg cephazolin, vial (with required solvent)	Injection	5	..	LY, SI
	Injection equivalent to 1 g cephazolin, vial (with required solvent)	Injection	5	..	LY, SI
Charcoal, Activated	Tablet 300 mg	Oral	500	1	EG, MM, WE
Chlorambucil	Tablet 2 mg	Oral	100	2	BW
	Tablet 5 mg	Oral	100	2	BW
Chloramphenicol	Capsule 250 mg	Oral	16	..	PD
	Ear drops (aqueous) 5 mg per mL, 5 mL	Application to the ear	1	2	PD
	Eye drops 5 mg per mL, 10 mL	Application to the eye	1	2	PD, SI
	Eye ointment 10 mg per g, 4 g	Application to the eye	1	..	PD, SI
Chloramphenicol Sodium Succinate with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1.2 g chloramphenicol, vial (with required solvent)	Injection	3	..	PD
Chloramphenicol with Polymyxin B Sulfate	Eye drops 5 mg-5,000 units per mL, 10 mL	Application to the eye	1	2	PD
	Eye ointment 10 mg-5,000 units per g, 4 g	Application to the eye	1	..	PD
Chlorhexidine Gluconate	Solution 50 mg per mL, 200 mL		1	1	IC
Chloroquine Phosphate	Tablet 250 mg	Oral	100	..	FC
Chlorothiazide	Tablet 500 mg	Oral	100	1	AD
Chlorpromazine Hydrochloride	Injection 50 mg in 2 mL ampoule	Injection	10	..	MB
	Oral solution 25 mg per 5 mL, 100 mL	Oral	1	5	MB
	Tablet 10 mg	Oral	100	5	MB
	Tablet 25 mg	Oral	100	5	MB
	Tablet 100 mg	Oral	100	5	MB
Chlorpropamide	Tablet 250 mg	Oral	100	5	PF
Chlorthalidone	Tablet 25 mg	Oral	100	1	CG

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Cholestyramine	Sachets containing 4.7 g oral powder (equivalent to 4 g cholestyramine), 50	Oral	2	5	BQ
	Sachets containing 9.4 g oral powder (equivalent to 8 g cholestyramine), 50	Oral	1	5	BQ
Choline Theophyllinate	Elixir 50 mg per 5 mL, 500 mL	Oral	1	5	PD
Chorionic Gonadotrophin	Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL	Injection	1	5	OR, SG
	Injection set containing 3 ampoules powder for injection 1,000 units and 3 ampoules solvent 1 mL	Injection	1	5	SG
	Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL	Injection	1	5	OR
	Injection set containing 3 ampoules powder for injection 2,000 units and 3 ampoules solvent 1 mL	Injection	1	5	SG
	Injection set containing 1 ampoule powder for injection 5,000 units and 1 ampoule solvent 1 mL	Injection	1	5	OR, SG
Cimetidine	Tablet 200 mg	Oral	120	2	AF, SK
	Tablet 400 mg	Oral	60	2	AF, SK
	Tablet 800 mg	Oral	30	1	AF, SK
Cimetidine Hydrochloride	Tablet, effervescent, equivalent to 800 mg cimetidine	Oral	30	1	SK
Ciprofloxacin Hydrochloride	Tablet equivalent to 250 mg ciprofloxacin	Oral	14	..	BN
	Tablet equivalent to 500 mg ciprofloxacin	Oral	14	..	BN
	Tablet equivalent to 750 mg ciprofloxacin	Oral	14	..	BN
Cisapride Monohydrate	Tablet equivalent to 5 mg cisapride	Oral	90	5	JC
	Tablet equivalent to 10 mg cisapride	Oral	90	5	JC
	Oral suspension equivalent to 1 mg cisapride per mL, 200 mL	Oral	1	5	JC
Cisplatin	I.V. injection 10 mg in 10 mL vial	Injection	1	..	BL, DW
	I.V. injection 50 mg in 50 mL vial	Injection	1	..	BL, DW
	I.V. injection 100 mg in 100 mL vial	Injection	1	..	BL
Cladribine	Solution for I.V. infusion 10 mg in 10 mL single use vial	Injection	7	..	JC
Clindamycin Hydrochloride	Capsule equivalent to 150 mg clindamycin	Oral	25	..	UP
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for mixture equivalent to 75 mg clindamycin per 5 mL, 100 mL	Oral	1	..	UP
Clioquinol	Cream 10 mg per g, 30 g	Application	1	..	SI

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Clofibrate	Capsule 500 mg	Oral	100	5	AF, IC
Clomiphene Citrate	Tablet 50 mg	Oral	10	5	ML
Clomipramine Hydrochloride	Tablet 25 mg	Oral	50	2	CG
Clonazepam	Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	5	..	RO
	Paediatric oral drops 2.5 mg per mL, 10 mL	Oral	2	..	RO
	Tablet 500 micrograms	Oral	200	2	RO
	Tablet 2 mg	Oral	200	2	RO
Clonidine Hydrochloride	Tablet 100 micrograms	Oral	100	5	BY
	Tablet 150 micrograms	Oral	100	5	BY
Clotrimazole	Cream 10 mg per g, 20 g	Application	1	1	AF, BN, SH
	Lotion 10 mg per mL, 20 mL	Application	1	1	BN, SH
	Pessaries 100 mg, 6		1	..	BN, SH
	Pessary 500 mg		1	..	BN
	Vaginal cream 50 mg per 5 g, 35 g		1	..	BN, SH
	Vaginal cream 100 mg per 5 g, 20 g		1	..	BN
Cloxacillin Sodium	Capsule equivalent to 250 mg cloxacillin	Oral	24	..	AF
	Capsule equivalent to 500 mg cloxacillin	Oral	24	..	AF
Codeine Phosphate	Tablet 30 mg	Oral	20	..	FA, FM, MB
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Codeine Phosphate with Aspirin	Tablet 30 mg-325 mg	Oral	20	..	BW
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Codeine Phosphate with Paracetamol	Tablet 30 mg-500 mg	Oral	20	..	BW, FM, SW
Colchicine	Tablet 500 micrograms	Oral	100	2	FC
Colestipol Hydrochloride	Oral powder, sachets 5 g, 120	Oral	1	5	UP
Colistin Sulfomethate Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 150 mg colistin, vial (with required solvent)	Injection	5	..	WW
Copper Sulfate	Tablets, diagnostic compound, 36		2	3	AM
Cortisone Acetate	Tablet 5 mg	Oral	50	4	FC
	Tablet 25 mg	Oral	60	4	FC
Cyclophosphamide	Tablet 50 mg	Oral	50	2	PS
Cyclophosphamide with any determined brand of sterilised Water for Injections or other solvent	Injection 100 mg (anhydrous), vial (with required solvent)	Injection	10	..	PS
	Injection 200 mg (anhydrous), vial (with required solvent)	Injection	10	..	PS
	Injection 500 mg (anhydrous), vial (with required solvent)	Injection	2	..	PS
	Injection 1 g (anhydrous), vial (with required solvent)	Injection	1	..	PS
Cyproheptadine Hydrochloride	Tablet 4 mg (anhydrous)	Oral	100	2	FR
Cyproterone Acetate	Tablet 50 mg	Oral	20	5	SC
Cytarabine	Injection set containing 100 mg vial and 5 mL solvent	Injection	10	1	BL
	Injection set containing 500 mg vial and 10 mL solvent	Injection	2	1	BL
Dalteparin Sodium	Injection 5,000 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe	Injection	10	..	FC
Danazol	Capsule 100 mg	Oral	100	5	AF, SW

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Capsule 200 mg	Oral	100	5	AF, SW
Dantrolene Sodium	Capsule 25 mg	Oral	100	2	PY
	Capsule 50 mg	Oral	100	2	PY
"De-Lact Infant"	Oral powder 500 g	Oral	4	1	SJ
Demeclocycline Hydrochloride	Capsule 150 mg	Oral	100	3	LE
Desipramine Hydrochloride	Tablet 25 mg	Oral	50	2	CG
Desmopressin	Intranasal solution 100 micrograms (acetate) per mL, 2.5 mL dropper bottle	Nasal	5	2	FC
Dexamethasone	Eye drops 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
	Tablet 500 micrograms	Oral	30	4	FC
	Tablet 4 mg	Oral	30	4	FC
Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin	Ear drops 500 micrograms (dexamethasone)-5 mg-50 micrograms per mL, 8 mL	Application to the ear	1	2	QM, RL
Dexamethasone Sodium Phosphate	Injection equivalent to 4 mg dexamethasone phosphate in 1 mL ampoule	Injection	5	..	MK
	Injection equivalent to 8 mg dexamethasone phosphate in 2 mL vial	Injection	5	1	MK
	Injection equivalent to 120 mg dexamethasone phosphate in 5 mL vial	Injection	1	..	MK
Dexamethasone with Framycetin Sulfate and Gramicidin	Ear ointment 500 micrograms-5 mg-50 micrograms per g, 5 g	Application to the ear	1	2	QM, RL
Dexamphetamine Sulfate	Tablet 5 mg	Oral	100	5	SI
Dextran 40 with Glucose	Intravenous infusion 100 mg per mL-139 mmol (anhydrous) per 500 mL, 500 mL	Injection	3	..	PS
Dextran 40 with Sodium Chloride	Intravenous infusion 100 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 with Sodium Chloride	Intravenous infusion 60 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Diazepam	Injection 10 mg in 2 mL ampoule	Injection	5	..	BL
	Tablet 2 mg	Oral	50	..	AF, RO, SU
	Tablet 5 mg	Oral	50	..	AF, RO, SU
Dichlorphenamide	Tablet 50 mg	Oral	50	6	SI
Diclofenac Potassium	Tablets 25 mg, 20	Oral	1	..	CG
	Tablets 50 mg, 20	Oral	1	..	CG
Diclofenac Sodium	Suppository 100 mg		40	3	CG
	Tablet 25 mg (enteric coated)	Oral	100	3	CG
	Tablet 50 mg (enteric coated)	Oral	50	3	AF, CG
	Tablets 50 mg (enteric coated), 20	Oral	1	..	AF
Dienoestrol	Cream 500 micrograms per 5 g, 85 g		1	1	JC
Diflunisal	Tablet 250 mg	Oral	100	3	MK
	Tablet 500 mg	Oral	50	3	MK
"Digestelact"	Oral powder 500 g	Oral	5	1	SJ
Digoxin	Paediatric oral solution 50 micrograms per mL, 100 mL	Oral	1	3	BW
	Tablet 62.5 micrograms	Oral	200	1	BW
	Tablet 250 micrograms	Oral	100	1	BW

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Dihydroergotamine Mesylate	Injection 1 mg in 1 mL ampoule	Injection	5	..	SZ
Dihydrotachysterol	Capsule 125 micrograms	Oral	100	5	SW
Diltiazem Hydrochloride	Capsule 90 mg (sustained release)	Oral	60	5	IC
	Capsule 120 mg (sustained release)	Oral	60	5	IC
	Capsule 180 mg (controlled delivery)	Oral	28	5	IC
	Capsule 240 mg (controlled delivery)	Oral	28	5	IC
	Tablet 60 mg	Oral	90	5	IC
Diphenoxylate Hydrochloride with Atropine Sulfate	Tablet 2.5 mg-25 micrograms	Oral	20	..	SR
Diphtheria and Tetanus Vaccine, Adsorbed	Injection 0.5 mL ampoule	Injection	3	..	CS
Diphtheria and Tetanus Vaccine, Adsorbed, Diluted	Injection 0.5 mL ampoule. For immunization of adults and children over the age of 8 years	Injection	3	..	CS
Diphtheria Antitoxin	Injection 10,000 units ampoule	Injection	2	1	CS
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed	Injection 0.5 mL ampoule	Injection	3	..	CS
Diphtheria Vaccine, Adsorbed	Injection 0.5 mL ampoule	Injection	2	1	CS
Diphtheria Vaccine, Adsorbed, Diluted	Injection 0.5 mL ampoule. For immunization of adults and children over the age of 8 years	Injection	2	..	CS
Dipivefrine Hydrochloride	Eye drops 1 mg per mL, 10 mL	Application to the eye	1	5	AG
Disodium Etidronate	Tablet 200 mg	Oral	60	5	PY
Disopyramide	Capsule 100 mg	Oral	100	5	RL
	Capsule 150 mg	Oral	100	5	RL
Disopyramide Phosphate	Capsule equivalent to 100 mg disopyramide	Oral	100	5	SR
	Capsule equivalent to 150 mg disopyramide	Oral	100	5	SR
Docusate Sodium with Bisacodyl	Suppositories 100 mg-10 mg, 5		6	5	FM
Domperidone	Tablet 10 mg	Oral	25	..	JC
Dothiepin Hydrochloride	Capsule 25 mg	Oral	50	2	AF, BT
	Tablet 75 mg	Oral	30	2	AF, BT
Doxepin Hydrochloride	Capsule equivalent to 10 mg doxepin	Oral	50	2	AF, PF
	Capsule equivalent to 25 mg doxepin	Oral	50	2	AF, PF
	Tablet equivalent to 50 mg doxepin	Oral	50	2	AF
Doxorubicin Hydrochloride	Solution for I.V. injection or intravesical administration 10 mg in 5 mL single dose vial	Injection or intravesical administration	4	..	BL, PS
	Solution for I.V. injection or intravesical administration 20 mg in 10 mL single dose vial	Injection or intravesical administration	4	..	BL, PS
	Solution for I.V. injection or intravesical administration 50 mg in 25 mL single dose vial	Injection or intravesical administration	3	..	BL, PS

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Doxycycline Hydrochloride	Capsule equivalent to 50 mg doxycycline (containing enteric coated pellets)	Oral	25	5	FA
	Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets)	Oral	7	1	FA
	Tablet equivalent to 50 mg doxycycline	Oral	25	5	AF, PF
	Tablet equivalent to 100 mg doxycycline	Oral	7	1	AF, PF
"Duocal"	Compound powder 400 g	Oral	8	5	SB
Dydrogesterone	Tablet 10 mg	Oral	50	5	JC
Econazole Nitrate	Cream 10 mg per g, 20 g	Application	1	1	BQ, SK
	Cream 75 mg per 5 g, 35 g	Application	1	..	BQ
	Lotion 10 mg per mL, 20 mL	Application	1	1	SK
	Pessaries 150 mg, 3		1	..	BQ, SK
Ecothiopate Iodide	Eye drops 300 micrograms per mL (1.5 mg and 5 mL vial of solvent)	Application to the eye	1	5	AY
	Eye drops 600 micrograms per mL (3 mg and 5 mL vial of solvent)	Application to the eye	1	5	AY
	Eye drops 1.25 mg per mL (6.25 mg and 5 mL vial of solvent)	Application to the eye	1	5	AY
	Eye drops 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)	Application to the eye	1	5	AY
Enalapril Maleate	Tablet 5 mg	Oral	30	5	AD, MK
	Tablet 10 mg	Oral	30	5	AD, MK
	Tablet 20 mg	Oral	30	5	AD, MK
Enoxacin	Tablet 400 mg	Oral	14	1	FA
Enoxaparin Sodium	Injection 20 mg in 0.2 mL pre-filled syringe	Injection	10	..	RR
	Injection 40 mg in 0.4 mL pre-filled syringe	Injection	10	..	RR
Epirubicin Hydrochloride	Solution for I.V. injection 10 mg in 5 mL single dose vial	Injection	4	..	PS
	Solution for I.V. injection 20 mg in 10 mL single dose vial	Injection	4	..	PS
	Solution for I.V. injection 50 mg in 25 mL single dose vial	Injection	3	..	PS
Ergocalciferol	Tablet 250 micrograms	Oral	100	5	BT
Ergometrine Maleate	Injection 250 micrograms in 1 mL ampoule	Injection	5	..	BL
Ergotamine Tartrate	Capsule 1 mg	Oral	50	2	PD
Ergotamine Tartrate with Caffeine	Suppositories 2 mg-100 mg, 5		1	2	SZ
Erythromycin	Capsule 125 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule 175 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule 250 mg (containing enteric coated pellets)	Oral	25	1	FA
	Injection 100 mg in 2 mL ampoule	I.M. injection	5	..	AB
	Tablet 250 mg (enteric coated)	Oral	25	1	UP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Erythromycin Estolate	Oral suspension equivalent to 125 mg erythromycin per 5 mL, 100 mL	Oral	1	1	LY
	Paediatric oral drops equivalent to 100 mg erythromycin per mL, 10 mL	Oral	1	1	LY
Erythromycin Ethyl Succinate	Tablet equivalent to 400 mg erythromycin	Oral	25	1	AB, AF
Erythromycin Ethyl Succinate with Purified Water B.P.	Granules for oral suspension equivalent to 200 mg erythromycin per 5 mL, 100 mL	Oral	1	1	AB, AF
	Granules for oral suspension equivalent to 400 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Lactobionate	Intravenous infusion equivalent to 300 mg erythromycin, vial	Injection	5	..	AB
	Intravenous infusion equivalent to 1 g erythromycin, vial	Injection	5	..	AB
Erythromycin Stearate	Capsule equivalent to 250 mg erythromycin	Oral	25	1	AB
	Oral suspension equivalent to 125 mg erythromycin per 5 mL, 100 mL	Oral	1	1	AB
	Oral suspension equivalent to 250 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB
	Tablet equivalent to 250 mg erythromycin	Oral	25	1	AB
Ethacrynic Acid	Tablet 50 mg	Oral	50	3	MK
Ethinyloestradiol	Tablet 10 micrograms	Oral	200	1	GL
	Tablet 20 micrograms	Oral	200	1	GL
	Tablet 50 micrograms	Oral	200	1	GL
Ethosuximide	Capsule 250 mg	Oral	200	2	PD
	Oral solution 250 mg per 5 mL, 250 mL	Oral	1	4	PD
Ethynodiol Diacetate with Ethinyloestradiol	Pack containing 21 tablets 500 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Tablets 500 micrograms-50 micrograms, 21	Oral	4	2	SR
	Tablets 1 mg-50 micrograms, 21	Oral	4	2	SR
Etoposide	Capsule 50 mg	Oral	20	..	BQ
	Capsule 100 mg	Oral	10	..	BQ
	Solution for I.V. infusion 100 mg in 5 mL vial	Injection	5	..	BL, BQ
Etretinate	Capsule 10 mg	Oral	100	2	RO
	Capsule 25 mg	Oral	100	2	RO
Famotidine	Tablet 20 mg	Oral	60	2	AD, MK
	Tablet 40 mg	Oral	30	1	AD, MK
Felodipine	Tablet 2.5 mg (extended release)	Oral	30	5	AP, HP
	Tablet 5 mg (extended release)	Oral	30	5	AP, HP
	Tablet 10 mg (extended release)	Oral	30	5	AP, HP
Ferrous Gluconate	Elixir 300 mg per 5 mL, 100 mL	Oral	1	4	SW

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Ferrous Sulfate, Dried	Tablet 350 mg, equivalent to 105 mg ferrous iron (sustained release)	Oral	30	2	AB
Ferrous Sulfate, Dried with Folic Acid	Tablet 270 mg, equivalent to 80 mg ferrous iron-300 micrograms (sustained release)	Oral	30	2	AB
Flecainide Acetate	Tablet 50 mg	Oral	60	5	MM
	Tablet 100 mg	Oral	60	5	MM
Fluclorolone Acetonide	Cream 250 micrograms per g, 15 g	Application	1	1	SD
Flucloxacillin Magnesium with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL, 100 mL	Oral	1	..	CS, SK
	Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL, 100 mL	Oral	1	..	CS, SK
Flucloxacillin Sodium	Capsule equivalent to 250 mg flucloxacillin	Oral	24	..	AF, CS, FC, SK
	Capsule equivalent to 500 mg flucloxacillin	Oral	24	..	AF, CS, FC, SK
Flucloxacillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg flucloxacillin, vial (with required solvent)	Injection	5	..	CS, SK
	Injection equivalent to 1 g flucloxacillin, vial (with required solvent)	Injection	5	1	CS, SK
Fluconazole	Capsule 50 mg	Oral	28	5	PF
	Capsule 100 mg	Oral	28	5	PF
	Capsule 200 mg	Oral	28	5	PF
	Solution for I.V. infusion 100 mg in 50 mL vial	Injection	7	..	PF
	Solution for I.V. infusion 200 mg in 100 mL vial	Injection	7	..	PF
Fludrocortisone Acetate	Tablet 100 micrograms	Oral	200	1	BQ
Flumethasone Pivalate with Clioquinol	Ear drops 200 micrograms-10 mg per mL, 7.5 mL	Application to the ear	1	..	CG
Fluocortolone Pivalate with Fluocortolone Hexanoate	Cream 1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the eye	1	5	AG, AQ
Fluorometholone Acetate	Eye drops 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
Fluorouracil Sodium	Injection equivalent to 250 mg fluorouracil in 10 mL vial	Injection	20	..	BL
	Injection equivalent to 500 mg fluorouracil in 10 mL vial	Injection	10	..	BL
Fluoxetine Hydrochloride	Capsule equivalent to 20 mg fluoxetine	Oral	28	2	LY
	Oral solution equivalent to 20 mg fluoxetine per 5 mL, 140 mL	Oral	1	2	LY
Fluoxymesterone	Tablet 5 mg	Oral	100	3	UP
Flupenthixol Decanoate	Oily I.M. injection 20 mg in 1 mL ampoule	Injection	5	..	FC
	Oily I.M. injection 40 mg in 2 mL ampoule	Injection	5	..	FC
	Oily I.M. injection 100 mg in 1 mL ampoule	Injection	5	..	FC

Name of pharmaceutical benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Maximum number of repeats	Brand
Fluphenazine Decanoate	Injection 12.5 mg in 0.5 mL ampoule	Injection	5	..	BQ
	Injection 25 mg in 1 mL ampoule	Injection	5	..	BQ
	Injection 50 mg in 2 mL ampoule	Injection	5	..	BQ
Fluphenazine Hydrochloride	Tablet 1 mg	Oral	100	5	BQ
	Tablet 2.5 mg	Oral	100	5	BQ
	Tablet 5 mg	Oral	100	5	BQ
Flutamide	Tablet 250 mg	Oral	100	5	SH
Folic Acid	Tablet 500 micrograms	Oral	200	..	AF, SI
	Tablet 5 mg	Oral	200	1	AF, NN, SI
Fosfestrol Sodium	Tablet 120 mg	Oral	100	5	AA
Fosinopril Sodium	Tablet 10 mg	Oral	30	5	BQ
	Tablet 20 mg	Oral	30	5	BQ
Framycetin Sulfate	Eye/ear drops 5 mg per mL, 8 mL	Application to the eye/ear	1	2	RL
	Eye ointment 5 mg per g, 5 g	Application to the eye	1	..	RL
Frusemide	Tablet 20 mg	Oral	100	1	FM, HP
	Tablet 40 mg	Oral	100	1	AF, FM, HP
	Tablet 500 mg	Oral	50	3	FM, HP
Frusemide Sodium	Injection equivalent to 20 mg frusemide in 2 mL ampoule	Injection	5	..	AF, HP
	Oral solution equivalent to 10 mg frusemide per mL, 30 mL	Oral	1	3	HP
Fusidic Acid	Oral suspension 50 mg per mL, 90 mL	Oral	1	..	CS
Gabapentin	Capsule 300 mg	Oral	100	5	PD
	Capsule 400 mg	Oral	100	5	PD
Gas-gangrene Antitoxin, Mixed	Injection, 1 ampoule containing 10,000 units Perfringens; 5,000 units Septicum; 10,000 units Novyi	Injection	2	1	CS
Gemfibrozil	Tablet 600 mg	Oral	60	5	PD
Gentamicin Sulfate	Eye drops equivalent to 3 mg gentamicin per mL, 5 mL	Application to the eye	1	2	AG
	Injection equivalent to 40 mg gentamicin in 1 mL ampoule	Injection	10	1	BL
	Injection equivalent to 60 mg gentamicin in 1.5 mL ampoule	Injection	10	1	BL
	Injection equivalent to 80 mg gentamicin in 2 mL ampoule	Injection	10	1	BL, RL
Glibenclamide	Tablet 2.5 mg	Oral	100	5	HP
	Tablet 5 mg	Oral	100	5	AF, BO, HP
Gliclazide	Tablet 80 mg	Oral	100	5	SE
Glipizide	Tablet 5 mg	Oral	100	5	AF, PS
Glucagon Hydrochloride	Injection set containing 1 I.U. with 1 mL vial diluent	Injection	1	1	LY
	Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe	Injection	1	1	NO
Glucose	Intravenous infusion 278 mmol (anhydrous) per L, 1 L	Injection	5	1	AB, BX
	Intravenous infusion 1,387 mmol (anhydrous) per 500 mL, 500 mL	Injection	2	1	AB
Glucose and Ketone Indicator—Urine	Reagent strips, 50 (Keto-Diabur-Test 5000)		2	2	BO
	Reagent strips, 100 (Keto-Diastix)		1	2	AM
Glucose Indicator—Blood	Electrode strips, 50 (Advantage)		2	5	BO

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Electrode strips, 100 (ExacTech)		1	5	MS
	Electrode strips, 100 (Pen 2/ Companion 2)		1	5	MS
	Reagent strips, 50 (Accutrend Glucose)		2	5	BO
	Reagent strips, 50 (Betachek)		2	5	NA
	Reagent strips, 50 (BM-Test-BG)		2	5	BO
	Reagent strips, 50 (BM-Test-Glycemie 20-800)		2	5	BO
	Reagent strips, 50 (Glucofilm)		2	5	AM
	Reagent strips, 50 (Glucostix)		2	5	AM
	Reagent strips, 50 (Hypoguard GA)		2	5	HG
	Reagent strips, 50 (Hypoguard Supreme)		2	5	HG
Glucose Indicator—Urine	Dispenser, 4 m		1	2	LY
	Reagent strips, 100 (Clinistix)		1	2	AM
	Reagent strips, 100 (Diastix)		1	2	AM
Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate	Oral rehydration salts 3.56 g-470 mg-300 mg-530 mg per sachet, 10	Oral	1	..	MB
Glycerol	Suppositories 700 mg, 12		3	5	PP
	Suppositories 1.4 g, 12		3	5	PP
	Suppositories 2.8 g, 12		3	5	PP
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Glyceryl Trinitrate	Buccal/sublingual pressurised spray 400 micrograms per dose, 200 doses	Buccal/ sublingual	1	5	FC
	Ointment 20 mg per g, 60 g	Application	1	5	FC
	Tablets 600 micrograms, 100	Oral	1	5	BW
	Transdermal disc 16 mg	Transdermal	30	5	SR
	Transdermal disc 32 mg	Transdermal	30	5	SR
	Transdermal patch 16 mg	Transdermal	30	5	AP
	Transdermal patch 25 mg	Transdermal	30	5	CG
	Transdermal patch 32 mg	Transdermal	30	5	AP
	Transdermal patch 50 mg	Transdermal	30	5	CG
Goserelin Acetate	Subcutaneous implant equivalent to 3.6 mg goserelin in pre-filled injection applicator	Subcutaneous implantation	1	..	IC
Griseofulvin	Tablet 125 mg	Oral	100	2	SI
	Tablet 330 mg	Oral	28	2	SH
	Tablet 500 mg	Oral	28	2	IC, SI
Haloperidol	Injection 5 mg in 1 mL ampoule	Injection	10	..	SR
	Oral solution 2 mg per mL, 15 mL	Oral	1	5	SR
	Oral solution 2 mg per mL, 100 mL	Oral	1	5	SR
	Tablet 500 micrograms	Oral	100	5	SR
	Tablet 1.5 mg	Oral	100	5	SR
	Tablet 5 mg	Oral	50	5	SR
Haloperidol Decanoate	I.M. injection equivalent to 50 mg haloperidol in 1 mL ampoule	Injection	5	..	JC
	I.M. injection equivalent to 150 mg haloperidol in 3 mL ampoule	Injection	5	..	JC
Heparin Calcium	Injection 5,000 I.U. in 0.2 mL	Injection	5	5	CS, FC, SW
Heparin Sodium	Injection 5,000 units in 0.2 mL ampoule	Injection	5	5	BL, CS, FC

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Injection 5,000 units in 1 mL ampoule	Injection	5	5	BL, CS, FC
	Injection 25,000 units in 5 mL ampoule	Injection	2	5	FC
	Injection 35,000 units in 35 mL vial	Injection	12	5	BL, CS
	Injection (preservative-free) 5,000 I.U. in 5 mL ampoule	Injection	50	5	FC
Hexamine Hippurate	Tablet 1 g	Oral	100	5	MM
Homatropine Hydrobromide	Eye drops 20 mg per mL, 15 mL	Application to the eye	1	2	AQ
	Eye drops 50 mg per mL, 15 mL	Application to the eye	1	2	AQ
Hydralazine Hydrochloride	Tablet 25 mg	Oral	200	2	AF
	Tablet 50 mg	Oral	200	2	AF
Hydrochlorothiazide	Tablet 25 mg	Oral	100	1	MK
	Tablet 50 mg	Oral	100	1	MK
Hydrochlorothiazide with Amiloride Hydrochloride	Tablet 50 mg-5 mg	Oral	100	1	AF, MK
Hydrochlorothiazide with Triamterene	Tablet 25 mg-50 mg	Oral	100	1	AF, SK
Hydrocortisone	Cream 10 mg per g, 50 g	Application	1	1	EO
	Eye drops 5 mg per mL, 10 mL	Application to the eye	1	5	SI
	Eye drops 10 mg per mL, 10 mL	Application to the eye	1	5	SI
	Tablet 4 mg	Oral	50	4	AF
	Tablet 20 mg	Oral	60	4	AF
Hydrocortisone Acetate	Cream 10 mg per g, 30 g	Application	1	1	BQ, NN, PD, SI, UP
	Cream 10 mg per g, 50 g	Application	1	1	BQ, NN, PD, SI, UP
	Eye ointment 5 mg per g, 5 g	Application to the eye	1	..	SI
	Eye ointment 10 mg per g, 5 g	Application to the eye	1	..	SI
	Ointment 10 mg per g, 30 g	Application	1	1	NN, SI
	Ointment 10 mg per g, 50 g	Application	1	1	BQ, NN, PD, SI
	Rectal foam 90 mg per applicatorful, 14 applications, aerosol, 21.1 g		2	3	SV
Hydrocortisone with Cinchocaine Hydrochloride	Ointment 5 mg-5 mg per g, 30 g		1	1	QM, RL
	Ointment 5 mg-5 mg per g, 2 g single use tubes, 5		2	1	QM, RL
	Suppositories 5 mg-5 mg, 12		1	1	QM, RL
Hydrocortisone Sodium Succinate	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	Injection	2	..	NR, UP
	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	Injection	1	..	UP
	Injection equivalent to 500 mg hydrocortisone with 4 mL solvent	Injection	2	..	UP
Hydroxocobalamin	Injection 1 mg in 1 mL ampoule	Injection	3	..	BL
Hydroxychloroquine Sulfate	Tablet 200 mg	Oral	100	1	SW
Hydroxypropylcellulose	Ophthalmic inserts 5 mg, 60	Application to the eye	1	5	SI
Hydroxyurea	Capsule 500 mg	Oral	100	..	BQ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Hyoscyamine Hydrobromide with Atropine Sulfate and Hyoscine Hydrobromide	Tablet 92.5 micrograms-13.5 micrograms-9.9 micrograms	Oral	100	2	FM
	Tablet 138.7 micrograms-20.3 micrograms-14.8 micrograms	Oral	100	2	FM
Hyoscyamine Sulfate with Atropine Sulfate and Hyoscine Hydrobromide	Tablet 103.7 micrograms-19.4 micrograms-6.5 micrograms	Oral	100	2	WT
Hypromellose 4500	Eye drops 5 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, SI
	Eye drops 10 mg per mL, 15 mL	Application to the eye	1	5	SI
Hypromellose 4500 with Dextran 70	Eye drops 3 mg-1 mg per mL, 15 mL	Application to the eye	1	5	AQ, IQ
Ibuprofen	Tablet 200 mg	Oral	100	3	AF
	Tablet 400 mg	Oral	100	3	BT
	Tablets 200 mg, 20	Oral	1	..	AF
	Tablets 400 mg, 20	Oral	1	..	BT
Idarubicin Hydrochloride	Powder for I.V. injection 5 mg in single dose vial	Injection	3	..	PS
	Powder for I.V. injection 10 mg in single dose vial	Injection	6	..	PS
Idoxuridine	Eye drops 1 mg per mL, 15 mL	Application to the eye	1	2	AG, SK
	Eye ointment 5 mg per g, 5 g	Application to the eye	1	..	SK
	Ointment 5 mg per g, 5 g	Topical application	1	..	SK
Imipramine Hydrochloride	Injection 25 mg in 2 mL ampoule	Injection	10	..	CG
	Tablet 10 mg	Oral	50	2	CG
	Tablet 25 mg	Oral	50	2	CG, UW
Indapamide Hemihydrate	Tablet 2.5 mg	Oral	90	1	AF, DP, SE
Indomethacin	Capsule 25 mg	Oral	100	3	AF, MK
	Capsules 25 mg, 20	Oral	1	..	AF
	Ophthalmic suspension 10 mg per mL, 5 mL	Application to the eye	1	..	SI
	Suppository 100 mg		40	3	MK
Influenza Vaccine (Split Virion), Inactivated	Injection containing antigens representative of the following types: A/Texas/36/91 (H_1N_1)-like strain 15 micrograms haemagglutinin; A/Beijing/32/92 (H_3N_2)-like strain 15 micrograms haemagglutinin; B/Panama/45/90-like strain 15 micrograms haemagglutinin; 0.5 mL pre-filled syringe	Injection	1	..	CS, PV, SK
Insect Allergen Extract—Honey Bee Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insect Allergen Extract—Paper Wasp Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Insect Allergen Extract—Yellow Jacket Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insulin, Acid	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	NO
Insulin, Isophane	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	FC, NO
	Injection (human) 100 units per mL, 10 mL vial	Injection	5	2	LY, NO
	Injections (human), cartridges, 100 units per mL, 1.5 mL, 5	Injection	10	1	LY, NO
	Injections (human), cartridges, 100 units per mL, 3 mL, 5	Injection	5	1	NO
Insulin, Neutral	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	FC
	Injection (human) 100 units per mL, 10 mL vial	Injection	5	2	LY, NO
	Injections (human), cartridges, 100 units per mL, 1.5 mL, 5	Injection	10	1	LY, NO
	Injections (human), cartridges, 100 units per mL, 3 mL, 5	Injection	5	1	NO
Insulin, Neutral with Insulin, Isophane	Injection (human) 20 units-80 units per mL, 10 mL vial	Injection	5	2	LY
	Injection (human) 30 units-70 units per mL, 10 mL vial	Injection	5	2	LY, NO
	Injection (human) 50 units-50 units per mL, 10 mL vial	Injection	5	2	LY, NO
	Injections (human), cartridges, 15 units-85 units per mL, 3 mL, 5	Injection	5	1	NO
	Injections (human), cartridges, 20 units-80 units per mL, 1.5 mL, 5	Injection	10	1	LY
	Injections (human), cartridges, 30 units-70 units per mL, 1.5 mL, 5	Injection	10	1	LY, NO
	Injections (human), cartridges, 30 units-70 units per mL, 3 mL, 5	Injection	5	1	NO
	Injections (human), cartridges, 50 units-50 units per mL, 3 mL, 5	Injection	5	1	NO
Insulin, Protamine Zinc	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	NO
Insulin Zinc Suspension	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	NO
	Injection (human) 100 units per mL, 10 mL vial	Injection	5	2	LY, NO
Insulin Zinc Suspension (Crystalline)	Injection (bovine) 100 units per mL, 10 mL vial	Injection	5	2	NO
	Injection (human) 100 units per mL, 10 mL vial	Injection	5	2	LY, NO
Interferon Alfa-2a	Injection set containing 5 vials powder for injection 3,000,000 I.U. and 5 ampoules solvent 1 mL	Injection	2	5	RO

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Interferon Alfa-2b	Injection set containing 5 vials powder for injection 3,000,000 I.U. and 5 ampoules solvent 2 mL	Injection	2	5	SH
	Injection set containing 1 vial powder for injection 10,000,000 I.U. and 1 vial solvent 5 mL	Injection	2	..	SH
Ipratropium Bromide	Nebuliser solution 250 micrograms per mL, 20 mL	Inhalation	2	2	BY
	Nebuliser solution 250 micrograms in 1 mL single dose units, 30	Inhalation	2	5	BY
	Nebuliser solution 500 micrograms in 2 mL single dose units, 30	Inhalation	2	5	BY
	Pressurised inhalation 20 micrograms per dose, 200 doses	Inhalation by mouth	1	5	BY
	Pressurised nasal spray 20 micrograms per dose, 200 doses	Nasal	1	5	BY
Iron Polymaltose Complex	Injection 100 mg (iron) in 2 mL ampoule	Injection	5	..	SI
Isoniazid	Tablet 100 mg	Oral	100	2	FM
Isosorbide Dinitrate	Tablet 5 mg (sublingual)	Oral	200	2	AY
	Tablet 10 mg	Oral	200	2	AF, AY
	Tablet 20 mg	Oral	100	5	AY
Isosorbide Mononitrate	Tablet 60 mg (sustained release)	Oral	30	5	AP
Isotretinoin	Capsule 10 mg	Oral	60	3	RO
	Capsule 20 mg	Oral	60	3	RO
Ketoconazole	Tablet 200 mg	Oral	10	..	JC
Ketoprofen	Capsule 50 mg	Oral	50	3	MB
	Capsule 100 mg	Oral	50	3	MB
	Capsule 100 mg (sustained release)	Oral	50	3	MB, RR
	Capsule 200 mg (sustained release)	Oral	28	3	MB, RR
	Capsules 100 mg (sustained release), 10	Oral	1	..	MB
	Capsules 200 mg (sustained release), 7	Oral	1	..	MB
	Suppository 100 mg		40	3	MB
Labetalol Hydrochloride	Tablet 100 mg	Oral	100	5	AF, GL
	Tablet 200 mg	Oral	100	5	AF, GL
Lactulose	Solution B.P. 3.34 g per 5 mL, 500 mL	Oral	1	5	AF, JC
Lamotrigine	Tablet 25 mg	Oral	56	5	BW
	Tablet 50 mg	Oral	56	5	BW
	Tablet 100 mg	Oral	56	5	BW
Lansoprazole	Capsule 30 mg	Oral	28	1	LE
Leuprorelin Acetate	I.M. injection (modified release), set containing 1 vial powder for injection 7.5 mg, 1 ampoule diluent 1.5 mL and 1 syringe with 2 needles	Injection	1	5	AB

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Levobunolol Hydrochloride	Eye drops 2.5 mg per mL, 5 mL	Application to the eye	1	5	AG
Levodopa with Benserazide Hydrochloride	Capsule 50 mg-12.5 mg (benserazide)	Oral	100	5	RO
	Capsule 100 mg-25 mg (benserazide)	Oral	100	5	RO
	Capsule 100 mg-25 mg (benserazide) (sustained release)	Oral	100	5	RO
	Capsule 200 mg-50 mg (benserazide)	Oral	100	5	RO
	Tablet 100 mg-25 mg (benserazide)	Oral	100	5	RO
	Tablet 200 mg-50 mg (benserazide)	Oral	100	5	RO
Levodopa with Carbidopa	Tablet 100 mg-10 mg (anhydrous)	Oral	100	5	MK
	Tablet 100 mg-25 mg (anhydrous)	Oral	100	5	MK
	Tablet 200 mg-50 mg (anhydrous) (modified release)	Oral	100	5	MK
	Tablet 250 mg-25 mg (anhydrous)	Oral	100	5	MK
Levonorgestrel	Tablets 30 micrograms, 28	Oral	4	2	SC, WY
Levonorgestrel with Ethinyloestradiol	Pack containing 21 tablets 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	AY, SC, SY, WY
	Pack containing 21 tablets 250 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	WY
	Pack containing 11 tablets 50 micrograms-50 micrograms and 10 tablets 125 micrograms-50 micrograms	Oral	4	2	WY
	Pack containing 11 tablets 50 micrograms-50 micrograms, 10 tablets 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms and 10 tablets 125 micrograms-30 micrograms	Oral	4	2	SC, WY
	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	AY, SC, SY, WY
	Tablets 125 micrograms-50 micrograms, 21	Oral	4	2	SC
	Tablets 150 micrograms-30 micrograms, 21	Oral	4	2	SC, WY
	Tablets 250 micrograms-50 micrograms, 21	Oral	4	2	WY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Lignocaine Hydrochloride	Injection 100 mg in 5 mL ampoule	Injection	2	..	AP
	Intravenous infusion 500 mg in 5 mL ampoule	Injection	5	..	AP
Lincomycin Hydrochloride	Injection equivalent to 600 mg lincomycin in 2 mL vial	Injection	5	..	UP
Liothyronine Sodium	Tablet 20 micrograms	Oral	100	2	BT
Lisinopril	Tablet 5 mg	Oral	30	5	AD, IC
	Tablet 10 mg	Oral	30	5	AD, IC
	Tablet 20 mg	Oral	30	5	AD, IC
Lithium Carbonate	Tablet 250 mg	Oral	200	2	FC
"Locasol"	Low calcium compound powder 400 g	Oral	8	5	NU
"Lofenalac"	Oral powder 454 g	Oral	5	8	MJ
Loperamide Hydrochloride	Capsule 2 mg	Oral	12	..	JC, RR
Medroxyprogesterone Acetate	Injection 50 mg in 1 mL vial	Injection	1	..	UP
	Injection 150 mg in 1 mL vial	Injection	1	..	UP
	Injection 500 mg in 2.5 mL vial	Injection	7	..	PS
	Tablet 5 mg	Oral	56	2	UP
	Tablet 10 mg	Oral	30	2	UP
	Tablet 100 mg	Oral	100	2	PS, UP
	Tablet 200 mg	Oral	60	2	PS, UP
	Tablet 250 mg	Oral	60	2	UP
	Tablet 500 mg	Oral	30	2	PS, UP
Medrysone	Eye drops 10 mg per mL, 5 mL	Application to the eye	1	5	AG
Mefenamic Acid	Capsule 250 mg	Oral	50	2	PD, WW
Megestrol Acetate	Tablet 40 mg	Oral	100	2	BQ
	Tablet 160 mg	Oral	30	2	BQ
Melphalan	Tablet 2 mg	Oral	100	..	BW
	Tablet 5 mg	Oral	100	..	BW
Menotrophin	Injection set containing 10 ampoules powder for injection providing 75 units follicle stimulating hormone and 75 units luteinising hormone and 10 ampoules solvent 1 mL	Injection	1	5	SG
	Injection set containing 10 ampoules powder for injection providing 150 units follicle stimulating hormone and 150 units luteinising hormone and 10 ampoules solvent 1 mL	Injection	1	5	SG
Menotrophin standardised using Chorionic Gonadotrophin	Injection set containing 10 ampoules powder for injection providing 75 units follicle stimulating hormone and 75 units luteinising activity and 10 ampoules solvent 1 mL	Injection	1	5	OR

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Injection set containing 10 ampoules powder for injection providing 150 units follicle stimulating hormone and 150 units luteinising activity and 10 ampoules solvent 1 mL	Injection	1	5	OR
Mercaptopurine	Tablet 50 mg	Oral	100	2	BW
Mesalazine	Tablet 250 mg	Oral	100	5	SK
Metformin Hydrochloride	Tablet 500 mg	Oral	100	5	AF, FC, LH
	Tablet 850 mg	Oral	60	5	LH
Methacycline Hydrochloride	Capsule 300 mg	Oral	10	1	WW
Methadone Hydrochloride	Injection 10 mg in 1 mL ampoule	Injection	5	..	BW
	Tablet 5 mg	Oral	20	..	BW
	Tablet 10 mg	Oral	20	..	BW
Methdilazine Hydrochloride	Tablet 4 mg	Oral	100	2	SI
	Tablet 8 mg	Oral	100	2	SI
Methenolone Acetate	Tablet 5 mg	Oral	100	3	SC
"Methionine, Threonine, Valine-free and Isoleucine low Amino Acid Mix"	Oral powder 200 g	Oral	5	5	SB
Methotrexate	Tablet 2.5 mg	Oral	100	2	BL, PS, LE
	Tablet 10 mg	Oral	50	2	PS
Methotrexate Sodium	Injection equivalent to 5 mg methotrexate in 2 mL vial	Injection	5	..	LE
	Injection equivalent to 50 mg methotrexate in 2 mL vial	Injection	5	..	BL, DW, LE, PS
Methyclothiazide	Tablet 2.5 mg	Oral	100	1	AB
	Tablet 5 mg	Oral	100	1	AB
Methyldopa	Tablet 125 mg	Oral	100	5	MK
	Tablet 250 mg	Oral	100	5	AF, MK
Methylphenobarbitone	Tablet 60 mg	Oral	200	2	SW
	Tablet 200 mg	Oral	200	2	SW
Methylprednisolone Acetate	Injection 40 mg in 1 mL vial	Injection	5	..	UP
Methylprednisolone Sodium Succinate	Injection equivalent to 40 mg methylprednisolone in 1 mL vial	Injection	5	..	UP
Methyl Salicylate	Liniment A.P.F., 100 mL	Application	1	1	MG, MM, NN, SI, WE
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Methysergide Maleate	Tablet equivalent to 1 mg methysergide	Oral	100	2	SZ
Metoclopramide Hydrochloride	Injection 10 mg in 2 mL ampoule	Injection	10	..	SK
	Oral solution 5 mg per 5 mL, 100 mL	Oral	1	..	SK
	Tablet 10 mg	Oral	25	..	AF, SK
Metolazone	Tablet 2.5 mg	Oral	100	1	SR
Metoprolol Tartrate	Tablet 50 mg	Oral	100	5	AF, AP, CG
	Tablet 100 mg	Oral	60	5	AF, AP, CG
Metronidazole	Intravenous infusion 500 mg in 100 mL	Injection	5	1	DW, MB
	Suppositories 500 mg, 10		1	..	MB
	Suppositories 1 g, 10		1	..	MB
	Tablet 200 mg	Oral	21	1	AF, MB, SR
	Tablet 400 mg	Oral	5	2	AF, MB
Metronidazole Benzoate	Oral suspension 320 mg per 5 mL, 100 mL	Oral	1	..	MB

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Mexiletine Hydrochloride	Capsule 50 mg	Oral	100	5	BY
	Capsule 200 mg	Oral	100	5	BY
Mianserin Hydrochloride	Tablet 10 mg	Oral	50	5	AF, OP, OR
	Tablet 20 mg	Oral	50	5	AF, OP, OR
Miconazole Nitrate	Cream 20 mg per g, 20 g	Application	1	1	JC
	Cream 20 mg per g, 40 g	Application	1	..	CL, JP
	Pessaries 100 mg, 7		1	..	CL, JP
Minocycline Hydrochloride	Capsule equivalent to 100 mg minocycline	Oral	11	..	LE
	Tablet equivalent to 50 mg minocycline	Oral	60	5	LE
Minoxidil	Tablet 10 mg	Oral	100	5	UP
Misoprostol	Tablet 200 micrograms	Oral	120	1	SR
Mitozantrone Hydrochloride	Injection equivalent to 10 mg mitozantrone in 5 mL vial	Injection	1	..	LE
	Injection equivalent to 20 mg mitozantrone in 10 mL vial	Injection	1	..	LE
	Injection equivalent to 25 mg mitozantrone in 12.5 mL vial	Injection	1	..	LE
	Injection equivalent to 30 mg mitozantrone in 15 mL vial	Injection	1	..	LE
Moclobemide	Tablet 150 mg	Oral	60	2	RO
Morphine Hydrochloride	Oral solution 2 mg per mL, 200 mL	Oral	1	..	DW
	Oral solution 5 mg per mL, 200 mL	Oral	1	..	DW
	Oral solution 10 mg per mL, 200 mL	Oral	1	..	DW
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Morphine Sulfate	Capsule 20 mg (containing sustained release pellets)	Oral	20	..	GL
	Capsule 50 mg (containing sustained release pellets)	Oral	20	..	GL
	Capsule 100 mg (containing sustained release pellets)	Oral	20	..	GL
	Injection 10 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 15 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 30 mg in 1 mL ampoule	Injection	5	..	BL
	Tablet 10 mg (controlled release)	Oral	20	..	PS
	Tablet 30 mg	Oral	20	..	FM
	Tablet 30 mg (controlled release)	Oral	20	..	PS
	Tablet 60 mg (controlled release)	Oral	20	..	PS
	Tablet 100 mg (controlled release)	Oral	20	..	PS
Morphine Tartrate	Injection 120 mg in 1.5 mL ampoule	Injection	5	..	BL
"M.S.U.D. AID"	Oral powder 200 g	Oral	10	5	SB
"M.S.U.D. Maxamaid"	Oral powder 200 g	Oral	20	5	SB
Nafarelin Acetate	Nasal spray (pump pack) equivalent to 200 micrograms nafarelin per dose, 60 doses	Nasal	1	5	SD
Nalidixic Acid	Tablet 500 mg	Oral	56	2	SW
Naloxone Hydrochloride	Injection 40 micrograms in 2 mL ampoule	Injection	5	..	BT
	Injection 400 micrograms in 1 mL disposable injection set	Injection	1	..	CS
	Injection 800 micrograms in 2 mL disposable injection set	Injection	1	..	CS

Name of pharmaceutical benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Maximum number of repeats	Brand
	Injection 2 mg in 5 mL disposable injection set	Injection	1	..	CS
Nandrolone Decanoate	Injection 50 mg in 1 mL disposable syringe	Injection	1	7	OR
Naphazoline Hydrochloride	Eye drops 1 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ
Naproxen	Oral suspension 125 mg per 5 mL, 500 mL	Oral	1	3	SD
	Suppository 500 mg		40	3	SD
	Tablet 250 mg	Oral	100	3	AF, SD
	Tablet 250 mg (enteric coated)	Oral	100	3	SD
	Tablet 500 mg	Oral	50	3	AF, SD
	Tablet 500 mg (enteric coated)	Oral	50	3	SD
	Tablet 750 mg (sustained release)	Oral	28	3	MD, SD
	Tablet 1 g (sustained release)	Oral	28	3	MD, SD
	Tablets 250 mg, 20	Oral	1	..	AF, SD
	Tablets 500 mg, 10	Oral	1	..	AF, SD
	Tablets 750 mg (sustained release), 7	Oral	1	..	SD
	Tablets 1 g (sustained release), 7	Oral	1	..	SD
Naproxen Sodium	Tablet 550 mg	Oral	50	3	SD
	Tablets 550 mg, 10	Oral	1	..	SD
"Neocate"	Elemental infant formula powder 400 g	Oral	20	2	SB
Neomycin Sulfate	Tablet 500 mg	Oral	25	1	AF
Neomycin Undecenoate with Bacitracin Zinc	Ear ointment 12 mg (3.5 mg neomycin)-400 units per g, 10 g	Application to the ear	1	..	HA
Neostigmine Bromide	Tablet 15 mg	Oral	200	1	RO
Niclosamide	Tablet 500 mg	Oral	4	..	BN
Nicotinic Acid	Tablet 250 mg	Oral	200	5	MB
Nifedipine	Capsule 5 mg	Oral	100	5	BN
	Capsule 10 mg	Oral	100	5	BN
	Tablet 10 mg	Oral	60	5	BN
	Tablet 20 mg	Oral	60	5	BN
	Tablet 30 mg (controlled release)	Oral	30	5	BN
	Tablet 60 mg (controlled release)	Oral	30	5	BN
Nitrazepam	Tablet 5 mg	Oral	25	..	AF, RO
Nitrofurantoin	Capsule 50 mg	Oral	30	1	PY
	Capsule 100 mg	Oral	30	1	PY
	Oral suspension 25 mg per 5 mL, 200 mL	Oral	1	..	PY
Nizatidine	Capsule 150 mg	Oral	60	2	LY
	Capsule 300 mg	Oral	30	1	LY
Norethisterone	Tablet 5 mg	Oral	30	2	SC
	Tablets 350 micrograms, 28	Oral	4	2	JC, MD, SD
Norethisterone with Ethinyloestradiol	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	Oral	4	2	MD, SD
	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	MD, SD

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Pack containing 12 tablets 500 micrograms-35 micrograms, 9 tablets 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	MD, SD
	Tablets 500 micrograms-35 micrograms, 21	Oral	4	2	SD
	Tablets 1 mg-35 micrograms, 21	Oral	4	2	SD
Norethisterone with Mestranol	Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets 1 mg-50 micrograms, 21	Oral	4	2	SD
Norfloxacin	Tablet 400 mg	Oral	14	1	MK
Nortriptyline Hydrochloride	Elixir equivalent to 10 mg nortriptyline per 5 mL, 100 mL	Oral	1	4	DL
	Tablet equivalent to 10 mg nortriptyline	Oral	50	2	DL
	Tablet equivalent to 25 mg nortriptyline	Oral	50	2	DL
"Nutramigen"	Oral powder 425 g	Oral	8	5	MJ
Nystatin	Capsule 500,000 units	Oral	50	..	BQ, LE
	Cream 100,000 units per g, 15 g	Application	1	1	BQ, LE
	Lozenge 100,000 units	Oral	20	1	LE
	Ointment 100,000 units per g, 15 g	Application	1	1	BQ, LE
	Oral suspension 100,000 units per mL, 24 mL	Oral	1	1	BQ, LE
	Pessaries 100,000 units, 15		1	1	BQ, LE
	Pessaries 100,000 units (cream base), 15		1	1	LE
	Tablet 500,000 units	Oral	50	..	BQ, LE
	Vaginal cream 100,000 units per 4 g, 75 g		1	1	BQ
	Vaginal cream 100,000 units per 5 g, 75 g		1	1	LE
Oestradiol	Transdermal patches 2 mg, 8	Transdermal	1	5	CG
	Transdermal patches 4 mg, 8	Transdermal	1	5	CG
	Transdermal patches 8 mg, 8	Transdermal	1	5	CG
	Vaginal tablets 25 micrograms, 15		1	2	NO
Oestradiol and Medroxyprogesterone Acetate	Pack containing 8 transdermal patches oestradiol 4 mg and 14 tablets medroxyprogesterone acetate 10 mg	Transdermal (patches) and oral (tablets)	1	5	CG
Oestradiol Valerate	Injection 10 mg in 1 mL ampoule	Injection	3	..	SC
	Tablets 1 mg, 28	Oral	2	2	SC
	Tablets 2 mg, 28	Oral	2	2	SC
Oestradiol with Norethisterone Acetate	Pack containing 12 tablets oestradiol 2 mg, 10 tablets oestradiol 2 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg	Oral	1	5	NO
	Pack containing 12 tablets oestradiol 4 mg, 10 tablets oestradiol 4 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg	Oral	1	5	NO
Oestriol	Tablets 1 mg, 30	Oral	2	2	OR
	Vaginal cream 1 mg per g, 15 g		1	1	OR

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Oestrogens—Conjugated	Tablets 300 micrograms, 28	Oral	2	2	AY
	Tablets 625 micrograms, 28	Oral	2	2	AY
Oestrogens—Conjugated and Medroxyprogesterone Acetate	Pack containing 28 tablets conjugated oestrogens 625 micrograms and 14 tablets medroxyprogesterone acetate 10 mg	Oral	1	5	AY, UP
Oestrone	Pessaries 100 micrograms, 12		1	2	OR
	Pessaries 1 mg, 12		1	2	OR
Olsalazine Sodium	Capsule 250 mg	Oral	100	5	PS
Omeprazole	Capsule 20 mg	Oral	28	1	AP
Ondansetron Hydrochloride Dihydrate	Tablet equivalent to 4 mg ondansetron	Oral	15	..	GL
	Tablet equivalent to 8 mg ondansetron	Oral	15	..	GL
	I.V. injection equivalent to 4 mg ondansetron in 2 mL ampoule	Injection	2	..	GL
	I.V. injection equivalent to 8 mg ondansetron in 4 mL ampoule	Injection	2	..	GL
Orphenadrine Hydrochloride	Tablet 50 mg	Oral	200	2	MM
Oxandrolone	Tablet 2.5 mg	Oral	100	1	CS
Oxazepam	Tablet 15 mg	Oral	25	..	AF, AY, WY
	Tablet 30 mg	Oral	25	..	AF, AY, WY
Oxprenolol Hydrochloride	Tablet 20 mg	Oral	100	5	AF
	Tablet 40 mg	Oral	100	5	AF
Oxycodone Hydrochloride	Tablet 5 mg	Oral	20	..	BT
Oxycodone Pectinate	Suppository equivalent to 30 mg oxycodone		12	..	BT
Oxymetholone	Tablet 50 mg	Oral	100	5	SD
Paclitaxel	Solution for I.V. infusion 30 mg in 5 mL vial	Injection	10	..	BQ
Pancreatin	Capsule providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	AY
	Tablet providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	AY
Pancrelipase	Capsule providing not less than 5,000 B.P. units of lipase activity	Oral	500	10	JC
	Capsule providing not less than 10,000 B.P. units of lipase activity	Oral	500	10	OR
Paracetamol	Elixir 240 mg per 5 mL, 200 mL	Oral	1	2	SW
	Mixture 120 mg per 5 mL, 100 mL	Oral	1	2	BW, SW
	Tablet 500 mg	Oral	100	1	BW, FM, JT, SW
Paraffin, Soft White with Liquid Paraffin	Eye ointment, compound, 3.5 g	Application to the eye	1	5	AQ
	Eye ointment, compound, 7 g	Application to the eye	1	5	AG
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Paroxetine Hydrochloride	Tablet equivalent to 20 mg paroxetine	Oral	30	2	SK
Penicillamine	Tablet 125 mg	Oral	100	1	DL
	Tablet 250 mg	Oral	100	1	DL
Pericyazine	Tablet 2.5 mg	Oral	100	5	MB
	Tablet 10 mg	Oral	100	5	MB
Pergolide Mesylate	Tablet equivalent to 50 micrograms pergolide	Oral	30	..	LY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Tablet equivalent to 250 micrograms pergolide	Oral	100	5	LY
	Tablet equivalent to 1 mg pergolide	Oral	100	5	LY
Perindopril Erbumine	Tablet 2 mg	Oral	30	5	SE
	Tablet 4 mg	Oral	30	5	SE
Pethidine Hydrochloride	Injection 50 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 100 mg in 2 mL ampoule	Injection	5	..	AP, BL, SI
Phenelzine Sulfate	Tablet equivalent to 15 mg phenelzine	Oral	50	2	WW
Phenobarbitone	Tablet 30 mg	Oral	200	4	SI
Phenobarbitone Sodium	Injection 200 mg in 1 mL ampoule	Injection	5	..	FM
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Phenoxybenzamine Hydrochloride	Capsule 10 mg	Oral	100	5	SK
Phenoxymethylpenicillin Benzathine	Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL, 100 mL	Oral	1	1	AB, CS, SI
	Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL, 100 mL	Oral	1	1	AB, CS, SI
	Tablet equivalent to 125 mg phenoxymethylpenicillin	Oral	25	1	AB
Phenoxymethylpenicillin Potassium	Capsule equivalent to 250 mg phenoxymethylpenicillin	Oral	25	1	AB, CS, LY, SI
	Capsule equivalent to 500 mg phenoxymethylpenicillin	Oral	25	1	CS, SI
	Tablet equivalent to 250 mg phenoxymethylpenicillin	Oral	25	1	AB, LY
	Tablet equivalent to 500 mg phenoxymethylpenicillin	Oral	25	1	AB, LY
Phenylephrine Hydrochloride	Eye drops 1.2 mg per mL, 15 mL	Application to the eye	1	5	AQ
Phenytoin	Oral suspension 30 mg per 5 mL, 500 mL	Oral	1	3	PD
	Tablet 50 mg	Oral	200	2	PD
Phenytoin Sodium	Capsule 30 mg	Oral	200	2	PD
	Capsule 100 mg	Oral	200	2	PD
Pilocarpine	Eye disc 5 mg (releasing 20 micrograms per hour)	Application to the eye	8	5	AG
	Eye disc 11 mg (releasing 40 micrograms per hour)	Application to the eye	8	5	AG
Pilocarpine Hydrochloride	Eye drops 5 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops 10 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops 20 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops 30 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops 40 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops 60 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, SI
Pindolol	Tablet 5 mg	Oral	100	5	AF, SZ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Tablet 15 mg	Oral	50	5	AF, SZ
Piperazine Oestrone Sulfate	Tablets 730 micrograms, 28	Oral	2	2	UP
	Tablets 1.46 mg, 28	Oral	2	2	UP
Piroxicam	Capsule 10 mg	Oral	50	3	GP, PF
	Capsule 20 mg	Oral	25	3	GP, PF
	Dispersible tablet 10 mg	Oral	50	3	PF
	Dispersible tablet 20 mg	Oral	25	3	PF
Pizotifen Malate	Tablet equivalent to 500 micrograms pizotifen	Oral	100	2	SZ
"PK AID II"	Oral powder 250 g	Oral	8	5	SB
Pneumococcal Vaccine, Polyvalent	Injection 0.5 mL vial (23 valent)	Injection	1	..	CS
Polygeline	Intravenous infusion 17.5 g per 500 mL with Na^+ 145 mmol per L, K^+ 5.1 mmol per L, Ca^{2+} 6.25 mmol per L and Cl^- 145 mmol per L; 500 mL	Injection	3	..	HP
Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate	Eye ointment 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	BW
Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin	Eye drops 5,000 units-2.5 mg-25 micrograms per mL, 10 mL	Application to the eye	1	2	BW
Polyvinyl Alcohol	Eye drops 14 mg per mL, 15 mL	Application to the eye	1	5	AG
	Eye drops 30 mg per mL, 15 mL	Application to the eye	1	5	AG
Polyvinyl Alcohol with Povidone	Eye drops 14 mg-6 mg per mL, 15 mL	Application to the eye	1	5	AB, AG
"Portagen"	Oral powder 454 g	Oral	8	5	MJ
Potassium Chloride	Elixir 1.5 g per 15 mL, 500 mL	Oral	2	1	SC
	Tablet 600 mg (sustained release)	Oral	200	1	AF, CG, FC
Potassium Chloride with Potassium Bicarbonate	Tablet, effervescent, 14 mmol K^+ and 8 mmol Cl^-	Oral	60	1	FC
Pravastatin Sodium	Tablet 5 mg	Oral	30	5	BQ
	Tablet 10 mg	Oral	30	5	BQ
	Tablet 20 mg	Oral	30	5	BQ
Prazosin Hydrochloride	Tablet equivalent to 1 mg prazosin	Oral	100	5	AF, PF
	Tablet equivalent to 2 mg prazosin	Oral	100	5	AF, PF
	Tablet equivalent to 5 mg prazosin	Oral	100	5	AF, PF
Prednisolone	Tablet 1 mg	Oral	100	4	FC
	Tablet 5 mg	Oral	60	4	FC, FM, NN
	Tablet 25 mg	Oral	30	4	FC, FM
Prednisolone Acetate	Eye drops 5 mg per mL, 5 mL	Application to the eye	1	2	AQ
Prednisolone Acetate with Phenylephrine Hydrochloride	Eye drops 10 mg-1.2 mg per mL, 10 mL	Application to the eye	1	2	AG
Prednisolone Sodium Phosphate	Enema, retention, equivalent to 20 mg prednisolone in 100 mL	Enema	28	3	SI
	Eye/ear drops 5 mg per mL, 5 mL	Application to the eye/ear	1	2	SI
	Suppositories equivalent to 5 mg prednisolone, 10		3	3	SI
Prednisone	Tablet 1 mg	Oral	100	4	FC
	Tablet 5 mg	Oral	60	4	FC, FM, NN

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Tablet 25 mg	Oral	30	4	FC, FM
"Pregestimil"	Oral powder 454 g	Oral	8	5	MJ
Primidone	Tablet 250 mg	Oral	200	2	IC
Probenecid	Tablet 500 mg	Oral	100	5	FR
Probucol	Tablet 250 mg	Oral	120	5	ML
Procainamide Hydrochloride	Capsule 250 mg	Oral	200	1	BQ
	Injection 100 mg per mL, 10 mL vial	Injection	1	..	BQ
Procaine Penicillin	Injection 1 g in disposable syringe	Injection	5	..	SI
	Injection 1.5 g in disposable syringe	Injection	5	..	SI
Prochlorperazine	Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate, 5		1	2	MB
	Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate, 5		1	2	MB
Prochlorperazine Edisylate	Injection 12.5 mg in 1 mL ampoule	Injection	10	..	SK
Prochlorperazine Maleate	Tablet 5 mg	Oral	25	..	MB
Prochlorperazine Mesylate	Injection 12.5 mg in 1 mL ampoule	Injection	10	..	MB
Procyclidine Hydrochloride	Tablet 5 mg	Oral	200	2	BW
Promethazine Hydrochloride	Injection 50 mg in 2 mL ampoule	Injection	10	..	BL
Promethazine Theoclate	Tablet 25 mg	Oral	30	1	MB
Propantheline Bromide	Tablet 15 mg	Oral	200	2	SR
Propranolol Hydrochloride	Tablet 10 mg	Oral	100	5	AF, IC
	Tablet 40 mg	Oral	100	5	AF, IC
	Tablet 160 mg	Oral	50	5	AF, IC
Propylthiouracil	Tablet 50 mg	Oral	200	2	JC
Protamine Sulfate	Injection 10 mg per mL, 10 mL ampoule	Injection	6	..	BT
Pyrantel Embonate	Tablet equivalent to 125 mg pyrantel	Oral	6	..	AF
	Tablet equivalent to 250 mg pyrantel	Oral	6	..	AF
Pyridostigmine Bromide	Tablet 10 mg	Oral	100	2	RO
	Tablet 60 mg	Oral	100	2	RO
	Tablet 180 mg (sustained release)	Oral	100	1	RO
Pyridoxine Hydrochloride	Injection 50 mg in 1 mL ampoule	Injection	5	1	FM
	Tablet 25 mg	Oral	100	..	FM
Pyrimethamine	Tablet 25 mg	Oral	50	..	BW
Quinapril Hydrochloride	Tablet equivalent to 5 mg quinapril	Oral	30	5	PD, SI
	Tablet equivalent to 10 mg quinapril	Oral	30	5	PD, SI
	Tablet equivalent to 20 mg quinapril	Oral	30	5	PD, SI
Quinidine Bisulfate	Tablet 250 mg (sustained release)	Oral	100	5	AP
Quinine Bisulfate	Tablet 300 mg	Oral	50	2	AF, FM, NN RR
Quinine Sulfate	Tablet 300 mg	Oral	50	2	AF, FM, NN, RR
Ramipril	Capsule 1.25 mg	Oral	28	5	AP, HP
	Capsule 2.5 mg	Oral	28	5	AP, HP
	Capsule 5 mg	Oral	28	5	AP, HP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Ranitidine Hydrochloride	Tablet, effervescent, equivalent to 150 mg ranitidine	Oral	60	2	GL
	Tablet equivalent to 150 mg ranitidine	Oral	60	2	GL
	Tablet equivalent to 300 mg ranitidine	Oral	30	1	GL
Red-back Spider Antivenom	Injection 500 units ampoule	Injection	2	..	CS
Rifampicin	Capsule 150 mg	Oral	10	..	AF
	Capsule 300 mg	Oral	10	..	AF
Roxithromycin	Tablet 150 mg	Oral	10	1	RL, SI
"RVHB Maxamaid"	Oral powder 200 g	Oral	20	5	SB
Salbutamol	Pressurised inhalation 100 micrograms per dose, 200 doses	Inhalation by mouth	2	5	AF, GL
Salbutamol Sulfate	Capsule equivalent to 200 micrograms salbutamol	Inhalation by mouth	200	5	GL
	Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units, 30	Inhalation	2	5	DW, GL
	Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units, 30	Inhalation	2	5	DW, GL
	Nebuliser solution equivalent to 5 mg salbutamol per mL, 30 mL	Inhalation	2	2	DW, GL, MM
	Oral solution equivalent to 2 mg salbutamol per 5 mL, 300 mL	Oral	1	5	GL
	Pressurised inhalation equivalent to 100 micrograms salbutamol per dose, 200 doses	Inhalation by mouth	2	5	MM
	Pressurised inhalation equivalent to 100 micrograms salbutamol per dose, 400 doses	Inhalation by mouth	1	5	MM
	Pressurised inhalation in breath actuated device equivalent to 100 micrograms salbutamol per dose, 400 doses	Inhalation by mouth	1	5	MM
	Tablet equivalent to 4 mg salbutamol	Oral	100	5	GL
Salcatonin	Injection 50 I.U. in 0.5 mL pre-filled single use syringe	Injection	30	5	MB, SZ
	Injection 80 I.U. in 0.8 mL ampoule	Injection	15	5	SZ
	Injection 100 I.U. in 1 mL pre-filled single use syringe	Injection	15	5	MB, SZ
	Injection 400 I.U. in 2 mL vial	Injection	4	5	MB
Selegiline Hydrochloride	Tablet 5 mg	Oral	100	5	RC
Sertraline Hydrochloride	Tablet equivalent to 50 mg sertraline	Oral	28	2	PF
	Tablet equivalent to 100 mg sertraline	Oral	28	2	PF
Silver Sulfadiazine with Chlorhexidine Gluconate	Cream 10 mg-2 mg per g, 50 g	Application	1	..	SN
	Cream 10 mg-2 mg per g, 100 g	Application	1	..	SN
Simvastatin	Tablet 5 mg	Oral	30	5	AD, MK
	Tablet 10 mg	Oral	30	5	AD, MK
	Tablet 20 mg	Oral	30	5	AD, MK
Sodium Acid Phosphate	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	100	5	SZ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate	Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL	Oral	2	5	RC
Sodium Aurothiomalate	Injection 10 mg ampoule	Injection	10	..	MB
	Injection 20 mg ampoule	Injection	10	1	MB
	Injection 50 mg ampoule	Injection	10	1	MB
Sodium Cellulose Phosphate	Oral powder, sachet, 5 g	Oral	100	5	MM
Sodium Chloride	Injection 9 mg per mL, 2 mL ampoule	Injection	5	1	AP
	Injection 9 mg per mL, 5 mL ampoule	Injection	5	1	AP
	Injection 9 mg per mL, 10 mL ampoule	Injection	5	1	AP
	Intravenous infusion 154 mmol per L, 1 L	Injection	5	1	BX
	Intravenous infusion 513 mmol per L, 1 L	Injection	2	1	BX
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Sodium Chloride with Glucose	Intravenous infusion 31 mmol-222 mmol (anhydrous) per L, 1 L	Injection	5	1	BX
	Intravenous infusion 19 mmol-104 mmol (anhydrous) per 500 mL, 500 mL	Injection	5	1	BX
	Intravenous infusion 39 mmol-69 mmol (anhydrous) per 500 mL, 500 mL	Injection	5	1	BX
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Sodium Chloride with Potassium Chloride and Calcium Chloride	Intravenous infusion containing approximately 148 mmol Na^+, 4 mmol K^+, 2 mmol Ca^{2+} and 156 mmol Cl^- per L, 1 L	Injection	4	1	BX
Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride	Electrolyte replacement solution 5.26 g-3.68 g-5.02 g-370 mg-300 mg per L, 1 L	Injection	2	1	BX
Sodium Citro-Tartrate	Sachets containing oral effervescent powder 3.7 g, 25 (Citralite)	Oral	1	4	FC
	Sachets containing oral effervescent powder 4 g, 25 (Citravescent Sachets)	Oral	1	4	FC
	Sachets containing oral effervescent powder 4 g, 25 (Ural Sachets)	Oral	1	4	AB
Sodium Cromoglycate	Eye drops 20 mg per mL, 10 mL	Application to the eye	1	5	FC
	Insufflation 20 mg per capsule	Inhalation by mouth	100	5	FC
	Nebuliser solution 20 mg per 2 mL ampoule	Inhalation	120	3	FC
	Pressurised inhalation 1 mg per dose, 200 doses	Inhalation by mouth	1	5	FC
	Pressurised inhalation 5 mg per dose, 112 doses	Inhalation by mouth	1	5	FC
Sodium Fusidate	Tablet 250 mg	Oral	36	1	CS

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride	Intravenous infusion containing approximately 131 mmol Na^+, 5 mmol K^+, 2 mmol Ca^{2+}, 29 mmol HCO_3^- (as lactate) and 111 mmol Cl^- per L, 1 L	Injection	5	1	BX
Sodium Nitroprusside	Intravenous infusion 50 mg vial	Injection	10	..	BL
Sodium Valproate	Oral liquid 200 mg per 5 mL, 300 mL	Oral	2	2	RC
	Oral solution 200 mg per 5 mL, 300 mL	Oral	2	2	RC
	Tablet 200 mg (enteric coated)	Oral	200	2	AF, RC
	Tablet 500 mg (enteric coated)	Oral	200	2	AF, RC
	Tablet, crushable, 100 mg	Oral	200	2	RC
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	Enema	2	2	PS
Sotalol Hydrochloride	Tablet 160 mg	Oral	60	5	AF, AP
Spectinomycin Hydrochloride	Injection equivalent to 2 g spectinomycin with 3.2 mL diluent	Injection	1	..	UP
Spironolactone	Tablet 25 mg	Oral	100	5	AF, SR
	Tablet 100 mg	Oral	100	5	AF, SR
Sterculia with Frangula Bark	Granules 473 mg-83 mg per g, 250 g	Oral	2	1	SC
	Granules 620 mg-80 mg per g, 500 g	Oral	1	1	NE
Streptokinase with any determined brand of sterilised Water for Injections or other solvent	Injection 1,500,000 I.U. (with required solvent)	Injection	1	..	HP, PS
Sucralfate	Tablet 1 g (hydrous)	Oral	120	2	SR
	Tablet equivalent to 1 g anhydrous sucralfate	Oral	120	2	AF, BT
Sulfacetamide Sodium	Eye drops 100 mg per mL, 15 mL	Application to the eye	1	2	AG, SI
Sulfamethizole	Tablet 500 mg	Oral	40	2	WW
	Tablet 1 g	Oral	20	2	WW
Sulfamethoxazole with Trimethoprim	Paediatric oral suspension 200 mg-40 mg per 5 mL, 100 mL	Oral	1	1	AF, BW, RO
	Tablet 400 mg-80 mg	Oral	10	1	AF, BW, RO
	Tablet 800 mg-160 mg	Oral	10	1	AF, BW, RO
Sulfasalazine	Tablet 500 mg	Oral	200	5	PS
	Tablet 500 mg (enteric coated)	Oral	200	5	PS
Sulfinpyrazone	Tablet 100 mg	Oral	100	5	CG
Sulindac	Tablet 100 mg	Oral	100	3	AF, FR
	Tablet 200 mg	Oral	50	3	AF, FR
	Tablets 100 mg, 20	Oral	1	..	AF
	Tablets 200 mg, 10	Oral	1	..	AF
Sulthiame	Tablet 50 mg	Oral	200	2	BN
	Tablet 200 mg	Oral	200	2	BN
Surgical Cement	Skin bond adhesive 118 mL	Application	1	2	SN
Surgical Cement Solvent	Liquid 237 mL	Application	1	2	SN
	Liquid 240 mL	Application	1	2	EG
	Liquid 250 mL	Application	1	2	EG
Tamoxifen Citrate	Tablet equivalent to 10 mg tamoxifen	Oral	60	5	AF, IC
	Tablet equivalent to 20 mg tamoxifen	Oral	60	5	AF, IC, PS

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Temazepam	Capsule 10 mg	Oral	25	..	AF, PS, WY
	Tablet 10 mg	Oral	25	..	WY
Tenoxicam	Tablet 10 mg	Oral	50	3	RO
Terbinafine Hydrochloride	Tablet equivalent to 250 mg terbinafine	Oral	28	2	SZ
Terbutaline Sulfate	Elixir 300 micrograms per mL, 300 mL	Oral	1	5	AP
	Injection 100 micrograms in 1 mL ampoule	Injection	5	..	AP
	Injection 500 micrograms in 1 mL ampoule	Injection	5	..	AP
	Nebuliser solution 5 mg in 2 mL single dose units, 30	Inhalation	2	5	AP
	Nebuliser solution 10 mg per mL, 50 mL	Inhalation	1	5	AP
	Powder for oral inhalation in breath actuated device 500 micrograms per dose, 200 doses	Inhalation by mouth	1	5	AP
	Pressurised inhalation 250 micrograms per dose, 400 doses	Inhalation by mouth	1	5	AP
	Tablet 5 mg	Oral	100	5	AP
Testosterone Enanthate	Injection 250 mg in 1 mL	Injection	3	3	SC
Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate	Injection 20 mg-40 mg-40 mg in 1 mL ampoule	Injection	3	3	OR
Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate	Injection 30 mg-60 mg-60 mg-100 mg in 1 mL ampoule	Injection	3	3	OR
Testosterone Undecanoate	Capsule 40 mg	Oral	60	5	OR
Tetanus Vaccine, Adsorbed	Injection 0.5 mL ampoule	Injection	3	..	CS
Tetrabenazine	Tablet 25 mg	Oral	100	2	RO
Tetracosactrin	Compound depot injection 1 mg in 1 mL ampoule	Injection	5	5	CG
Tetracycline Hydrochloride	Capsule 250 mg	Oral	25	1	LE
	Eye ointment 10 mg per g, 5 g	Application to the eye	1	..	BZ
Tetracycline Hydrochloride with a buffering agent	Capsule 250 mg	Oral	25	1	BC, BQ, LE
Theophylline	Capsule 50 mg (containing sustained release beads)	Oral	100	5	MB, MM
	Capsule 100 mg (containing sustained release beads)	Oral	100	5	MB, MM
	Capsule 100 mg (containing sustained release pellets)	Oral	100	5	FA
	Capsule 200 mg (containing sustained release pellets)	Oral	100	5	FA
	Capsule 300 mg (containing sustained release pellets)	Oral	100	5	FA
	Oral solution 80 mg per 15 mL, 500 mL	Oral	1	5	MM
	Tablet 50 mg	Oral	100	5	MM
	Tablet 125 mg	Oral	100	5	MM
	Tablet 200 mg	Oral	100	5	MM
	Tablet 200 mg (sustained release)	Oral	100	5	AP
	Tablet 250 mg (sustained release)	Oral	100	5	MM
	Tablet 300 mg (sustained release)	Oral	100	5	AP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Thiabendazole	Tablet 500 mg	Oral	16	..	MK
Thiamine Hydrochloride	Injection 100 mg in 1 mL ampoule	Injection	5	1	FM
	Tablet 100 mg	Oral	100	2	NN, RR
Thioguanine	Tablet 40 mg	Oral	25	1	BW
Thioridazine	Oral solution 30 mg per mL, 30 mL	Oral	1	5	SZ
Thioridazine Hydrochloride	Tablet 10 mg	Oral	100	5	AF, SZ
	Tablet 25 mg	Oral	100	5	AF, SZ
	Tablet 50 mg	Oral	100	5	AF, SZ
	Tablet 100 mg	Oral	100	5	AF, SZ
Thiotepa	Eye drops set containing 15 mg vial, 2 ampoules sterile water 10 mL, syringe with needle and 15 mL dropper bottle	Application to the eye	1	5	LE
Thiotepa with any determined brand of sterilised Water for Injections or other solvent	Injection 15 mg (with required solvent)	Injection or intravesical administration	2	1	LE
Thyroxine Sodium	Tablet equivalent to 50 micrograms anhydrous thyroxine sodium	Oral	200	1	BW
	Tablet equivalent to 100 micrograms anhydrous thyroxine sodium	Oral	200	1	BW
	Tablet equivalent to 200 micrograms anhydrous thyroxine sodium	Oral	200	1	BW
Tiaprofenic Acid	Tablet 200 mg	Oral	50	3	RL
	Tablet 300 mg	Oral	50	3	RL
	Tablets 200 mg, 20	Oral	1	..	RL
	Tablets 300 mg, 10	Oral	1	..	RL
Ticarcillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g ticarcillin, vial (with required solvent)	Injection	10	..	CS, SK
	Injection equivalent to 3 g ticarcillin, vial (with required solvent)	Injection	10	..	CS, SK
Ticarcillin Sodium with Potassium Clavulanate and any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 3 g ticarcillin-100 mg clavulanic acid, vial (with required solvent)	Injection	10	..	SK
Ticlopidine Hydrochloride	Tablet 250 mg	Oral	60	5	SD
Timolol Maleate	Eye drops equivalent to 2.5 mg timolol per mL, 5 mL	Application to the eye	1	5	FR, SI
	Eye drops equivalent to 5 mg timolol per mL, 5 mL	Application to the eye	1	5	FR, SI
	Tablet 5 mg	Oral	100	5	FR
Timolol Maleate with Pilocarpine Hydrochloride	Eye drops 5 mg (timolol)-20 mg per mL, 5 mL	Application to the eye	1	5	MK
	Eye drops 5 mg (timolol)-40 mg per mL, 5 mL	Application to the eye	1	5	MK
Tinidazole	Tablet 500 mg	Oral	4	..	GP, PF
Tobramycin	Eye drops 3 mg per mL, 5 mL	Application to the eye	1	2	AQ
	Eye ointment 3 mg per g, 3.5 g	Application to the eye	1	..	AQ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Tobramycin Sulfate	Injection equivalent to 80 mg tobramycin in 2 mL vial	Injection	10	1	LY
Tolbutamide	Tablet 500 mg	Oral	200	2	HP
	Tablet 1 g	Oral	100	5	HP
Tranexamic Acid	Tablet 500 mg	Oral	100	2	PS
Tranylcypromine Sulfate	Tablet equivalent to 10 mg tranylcypromine	Oral	50	2	SK
Triamcinolone Acetonide	Cream 200 micrograms per g, 100 g	Application	2	..	BQ, LE
	Cream 500 micrograms per g, 15 g	Application	1	1	BQ, LE
	Injection 10 mg in 1 mL ampoule	Injection	5	..	BQ
	Ointment 200 micrograms per g, 100 g	Application	2	..	LE
	Ointment 500 micrograms per g, 15 g	Application	1	1	LE
Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin	Ear cream 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	BQ
	Ear drops 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g, 7.5 mL	Application to the ear	1	2	BQ
	Ear ointment 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	BQ
Trifluoperazine Hydrochloride	Tablet equivalent to 1 mg trifluoperazine	Oral	100	5	SK
	Tablet equivalent to 2 mg trifluoperazine	Oral	100	5	SK
	Tablet equivalent to 5 mg trifluoperazine	Oral	100	5	SK
Triglycerides Oil, Medium Chain	500 mL	Oral	2	5	NU
	1 L	Oral	1	5	MJ
Trimethoprim	Tablet 300 mg	Oral	7	1	AF, BW
Trimipramine Maleate	Capsule equivalent to 50 mg trimipramine	Oral	50	2	MB
Tropisetron Hydrochloride	Capsule equivalent to 5 mg tropisetron	Oral	5	..	SZ
	I.V. injection equivalent to 5 mg tropisetron in 5 mL ampoule	Injection	1	..	SZ
Urea	Cream 100 mg per g, 100 g	Application	1	2	AG, GA, HA, OL, PY
Urofollitrophin	Injection set containing 10 ampoules powder for injection providing 75 units follicle stimulating hormone and 10 ampoules solvent 1 mL	Injection	1	5	SG
	Injection set containing 10 ampoules powder for injection providing 150 units follicle stimulating hormone and 10 ampoules solvent 1 mL	Injection	1	5	SG
Vancomycin Hydrochloride	Capsule equivalent to 125 mg (125,000 I.U.) vancomycin activity	Oral	40	..	LY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Capsule equivalent to 250 mg (250,000 I.U.) vancomycin activity	Oral	40	..	LY
Vancomycin Hydrochloride with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg (500,000 I.U.) vancomycin activity (with required solvent)	Injection	2	..	LY
Verapamil Hydrochloride	Capsule 160 mg (sustained release)	Oral	30	5	SI
	Capsule 240 mg (sustained release)	Oral	30	5	SI
	Injection 5 mg in 2 mL ampoule	Injection	5	..	KN, SC
	Tablet 40 mg	Oral	100	5	AF, KN, SC
	Tablet 80 mg	Oral	100	5	AF, KN, SC
	Tablet 120 mg	Oral	100	5	KN, SC
	Tablet 160 mg	Oral	30	5	KN, SC
	Tablet 180 mg (sustained release)	Oral	30	5	KN, SC
	Tablet 240 mg (sustained release)	Oral	30	5	KN, SC
Vidarabine	Eye ointment 30 mg per g, 3.5 g	Application to the eye	1	..	PD
Vigabatrin	Oral powder, sachet 500 mg	Oral	60	5	ML
	Tablet 500 mg	Oral	120	5	ML
Vinblastine Sulfate	Injection 10 mg vial and 10 mL solvent	Injection	2	..	BL
Vinblastine Sulfate with any determined brand of sterilised Water for Injections or other solvent	Injection 10 mg vial (with required solvent)	Injection	2	..	LY
Vincristine Sulfate	Injection 1 mg vial and 10 mL solvent	Injection	10	..	BL, LY
Warfarin Sodium	Tablet 1 mg	Oral	50	2	BA, BT
	Tablet 2 mg	Oral	50	2	BT
	Tablet 3 mg	Oral	50	2	BA
	Tablet 5 mg	Oral	50	2	BA, BT
Water for Injections, sterilised	Injection 2 mL ampoule	Injection	5	3	AP
	Injection 5 mL ampoule	Injection	5	3	AP
	Injection 10 mL ampoule	Injection	5	3	AP
	Extemporaneously-prepared eye drops and eye lotions	Application to the eye	Sch. 3	Sch. 3	
Wool Alcohols	Ointment B.P., 100 g	Application	1	1	SN
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
"XP Albumaid"	Oral powder 500 g	Oral	8	5	SB
"XP Analog"	Oral powder 400 g	Oral	8	5	SB
"XPhen, Tyr Maxamum"	Oral powder 200 g	Oral	20	5	SB
"XP Maxamaid"	Oral powder 500 g	Oral	8	5	SB
"XP Maxamum"	Oral powder 500 g	Oral	8	5	SB
Zinc Oxide	Ointment, compound, 50 g		1	1	WW
	Suppositories, compound, 12		1	1	WW
	Forms specified in Sch. 3		Sch. 3	Sch. 3	
Zinc Sulfate with Phenylephrine Hydrochloride	Eye drops 2.5 mg-1.2 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ

FIRST SCHEDULE—PART 2

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Acyclovir	Tablets 200 mg, 90	In compliance with authority procedures set out in subparagraph 11 (d): Suppression of genital herpes in severely immunocompromised patients	Oral	1	5	AD, BW
Bromocriptine Mesylate	Tablet equivalent to 2.5 mg bromocriptine	In compliance with authority procedures set out in subparagraph 11 (d): Acromegaly Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution	Oral	60	5	SZ
Ceftriaxone Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 250 mg ceftriaxone, vial (with required solvent)	Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven	Injection	5	..	RO
Chorionic Gonadotrophin	Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL	Cryptorchism not due to organic obstruction in boys over 12 months of age	Injection	2	1	OR, SG
	Injection set containing 3 ampoules powder for injection 1,000 units and 3 ampoules solvent 1 mL	Cryptorchism not due to organic obstruction in boys over 12 months of age	Injection	2	1	SG
Codeine Phosphate with Aspirin	Tablet 30 mg-325 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	BW
Codeine Phosphate with Paracetamol	Tablet 30 mg-500 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	BW, FM, SW
Cyproterone Acetate	Tablet 50 mg	In compliance with authority procedures set out in subparagraph 11 (d): Advanced carcinoma of the prostate Reduction of drive in sexual deviations of males	Oral	100	5	SC
"De-Lact Infant"	Oral powder 500 g	In compliance with authority procedures set out in subparagraph 11 (d): Proven chronic lactose intolerance in patients up to the age of 12 months, where the age of the patient is shown on the prescription	Oral	4	10	SJ

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Diazepam	Tablet 2 mg	In compliance with authority procedures set out in subparagraph 11 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	100	..	AF, RO, SU
	Tablet 5 mg	In compliance with authority procedures set out in subparagraph 11 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	100	..	AF, RO, SU
"Digestelact"	Oral powder 500 g	In compliance with authority procedures set out in subparagraph 11 (d): Proven chronic lactose intolerance in children over 1 year of age	Oral	5	10	SJ
Doxycycline Hydrochloride	Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets)	Urethritis	Oral	21	..	FA
		Pelvic inflammatory disease	Oral	28	..	FA
	Tablet equivalent to 100 mg doxycycline	Urethritis	Oral	21	..	AF, PF
		Pelvic inflammatory disease	Oral	28	..	AF, PF
Hydrocortisone Sodium Succinate	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	For use in a hospital	Injection	6	..	NR, UP
	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	For use in a hospital	Injection	6	..	UP
Ketoconazole	Tablet 200 mg	In compliance with authority procedures set out in subparagraph 11 (d): Oral candidiasis in severely immunocompromised persons where other forms of therapy have failed Systemic or deep mycoses where other forms of therapy have failed	Oral	30	5	JC

Name of pharmaceutical benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Maximum number of repeats	Brand
Lansoprazole	Capsule 30 mg	In compliance with authority procedures set out in subparagraph 11 (d): Scleroderma oesophagus, proven by endoscopy and unresponsive to other measures	Oral	28	5	LE
Medroxyprogesterone Acetate	Tablet 10 mg	Endometriosis	Oral	100	2	UP
Methadone Hydrochloride	Injection 10 mg in 1 mL ampoule	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Injection	10	..	BW
	Tablet 5 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
	Tablet 10 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
Metronidazole	Tablet 400 mg	Treatment of anaerobic infections	Oral	21	1	AF, MB
Morphine Hydrochloride	Oral solution 2 mg per mL, 200 mL	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	2	..	DW
	Oral solution 5 mg per mL, 200 mL	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	2	..	DW

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Oral solution 10 mg per mL, 200 mL	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	2	..	DW
Morphine Sulfate	Capsule 20 mg (containing sustained release pellets)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	GL
	Capsule 50 mg (containing sustained release pellets)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	GL
	Capsule 100 mg (containing sustained release pellets)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	GL
	Tablet 10 mg (controlled release)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	PS
	Tablet 30 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	FM

Name of pharmaceutical benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Maximum number of repeats	Brand
	Tablet 30 mg (controlled release)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	PS
	Tablet 60 mg (controlled release)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	PS
	Tablet 100 mg (controlled release)	In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	PS
Niclosamide	Tablet 500 mg	Hymenolepiasis nana	Oral	16	..	BN
Nitrazepam	Tablet 5 mg	In compliance with authority procedures set out in subparagraph 11 (d): For use by patients who are receiving long-term nursing care in hospitals or nursing homes and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage) Myoclonic epilepsy	Oral	50	5	AF, RO
Omeprazole	Capsule 20 mg	In compliance with authority procedures set out in subparagraph 11 (d): Scleroderma oesophagus, proven by endoscopy and unresponsive to other measures	Oral	28	5	AP
		In compliance with authority procedures set out in subparagraph 11 (d): Zollinger-Ellison syndrome	Oral	56	5	AP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Oxazepam	Tablet 15 mg	In compliance with authority procedures set out in subparagraph 11 (d): For use by patients who are receiving long-term nursing care in hospitals or nursing homes and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	50	5	AF, AY, WY
	Tablet 30 mg	In compliance with authority procedures set out in subparagraph 11 (d): For use by patients who are receiving long-term nursing care in hospitals or nursing homes and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	50	5	AF, AY, WY
Oxycodone Hydrochloride	Tablet 5 mg	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BT
Oxycodone Pectinate	Suppository equivalent to 30 mg oxycodone	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)		24	..	BT

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Pethidine Hydrochloride	Injection 50 mg in 1 mL ampoule	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Injection	10	..	AP, BL, SI
	Injection 100 mg in 2 mL ampoule	In compliance with authority procedures set out in subparagraph 11 (d): Severe disabling pain associated with proven malignant neoplasia Chronic severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Injection	10	..	AP, BL, SI
Phenoxymethylpenicillin Benzathine	Tablet equivalent to 125 mg phenoxymethylpenicillin	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB
Phenoxymethylpenicillin Potassium	Capsule equivalent to 250 mg phenoxymethylpenicillin	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, LY, SI
	Tablet equivalent to 250 mg phenoxymethylpenicillin	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, LY
Rifampicin	Capsule 150 mg	In compliance with authority procedures set out in subparagraph 11 (d): Leprosy in adults	Oral	100	..	AF
	Capsule 300 mg	In compliance with authority procedures set out in subparagraph 11 (d): Leprosy in adults	Oral	100	..	AF
Temazepam	Capsule 10 mg	In compliance with authority procedures set out in subparagraph 11 (d): For use by patients who are receiving long-term nursing care in hospitals or nursing homes and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	50	5	AF, PS, WY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Tablet 10 mg	In compliance with authority procedures set out in subparagraph 11 (d): For use by patients who are receiving long-term nursing care in hospitals or nursing homes and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	50	5	WY
Tetracycline Hydrochloride	Capsule 250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	LE
Tetracycline Hydrochloride with a buffering agent	Capsule 250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	BC, BQ, LE
Vancomycin Hydrochloride with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg (500,000 I.U.) vancomycin activity (with required solvent)	Endophthalmitis Use initiated in a hospital	Injection	5	..	LY

SECOND SCHEDULE—PART 1

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Adrenaline Acid Tartrate	Injection equivalent to adrenaline 1 in 1,000, 1 mL	Injection	5	..	AP
Amoxycillin Trihydrate	Capsule equivalent to 250 mg amoxycillin	Oral	20	..	AF, CS, FC, SI, SK
	Capsule equivalent to 500 mg amoxycillin	Oral	20	..	AF, CS, FC, SI, SK
	Sachet containing oral powder equivalent to 3 g amoxycillin	Oral	1	..	CS, SK
	Tablet, chewable, equivalent to 250 mg amoxycillin	Oral	20	..	CS, SK
Amoxycillin Trihydrate with Potassium Clavulanate	Tablet equivalent to 250 mg amoxycillin-125 mg clavulanic acid	Oral	15	..	CS, SK
	Tablet equivalent to 500 mg amoxycillin-125 mg clavulanic acid	Oral	15	..	CS, SK
Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL, 75 mL	Oral	1	..	SK
	Powder for oral suspension equivalent to 250 mg amoxycillin-62.5 mg clavulanic acid per 5 mL, 75 mL	Oral	1	..	SK
Amoxycillin Trihydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL	Oral	1	..	AF, CS, FC, SI, SK
	Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL	Oral	1	..	AF, CS, FC, SI, SK
	Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL, 20 mL	Oral	1	..	SK
Amphotericin	Lozenge 10 mg	Oral	20	..	BQ
Ampicillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg ampicillin, vial (with required solvent)	Injection	5	..	CS, FC
	Injection equivalent to 1 g ampicillin, vial (with required solvent)	Injection	5	..	CS, FC
Ampicillin Trihydrate	Capsule equivalent to 250 mg ampicillin	Oral	24	..	AF, SK
	Capsule equivalent to 500 mg ampicillin	Oral	24	..	AF, SK
Aspirin	Tablet 300 mg	Oral	100	..	SI
	Tablet 325 mg (buffered)	Oral	100	..	MJ
	Tablet 650 mg (enteric coated)	Oral	100	..	SK
	Tablet, dispersible, 300 mg	Oral	100	..	RC
Atropine Sulfate	Injection 600 micrograms in 1 mL ampoule	Injection	5	..	AP
Benzathine Penicillin	Injection 1.8 g in 4 mL disposable syringe	Injection	1	..	WY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium	Injection set containing 1 vial powder for injection 450 mg-300 mg-187 mg and 2 mL sterilised water for injections	Injection	1	..	WY
Benztropine Mesylate	Injection 2 mg in 2 mL ampoule	Injection	5	..	MK
Benzydamine Hydrochloride	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	Topical	1	..	MM
Benzylpenicillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 600 mg benzylpenicillin, vial (with required solvent)	Injection	10	..	CS
	Injection equivalent to 3 g benzylpenicillin, vial (with required solvent)	Injection	10	..	CS
Betamethasone Acetate with Betamethasone Sodium Phosphate	Injection 3 mg-3.9 mg in 1 mL ampoule	Injection	5	..	SH
Carbamazepine	Oral suspension 100 mg per 5 mL, 300 mL	Oral	1	..	CG
	Tablet 100 mg	Oral	200	..	CG
	Tablet 200 mg	Oral	200	..	AF, CG
	Tablet 200 mg (controlled release)	Oral	200	..	CG
Cefaclor Monohydrate	Capsule equivalent to 250 mg cefaclor	Oral	15	..	LY
Cefaclor Monohydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL	Oral	1	..	LY
	Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL, 75 mL	Oral	1	..	LY
Cefotaxime Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cefotaxime, vial (with required solvent)	Injection	5	..	RL
	Injection equivalent to 2 g cefotaxime, vial (with required solvent)	Injection	5	..	RL
Cefotetan Disodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cefotetan, vial (with required solvent)	Injection	10	..	LE
	Injection equivalent to 2 g cefotetan, vial (with required solvent)	Injection	10	..	LE
Cephalexin	Capsule 250 mg (anhydrous)	Oral	20	..	AF, GL, LY
	Capsule 500 mg (anhydrous)	Oral	20	..	AF, GL, LY
Cephalexin with Purified Water B.P.	Granules for oral suspension 125 mg per 5 mL, 100 mL	Oral	1	..	AF, GL, LY
	Granules for oral suspension 250 mg per 5 mL, 100 mL	Oral	1	..	AF, GL, LY
Cephalothin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g cephalothin, vial (with required solvent)	Injection	10	..	LY
Chloramphenicol	Eye drops 5 mg per mL, 10 mL	Application to the eye	1	..	PD, SI
Chlorhexidine Gluconate	Solution 50 mg per mL, 200 mL		1	..	IC
Clindamycin Hydrochloride	Capsule equivalent to 150 mg clindamycin	Oral	25	..	UP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for mixture equivalent to 75 mg clindamycin per 5 mL, 100 mL	Oral	1	..	UP
Cloxacillin Sodium	Capsule equivalent to 250 mg cloxacillin	Oral	24	..	AF
	Capsule equivalent to 500 mg cloxacillin	Oral	24	..	AF
Codeine Phosphate	Tablet 30 mg	Oral	20	..	FA, FM, MB
Codeine Phosphate with Aspirin	Tablet 30 mg-325 mg	Oral	20	..	BW
Codeine Phosphate with Paracetamol	Tablet 30 mg-500 mg	Oral	20	..	BW, FM, SW
Dextran 40 with Glucose	Intravenous infusion 100 mg per mL-139 mmol (anhydrous) per 500 mL, 500 mL	Injection	3	..	PS
Dextran 40 with Sodium Chloride	Intravenous infusion 100 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 with Sodium Chloride	Intravenous infusion 60 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Diazepam	Injection 10 mg in 2 mL ampoule	Injection	5	..	BL
	Tablet 2 mg	Oral	50	..	AF, RO, SU
	Tablet 5 mg	Oral	50	..	AF, RO, SU
Diclofenac Potassium	Tablets 25 mg, 20	Oral	1	..	CG
	Tablets 50 mg, 20	Oral	1	..	CG
Diclofenac Sodium	Suppository 100 mg		40	..	CG
	Tablet 25 mg (enteric coated)	Oral	100	..	CG
	Tablet 50 mg (enteric coated)	Oral	50	..	AF, CG
	Tablets 50 mg (enteric coated), 20	Oral	1	..	AF
Diflunisal	Tablet 250 mg	Oral	100	..	MK
	Tablet 500 mg	Oral	50	..	MK
Doxycycline Hydrochloride	Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets)	Oral	7	..	FA
	Tablet equivalent to 100 mg doxycycline	Oral	7	..	AF, PF
Erythromycin	Capsule 125 mg (containing enteric coated pellets)	Oral	25	..	FA
	Capsule 175 mg (containing enteric coated pellets)	Oral	25	..	FA
	Capsule 250 mg (containing enteric coated pellets)	Oral	25	..	FA
	Injection 100 mg in 2 mL ampoule	I.M. injection	5	..	AB
	Tablet 250 mg (enteric coated)	Oral	25	..	UP
Erythromycin Estolate	Oral suspension equivalent to 125 mg erythromycin per 5 mL, 100 mL	Oral	1	..	LY
	Paediatric oral drops equivalent to 100 mg erythromycin per mL, 10 mL	Oral	1	..	LY
Erythromycin Ethyl Succinate	Tablet equivalent to 400 mg erythromycin	Oral	25	..	AB, AF
Erythromycin Ethyl Succinate with Purified Water B.P.	Granules for oral suspension equivalent to 200 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB, AF

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
	Granules for oral suspension equivalent to 400 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Lactobionate	Intravenous infusion equivalent to 300 mg erythromycin, vial	Injection	5	..	AB
Erythromycin Stearate	Capsule equivalent to 250 mg erythromycin	Oral	25	..	AB
	Oral suspension equivalent to 125 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB
	Oral suspension equivalent to 250 mg erythromycin per 5 mL, 100 mL	Oral	1	..	AB
	Tablet equivalent to 250 mg erythromycin	Oral	25	..	AB
Flucloxacillin Magnesium with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL, 100 mL	Oral	1	..	CS, SK
	Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL, 100 mL	Oral	1	..	CS, SK
Flucloxacillin Sodium	Capsule equivalent to 250 mg flucloxacillin	Oral	24	..	AF, CS, FC, SK
	Capsule equivalent to 500 mg flucloxacillin	Oral	24	..	AF, CS, FC, SK
Flucloxacillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg flucloxacillin, vial (with required solvent)	Injection	5	..	CS, SK
	Injection equivalent to 1 g flucloxacillin, vial (with required solvent)	Injection	5	..	CS, SK
Gas-gangrene Antitoxin, Mixed	Injection, 1 ampoule containing 10,000 units Perfringens; 5,000 units Septicum; 10,000 units Novyi	Injection	2	..	CS
Glucagon Hydrochloride	Injection set containing 1 I.U. with 1 mL vial diluent	Injection	1	..	LY
	Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe	Injection	1	..	NO
Glucose	Intravenous infusion 278 mmol (anhydrous) per L, 1 L	Injection	5	..	AB, BX
Glyceryl Trinitrate	Tablets 600 micrograms, 100	Oral	1	..	BW
Hydrocortisone Acetate	Cream 10 mg per g, 30 g	Application	1	..	BQ, NN, PD, SI, UP
	Cream 10 mg per g, 50 g	Application	1	..	BQ, NN, PD, SI, UP
	Ointment 10 mg per g, 30 g	Application	1	..	NN, SI
	Ointment 10 mg per g, 50 g	Application	1	..	BQ, NN, PD, SI
Hydrocortisone Sodium Succinate	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	Injection	6	..	NR, UP
	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	Injection	6	..	UP
	Injection equivalent to 500 mg hydrocortisone with 4 mL solvent	Injection	2	..	UP

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Ibuprofen	Tablet 200 mg	Oral	100	..	AF
	Tablet 400 mg	Oral	100	..	BT
	Tablets 200 mg, 20	Oral	1	..	AF
	Tablets 400 mg, 20	Oral	1	..	BT
Idoxuridine	Ointment 5 mg per g, 5 g	Topical application	1	..	SK
Indomethacin	Capsule 25 mg	Oral	100	..	AF, MK
	Capsules 25 mg, 20	Oral	1	..	AF
	Suppository 100 mg		40	..	MK
Ketoprofen	Capsule 50 mg	Oral	50	..	MB
	Capsule 100 mg (sustained release)	Oral	50	..	MB, RR
	Capsule 200 mg (sustained release)	Oral	28	..	MB, RR
	Suppository 100 mg		40	..	MB
Lignocaine Hydrochloride	Injection 100 mg in 5 mL ampoule	Injection	2	..	AP
Lincomycin Hydrochloride	Injection equivalent to 600 mg lincomycin in 2 mL vial	Injection	5	..	UP
Methacycline Hydrochloride	Capsule 300 mg	Oral	10	..	WW
Methylprednisolone Acetate	Injection 40 mg in 1 mL vial	Injection	5	..	UP
Metoclopramide Hydrochloride	Injection 10 mg in 2 mL ampoule	Injection	10	..	SK
	Oral solution 5 mg per 5 mL, 100 mL	Oral	1	..	SK
	Tablet 10 mg	Oral	25	..	AF, SK
Metronidazole	Intravenous infusion 500 mg in 100 mL	Injection	5	..	DW, MB
	Suppositories 500 mg, 10		1	..	MB
	Suppositories 1 g, 10		1	..	MB
	Tablet 200 mg	Oral	21	..	AF, MB, SR
	Tablet 400 mg	Oral	5	..	AF
Metronidazole Benzoate	Oral suspension 320 mg per 5 mL, 100 mL	Oral	1	..	MB
Miconazole Nitrate	Cream 20 mg per g, 20 g	Application	1	..	JC
Morphine Hydrochloride	Oral solution 2 mg per mL, 200 mL	Oral	1	..	DW
	Oral solution 5 mg per mL, 200 mL	Oral	1	..	DW
	Oral solution 10 mg per mL, 200 mL	Oral	1	..	DW
Morphine Sulfate	Capsule 20 mg (containing sustained release pellets)	Oral	20	..	GL
	Capsule 50 mg (containing sustained release pellets)	Oral	20	..	GL
	Capsule 100 mg (containing sustained release pellets)	Oral	20	..	GL
	Injection 10 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 15 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 30 mg in 1 mL ampoule	Injection	5	..	BL
	Tablet 10 mg (controlled release)	Oral	20	..	PS
	Tablet 30 mg	Oral	20	..	FM
	Tablet 30 mg (controlled release)	Oral	20	..	PS
	Tablet 60 mg (controlled release)	Oral	20	..	PS
	Tablet 100 mg (controlled release)	Oral	20	..	PS

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Naloxone Hydrochloride	Injection 400 micrograms in 1 mL disposable injection set	Injection	1	..	CS
	Injection 800 micrograms in 2 mL disposable injection set	Injection	1	..	CS
	Injection 2 mg in 5 mL disposable injection set	Injection	1	..	CS
Naproxen	Oral suspension 125 mg per 5 mL, 500 mL	Oral	1	..	SD
	Suppository 500 mg		40	..	SD
	Tablet 250 mg	Oral	100	..	AF, SD
	Tablet 250 mg (enteric coated)	Oral	100	..	SD
	Tablet 500 mg	Oral	50	..	AF, SD
	Tablet 500 mg (enteric coated)	Oral	50	..	SD
	Tablet 750 mg (sustained release)	Oral	28	..	MD, SD
	Tablet 1 g (sustained release)	Oral	28	..	MD, SD
	Tablets 250 mg, 20	Oral	1	..	AF, SD
	Tablets 500 mg, 10	Oral	1	..	AF, SD
	Tablets 750 mg (sustained release), 7	Oral	1	..	SD
	Tablets 1 g (sustained release), 7	Oral	1	..	SD
Naproxen Sodium	Tablet 550 mg	Oral	50	..	SD
	Tablets 550 mg, 10	Oral	1	..	SD
Nitrazepam	Tablet 5 mg	Oral	25	..	AF, RO
Nystatin	Capsule 500,000 units	Oral	50	..	BQ, LE
	Cream 100,000 units per g, 15 g	Application	1	..	BQ, LE
	Lozenge 100,000 units	Oral	20	..	LE
	Ointment 100,000 units per g, 15 g	Application	1	..	BQ, LE
	Oral suspension 100,000 units per mL, 24 mL	Oral	1	..	BQ, LE
	Tablet 500,000 units	Oral	50	..	BQ, LE
Oxazepam	Tablet 15 mg	Oral	25	..	AF, AY, WY
	Tablet 30 mg	Oral	25	..	AF, AY, WY
Oxycodone Hydrochloride	Tablet 5 mg	Oral	20	..	BT
Oxycodone Pectinate	Suppository equivalent to 30 mg oxycodone		12	..	BT
Paracetamol	Elixir 240 mg per 5 mL, 200 mL	Oral	1	..	SW
	Mixture 120 mg per 5 mL, 100 mL	Oral	1	..	BW, SW
	Tablet 500 mg	Oral	100	..	BW, FM, JT, SW
Pethidine Hydrochloride	Injection 50 mg in 1 mL ampoule	Injection	5	..	AP, BL, SI
	Injection 100 mg in 2 mL ampoule	Injection	5	..	AP, BL, SI
Phenoxymethylpenicillin Benzathine	Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL, 100 mL	Oral	1	..	AB, CS, SI
	Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL, 100 mL	Oral	1	..	AB, CS, SI
	Tablet equivalent to 125 mg phenoxymethylpenicillin	Oral	25	..	AB

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Phenoxymethylpenicillin Potassium	Capsule equivalent to 250 mg phenoxymethylpenicillin	Oral	25	..	AB, CS, LY, SI
	Capsule equivalent to 500 mg phenoxymethylpenicillin	Oral	25	..	CS, SI
	Tablet equivalent to 250 mg phenoxymethylpenicillin	Oral	25	..	AB, LY
	Tablet equivalent to 500 mg phenoxymethylpenicillin	Oral	25	..	AB, LY
Piroxicam	Capsule 10 mg	Oral	50	..	GP, PF
	Capsule 20 mg	Oral	25	..	GP, PF
	Dispersible tablet 10 mg	Oral	50	..	PF
	Dispersible tablet 20 mg	Oral	25	..	PF
Procaine Penicillin	Injection 1 g in disposable syringe	Injection	5	..	SI
	Injection 1.5 g in disposable syringe	Injection	5	..	SI
Prochlorperazine	Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate, 5		1	..	MB
	Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate, 5		1	..	MB
Prochlorperazine Edisylate	Injection 12.5 mg in 1 mL ampoule	Injection	10	..	SK
Prochlorperazine Maleate	Tablet 5 mg	Oral	25	..	MB
Prochlorperazine Mesylate	Injection 12.5 mg in 1 mL ampoule	Injection	10	..	MB
Promethazine Hydrochloride	Injection 50 mg in 2 mL ampoule	Injection	10	..	BL
Promethazine Theoclate	Tablet 25 mg	Oral	30	..	MB
Sodium Chloride	Injection 9 mg per mL, 2 mL ampoule	Injection	5	..	AP
	Injection 9 mg per mL, 5 mL ampoule	Injection	5	..	AP
	Injection 9 mg per mL, 10 mL ampoule	Injection	5	..	AP
	Intravenous infusion 154 mmol per L, 1 L	Injection	5	..	BX
	Intravenous infusion 513 mmol per L, 1 L	Injection	2	..	BX
Sodium Chloride with Glucose	Intravenous infusion 31 mmol-222 mmol (anhydrous) per L, 1 L	Injection	5	..	BX
	Intravenous infusion 19 mmol-104 mmol (anhydrous) per 500 mL, 500 mL	Injection	5	..	BX
	Intravenous infusion 39 mmol-69 mmol (anhydrous) per 500 mL, 500 mL	Injection	5	..	BX
Sulfamethoxazole with Trimethoprim	Paediatric oral suspension 200 mg-40 mg per 5 mL, 100 mL	Oral	1	..	AF, BW, RO
	Tablet 400 mg-80 mg	Oral	10	..	AF, BW, RO
	Tablet 800 mg-160 mg	Oral	10	..	AF, BW, RO
Sulindac	Tablet 100 mg	Oral	100	..	AF, FR
	Tablet 200 mg	Oral	50	..	AF, FR
	Tablets 100 mg, 20	Oral	1	..	AF
	Tablets 200 mg, 10	Oral	1	..	AF
Temazepam	Capsule 10 mg	Oral	25	..	AF, PS, WY
	Tablet 10 mg	Oral	25	..	WY

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Tenoxicam	Tablet 10 mg	Oral	50	..	RO
Tetanus Vaccine, Adsorbed	Injection 0.5 mL ampoule	Injection	3	..	CS
Tetracycline Hydrochloride	Capsule 250 mg	Oral	25	..	LE
Tetracycline Hydrochloride with a buffering agent	Capsule 250 mg	Oral	25	..	BC, BQ, LE
Ticarcillin Sodium with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 1 g ticarcillin, vial (with required solvent)	Injection	10	..	CS, SK
	Injection equivalent to 3 g ticarcillin, vial (with required solvent)	Injection	10	..	CS, SK
Ticarcillin Sodium with Potassium Clavulanate and any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 3 g ticarcillin-100 mg clavulanic acid, vial (with required solvent)	Injection	10	..	SK
Triamcinolone Acetonide	Injection 10 mg in 1 mL ampoule	Injection	5	..	BQ
Vancomycin Hydrochloride with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 500 mg (500,000 I.U.) vancomycin activity (with required solvent)	Injection	2	..	LY
Water for Injections, sterilised	Injection 2 mL ampoule	Injection	5	..	AP
	Injection 5 mL ampoule	Injection	5	..	AP
	Injection 10 mL ampoule	Injection	5	..	AP

SECOND SCHEDULE—PART 2

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Maximum number of repeats*	*Brand*
Metronidazole	Tablet 400 mg	Treatment of anaerobic infections	Oral	21	..	AF, MB

THIRD SCHEDULE

Form of pharmaceutical benefit	*Maximum quantity*	*Maximum number of repeats*
Creams	100 g	1
Ear Drops	15 mL	2
Eye Drops		
Cocaine	15 mL	..
Others	15 mL	5
Eye Lotions	200 mL	2
Glycerins	100 mL	1
Inhalations	50 mL	1
Linctuses	100 mL	2
Liniments	100 mL	1
Lotions	200 mL	2
Mixtures	200 mL	4
Mixtures for Children	100 mL	4
Mouth Washes	200 mL	1
Nasal Instillations	15 mL	2
Ointments and Waxes	100 g	1
Paints	25 mL	1
Pastes		
Cocaine	25 g	..
Others	100 g	1
Powders, Dusting	100 g	1
Powders for Internal Use	100 g	2
Soaps	200 mL	1
Solutions	200 mL	2

Dated this Sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER PARAGRAPH 98C (1) (b)

No. PB 19 of 1994

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, pursuant to paragraph 98C (1) (b) of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1994.

2. Determination No. PB 12 of 1994 under paragraph 98C (1) (b) of the Act made on 15 July 1994 with effect from 1 August 1994, as amended by Determination No. PB 14 of 1994 under paragraph 98C (1) (b) of the Act made on 14 September 1994 with effect from 1 October 1994, is hereby revoked.

3. In this Determination:
"the Act" means the *National Health Act 1953*;
"the Regulations" means the National Health (Pharmaceutical Benefits) Regulations made under the Act;
"the Department" means the Department of Human Services and Health;
"the Secretary" means the Secretary to the Department of Human Services and Health;
"the Commission" means the Health Insurance Commission established by the *Health Insurance Commission Act 1973*;
"the Managing Director" means the Managing Director of the Commission;
"approved price to pharmacists" has the same meaning as in subsection 98B (3) of the Act;
"ready-prepared pharmaceutical benefit" means a drug or medicinal preparation in respect of which there is in force a determination under subsection 85 (6) of the Act;
"extemporaneously-prepared pharmaceutical benefit" means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit;
"prescription" includes a prescription written on an authority pursuant to regulation 13 of the Regulations, subparagraph 14 (d) of the declaration made under subsection 85 (2) of the Act or subparagraph 10 (d) of the determinations made under sections 85, 85A and 88 of the Act, a repeat authorization or a deferred supply authorization;
"Standard Formulae List" means the list of those Standard Formulae, taken from formularies in common use, which are included as pre-priced extemporaneously-prepared pharmaceutical benefits in the *Schedule of Pharmaceutical Benefits* published by the Department.

4. For the purpose of this Determination:

(a) benefits which involve the admixture of ready-prepared ingredients are set out in Schedule 1 to this Determination;

(b) benefits which are classified as dangerous drugs for the purpose of payment of a dangerous drug fee are set out in Schedule 2 to this Determination;

(c) drugs which are used in the preparation of extemporaneously-prepared pharmaceutical benefits and which are unstable or packed sterile and unused quantities of which are unsuitable for future use are set out in Schedule 3 to this Determination;

(d) benefits the complete pack of which shall be supplied regardless of any lesser quantity ordered are set out in Schedule 4 to this Determination.

5. The basic wholesale price of a drug used in the preparation of extemporaneously-prepared pharmaceutical benefits shall be calculated as the arithmetic average of wholesale costs of the drug, in a purchase quantity agreed upon by the Secretary and the Pharmacy Guild of Australia and available from wholesale drug distributors. For this purpose the basic wholesale cost of a drug shall be ascertained and shall take effect in accordance with the following timetable:

Basic wholesale cost ascertained	*Price takes effect for pharmaceutical benefits*
As at 1 January	As at 1 April of same year
As at 1 May	As at 1 August of same year
As at 1 September	As at 1 December of same year

6. Where the prescription identifies the ready-prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved price to pharmacists for that brand.

7. Where the prescription does not identify the ready-prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved price to pharmacists of the brand which is lowest in price specified in the *Schedule of Pharmaceutical Benefits* published by the Department, and which is available from a wholesale source in the capital city of the State in which the benefit is supplied.

8. A medicinal preparation which is a variation of a formula included in the Standard Formulae List, due to the addition or deletion of an ingredient or to variation of the dose, shall be deemed not to be included in the Standard Formulae List.

9. A medicinal preparation which is a combination of preparations set out in the Standard Formulae List shall be deemed not to be included in the Standard Formulae List.

10. Where a prescription calls for a quantity of one of the benefits listed in Schedule 4 to this Determination which is less than the quantity contained in the pack size specified in that Schedule in relation to that benefit, the complete pack shall be supplied.

11. Prices payable for containers shall be specified in the *Schedule of Pharmaceutical Benefits* published by the Department.

12. An election made pursuant to paragraph 38 of the determination made under subsection 98B (1) of the Act shall be made in writing to the Managing Director and shall remain in force for a period of not less than 3 months from and including the date of election, but may be revoked in writing at any time after the expiration of that period. While the election remains in force, the approved pharmacist or approved medical practitioner shall be entitled to receive the amount payable in accordance with paragraph 20 of the determination made under subsection 98B (1) of the Act.

13. Where an approved pharmacist or approved medical practitioner who has not made an election pursuant to paragraph 38 of the determination made under subsection 98B (1) of the Act supplies an extemporaneously-prepared pharmaceutical benefit and no preparation of the type supplied is included in the Standard Formulae List (and an average price is therefore not available), the amount payable shall be calculated in accordance with paragraph 20 of that determination.

14. Where the prescription to be priced comprises a preparation included in the Standard Formulae List plus an additive, and the approved pharmacist or approved medical practitioner has not made an election pursuant to paragraph 38 of the determination made under subsection 98B (1) of the Act, the amount payable shall be the average price calculated in accordance with paragraph 37 of that determination, unless the approved pharmacist or approved medical practitioner indicates that the prescription is to be priced as if it had specified only the preparation included in the Standard Formulae List without the additive, in which case the amount payable shall be the price payable for the preparation included in the Standard Formulae List without the additive.

SCHEDULE 1

LIST OF BENEFITS WHICH INVOLVE THE ADMIXTURE OF READY-PREPARED INGREDIENTS

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*
Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL, 75 mL Powder for oral suspension equivalent to 250 mg amoxycillin-62.5 mg clavulanic acid per 5 mL, 75 mL
Amoxycillin Trihydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL, 20 mL
Cefaclor Monohydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL, 75 mL
Cephalexin with Purified Water B.P.	Granules for oral suspension 125 mg per 5 mL, 100 mL Granules for oral suspension 250 mg per 5 mL, 100 mL
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for mixture equivalent to 75 mg clindamycin per 5 mL, 100 mL
Ecothiopate Iodide	Eye drops 300 micrograms per mL (1.5 mg and 5 mL vial of solvent) Eye drops 600 micrograms per mL (3 mg and 5 mL vial of solvent) Eye drops 1.25 mg per mL (6.25 mg and 5 mL vial of solvent) Eye drops 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)
Erythromycin Ethyl Succinate with Purified Water B.P.	Granules for oral suspension equivalent to 200 mg erythromycin per 5 mL, 100 mL Granules for oral suspension equivalent to 400 mg erythromycin per 5 mL, 100 mL
Flucloxacillin Magnesium with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL, 100 mL Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL, 100 mL
Thiotepa	Eye drops set containing 15 mg vial, 2 ampoules sterile water 10 mL, syringe with needle and 15 mL dropper bottle

SCHEDULE 2

LIST OF BENEFITS WHICH ARE CLASSIFIED AS DANGEROUS DRUGS FOR THE PURPOSE OF PAYMENT OF A DANGEROUS DRUG FEE

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*
Codeine Phosphate	Tablet 30 mg
Dexamphetamine Sulfate	Tablet 5 mg
Methadone Hydrochloride	Injection 10 mg in 1 mL ampoule Tablet 5 mg Tablet 10 mg
Morphine Hydrochloride	Oral solution 2 mg per mL, 200 mL Oral solution 5 mg per mL, 200 mL Oral solution 10 mg per mL, 200 mL
Morphine Sulfate	Capsule 20 mg (containing sustained release pellets) Capsule 50 mg (containing sustained release pellets) Capsule 100 mg (containing sustained release pellets) Injection 10 mg in 1 mL ampoule Injection 15 mg in 1 mL ampoule Injection 30 mg in 1 mL ampoule Tablet 10 mg (controlled release) Tablet 30 mg Tablet 30 mg (controlled release) Tablet 60 mg (controlled release) Tablet 100 mg (controlled release)
Morphine Tartrate	Injection 120 mg in 1.5 mL ampoule
Oxycodone Hydrochloride	Tablet 5 mg
Oxycodone Pectinate	Suppository equivalent to 30 mg oxycodone
Pethidine Hydrochloride	Injection 50 mg in 1 mL ampoule Injection 100 mg in 2 mL ampoule

SCHEDULE 3

LIST OF DRUGS WHICH ARE USED IN THE PREPARATION OF EXTEMPORANEOUSLY-PREPARED PHARMACEUTICAL BENEFITS AND WHICH ARE UNSTABLE OR PACKED STERILE AND UNUSED QUANTITIES OF WHICH ARE UNSUITABLE FOR FUTURE USE

Water for Injections, sterilised B.P.

SCHEDULE 4

LIST OF PHARMACEUTICAL BENEFITS THE COMPLETE PACK OF WHICH SHALL BE SUPPLIED REGARDLESS OF ANY LESSER QUANTITY ORDERED

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Acyclovir	Eye ointment 30 mg per g	4.5 g
	Tablets 200 mg	90
	Tablets 400 mg	70
	Tablets 800 mg	35
Adrenaline	Eye drops 5 mg per mL	7.5 mL
Adrenaline Hydrochloride	Eye drops equivalent to 10 mg adrenaline per mL	10 mL
	Eye drops equivalent to 20 mg adrenaline per mL	10 mL
Aluminium Hydroxide, Dried with Light Kaolin or Light Kaolin (Natural)	Oral suspension 137 mg-1 g per 5 mL	500 mL
Aminacrine Hydrochloride	Eye drops 3 mg in 15 mL	15 mL
"Aminogran Mineral Mixture"	Oral powder	250 g
Amoxycillin Trihydrate with Potassium Clavulanate and Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL	75 mL
	Powder for oral suspension equivalent to 250 mg amoxycillin-62.5 mg clavulanic acid per 5 mL	75 mL
Amoxycillin Trihydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL	100 mL
	Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL	100 mL
	Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL	20 mL
Antazoline Phosphate with Naphazoline Hydrochloride	Eye drops 5 mg-500 micrograms per mL	15 mL
Antazoline Sulfate with Naphazoline Nitrate	Eye drops 5 mg-250 micrograms per mL	10 mL
Atropine Sulfate	Eye drops 5 mg per mL	15 mL
	Eye drops 10 mg per mL	15 mL
Beclomethasone Dipropionate	Aqueous nasal spray (pump pack) 50 micrograms per dose	200 doses
	Aqueous nasal spray refill 50 micrograms per dose	200 doses
	Aqueous nasal spray 50 micrograms per dose, 400 doses set containing 1 pump pack, 200 doses and 1 refill, 200 doses	1 set
	Pressurised inhalation 50 micrograms per dose	200 doses
	Pressurised inhalation 100 micrograms per dose	200 doses
	Pressurised inhalation 250 micrograms per dose	200 doses
Benzydamine Hydrochloride	Mouth and throat rinse 22.5 mg per 15 mL	500 mL
Benzyl Benzoate	Application 50 g in 200 mL	200 mL

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Betamethasone Dipropionate	Cream equivalent to 500 micrograms betamethasone per g	15 g
	Ointment equivalent to 500 micrograms betamethasone per g	15 g
	Scalp lotion equivalent to 500 micrograms betamethasone per g	30 mL
Betamethasone Valerate	Cream equivalent to 500 micrograms betamethasone per g	15 g
	Gel equivalent to 500 micrograms betamethasone per g	15 g
	Ointment equivalent to 500 micrograms betamethasone per g	15 g
Betaxolol Hydrochloride	Eye drops, solution, equivalent to 5 mg betaxolol per mL	5 mL
	Eye drops, suspension, equivalent to 2.5 mg betaxolol per mL	5 mL
Bisacodyl	Enema 10 mg in 5 mL	25
Budesonide	Aqueous nasal spray (pump pack) 100 micrograms per dose	200 doses
	Nebuliser suspension 500 micrograms in 2 mL single dose units	30
	Nebuliser suspension 1 mg in 2 mL single dose units	30
	Powder for oral inhalation in breath actuated device 100 micrograms per dose	200 doses
	Powder for oral inhalation in breath actuated device 200 micrograms per dose	200 doses
	Powder for oral inhalation in breath actuated device 400 micrograms per dose	200 doses
	Pressurised inhalation 50 micrograms per dose	200 doses
	Pressurised inhalation 100 micrograms per dose	200 doses
	Pressurised inhalation 200 micrograms per dose	200 doses
Carbachol	Eye drops 15 mg per mL	15 mL
	Eye drops 30 mg per mL	15 mL
Carbamazepine	Oral suspension 100 mg per 5 mL	300 mL
Cefaclor Monohydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL	100 mL
	Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL	75 mL
Cephalexin with Purified Water B.P.	Granules for oral suspension 125 mg per 5 mL	100 mL
	Granules for oral suspension 250 mg per 5 mL	100 mL
Chloramphenicol	Ear drops (aqueous) 5 mg per mL	5 mL
	Eye drops 5 mg per mL	10 mL
	Eye ointment 10 mg per g	4 g
Chloramphenicol with Polymyxin B Sulfate	Eye drops 5 mg-5,000 units per mL	10 mL
	Eye ointment 10 mg-5,000 units per g	4 g
Chlorhexidine Gluconate	Solution 50 mg per mL	200 mL
Chlorpromazine Hydrochloride	Oral solution 25 mg per 5 mL	100 mL
Cholestyramine	Sachets containing 9.4 g oral powder (equivalent to 8 g cholestyramine)	50

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Choline Theophyllinate	Elixir 50 mg per 5 mL	500 mL
Cisapride Monohydrate	Oral suspension equivalent to 1 mg cisapride per mL	200 mL
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for mixture equivalent to 75 mg clindamycin per 5 mL	100 mL
Clioquinol	Cream 10 mg per g	30 g
Clotrimazole	Cream 10 mg per g	20 g
	Lotion 10 mg per mL	20 mL
	Pessaries 100 mg	6
	Vaginal cream 50 mg per 5 g	35 g
	Vaginal cream 100 mg per 5 g	20 g
Colestipol Hydrochloride	Oral powder, sachets 5 g	120
Dexamethasone	Eye drops 1 mg per mL	5 mL
Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin	Ear drops 500 micrograms (dexamethasone)-5 mg-50 micrograms per mL	8 mL
Dexamethasone with Framycetin Sulfate and Gramicidin	Ear ointment 500 micrograms-5 mg-50 micrograms per g	5 g
Diclofenac Potassium	Tablets 25 mg	20
	Tablets 50 mg	20
Diclofenac Sodium	Tablets 50 mg (enteric coated)	20
Dienoestrol	Cream 500 micrograms per 5 g	85 g
Digoxin	Paediatric oral solution 50 micrograms per mL	100 mL
Dipivefrine Hydrochloride	Eye drops 1 mg per mL	10 mL
Econazole Nitrate	Cream 10 mg per g	20 g
	Cream 75 mg per 5 g	35 g
	Lotion 10 mg per mL	20 mL
	Pessaries 150 mg	3
Ecothiopate Iodide	Eye drops 300 micrograms per mL (1.5 mg and 5 mL vial of solvent)	5 mL
	Eye drops 600 micrograms per mL (3 mg and 5 mL vial of solvent)	5 mL
	Eye drops 1.25 mg per mL (6.25 mg and 5 mL vial of solvent)	5 mL
	Eye drops 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)	5 mL
Ergotamine Tartrate with Caffeine	Suppositories 2 mg-100 mg	5

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*	
Erythromycin Estolate	Oral suspension equivalent to 125 mg erythromycin per 5 mL	100	mL
	Paediatric oral drops equivalent to 100 mg erythromycin per mL	10	mL
Erythromycin Ethyl Succinate with Purified Water B.P.	Granules for oral suspension equivalent to 200 mg erythromycin per 5 mL	100	mL
	Granules for oral suspension equivalent to 400 mg erythromycin per 5 mL	100	mL
Erythromycin Stearate	Oral suspension equivalent to 125 mg erythromycin per 5 mL	100	mL
	Oral suspension equivalent to 250 mg erythromycin per 5 mL	100	mL
Ethosuximide	Oral solution 250 mg per 5 mL	250	mL
Ferrous Gluconate	Elixir 300 mg per 5 mL	100	mL
Fluclorolone Acetonide	Cream 250 micrograms per g	15	g
Flucloxacillin Magnesium with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL	100	mL
	Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL	100	mL
Flumethasone Pivalate with Clioquinol	Ear drops 200 micrograms-10 mg per mL	7.5	mL
Fluocortolone Pivalate with Fluocortolone Hexanoate	Cream 1 mg-1 mg per g	15	g
Fluorometholone	Eye drops 1 mg per mL	5	mL
Fluorometholone Acetate	Eye drops 1 mg per mL	5	mL
Fluoxetine Hydrochloride	Oral solution equivalent to 20 mg fluoxetine per 5 mL	140	mL
Framycetin Sulfate	Eye/ear drops 5 mg per mL	8	mL
	Eye ointment 5 mg per g	5	g
Frusemide Sodium	Oral solution equivalent to 10 mg frusemide per mL	30	mL
Fusidic Acid	Oral suspension 50 mg per mL	90	mL
Gentamicin Sulfate	Eye drops equivalent to 3 mg gentamicin per mL	5	mL
Glucose and Ketone Indicator—Urine	Reagent strips (Keto-Diastix)	100	
Glucose Indicator—Blood	Electrode strips (ExacTech)	100	
	Electrode strips (Pen 2/Companion 2)	100	
Glucose Indicator—Urine	Dispenser	4	m
	Reagent strips (Clinistix)	100	
	Reagent strips (Diastix)	100	
Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate	Oral rehydration salts 3.56 g-470 mg-300 mg-530 mg per sachet	10	

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Glyceryl Trinitrate	Buccal/sublingual pressurised spray 400 micrograms per dose	200 doses
	Ointment 20 mg per g	60 g
	Tablets 600 micrograms	100
Haloperidol	Oral solution 2 mg per mL	15 mL
	Oral solution 2 mg per mL	100 mL
Homatropine Hydrobromide	Eye drops 20 mg per mL	15 mL
	Eye drops 50 mg per mL	15 mL
Hydrocortisone	Cream 10 mg per g	50 g
	Eye drops 5 mg per mL	10 mL
	Eye drops 10 mg per mL	10 mL
Hydrocortisone Acetate	Cream 10 mg per g	30 g
	Cream 10 mg per g	50 g
	Eye ointment 5 mg per g	5 g
	Eye ointment 10 mg per g	5 g
	Ointment 10 mg per g	30 g
	Ointment 10 mg per g	50 g
Hydrocortisone with Cinchocaine Hydrochloride	Ointment 5 mg-5 mg per g	30 g
	Suppositories 5 mg-5 mg	12
Hydroxypropylcellulose	Ophthalmic inserts 5 mg	60
Hypromellose 4500	Eye drops 5 mg per mL	15 mL
	Eye drops 10 mg per mL	15 mL
Hypromellose 4500 with Dextran 70	Eye drops 3 mg-1 mg per mL	15 mL
Ibuprofen	Tablets 200 mg	20
	Tablets 400 mg	20
Idoxuridine	Eye drops 1 mg per mL	15 mL
	Eye ointment 5 mg per g	5 g
	Ointment 5 mg per g	5 g
Indomethacin	Capsules 25 mg	20
	Ophthalmic suspension 10 mg per mL	5 mL
Ipratropium Bromide	Pressurised inhalation 20 micrograms per dose	200 doses
	Pressurised nasal spray 20 micrograms per dose	200 doses
Ketoprofen	Capsules 100 mg (sustained release)	10
	Capsules 200 mg (sustained release)	7
Lactulose	Solution B.P. 3.34 g per 5 mL	500 mL
Levobunolol Hydrochloride	Eye drops 2.5 mg per mL	5 mL
Lignocaine Hydrochloride	Injection 100 mg in 5 mL ampoule	2
Medrysone	Eye drops 10 mg per mL	5 mL
Methyl Salicylate	Liniment A.P.F.	100 mL
Metoclopramide Hydrochloride	Oral solution 5 mg per 5 mL	100 mL

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Metronidazole	Suppositories 500 mg	10
	Suppositories 1 g	10
Metronidazole Benzoate	Oral suspension 320 mg per 5 mL	100 mL
Miconazole Nitrate	Cream 20 mg per g	20 g
	Cream 20 mg per g	40 g
	Pessaries 100 mg	7
Nafarelin Acetate	Nasal spray (pump pack) equivalent to 200 micrograms nafarelin per dose	60 doses
Naphazoline Hydrochloride	Eye drops 1 mg per mL	15 mL
Naproxen	Oral suspension 125 mg per 5 mL	500 mL
	Tablets 250 mg	20
	Tablets 500 mg	10
	Tablets 750 mg (sustained release)	7
	Tablets 1 g (sustained release)	7
Naproxen Sodium	Tablets 550 mg	10
Neomycin Undecenoate with Bacitracin Zinc	Ear ointment 12 mg (3.5 mg neomycin)-400 units per g	10 g
Nitrofurantoin	Oral suspension 25 mg per 5 mL	200 mL
Nortriptyline Hydrochloride	Elixir equivalent to 10 mg nortriptyline per 5 mL	100 mL
Nystatin	Cream 100,000 units per g	15 g
	Ointment 100,000 units per g	15 g
	Oral suspension 100,000 units per mL	24 mL
	Pessaries 100,000 units	15
	Pessaries 100,000 units (cream base)	15
	Vaginal cream 100,000 units per 4 g	75 g
	Vaginal cream 100,000 units per 5 g	75 g
Oestradiol	Transdermal patches 2 mg	8
	Transdermal patches 4 mg	8
	Transdermal patches 8 mg	8
	Vaginal tablets 25 micrograms	15
Oestradiol and Medroxyprogesterone Acetate	Pack containing 8 transdermal patches oestradiol 4 mg and 14 tablets medroxyprogesterone acetate 10 mg	1
Oestradiol with Norethisterone Acetate	Pack containing 12 tablets oestradiol 2 mg, 10 tablets oestradiol 2 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg	1
	Pack containing 12 tablets oestradiol 4 mg, 10 tablets oestradiol 4 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg	1
Oestriol	Vaginal cream 1 mg per g	15 g
Oestrogens—Conjugated and Medroxyprogesterone Acetate	Pack containing 28 tablets conjugated oestrogens 625 micrograms and 14 tablets medroxyprogesterone acetate 10 mg	1

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Oestrone	Pessaries 100 micrograms	12
	Pessaries 1 mg	12
Paracetamol	Elixir 240 mg per 5 mL	200 mL
	Mixture 120 mg per 5 mL	100 mL
Paraffin, Soft White with Liquid Paraffin	Eye ointment, compound	3.5 g
	Eye ointment, compound	7 g
Phenoxymethylpenicillin Benzathine	Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL	100 mL
	Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL	100 mL
Phenylephrine Hydrochloride	Eye drops 1.2 mg per mL	15 mL
Phenytoin	Oral suspension 30 mg per 5 mL	500 mL
Pilocarpine Hydrochloride	Eye drops 5 mg per mL	15 mL
	Eye drops 10 mg per mL	15 mL
	Eye drops 20 mg per mL	15 mL
	Eye drops 30 mg per mL	15 mL
	Eye drops 40 mg per mL	15 mL
	Eye drops 60 mg per mL	15 mL
Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate	Eye ointment 5,000 units-400 units-5 mg per g	4 g
Polymyxin B Sulfate with Neomycin Sulfate and Gramicidin	Eye drops 5,000 units-2.5 mg-25 micrograms per mL	10 mL
Polyvinyl Alcohol	Eye drops 14 mg per mL	15 mL
	Eye drops 30 mg per mL	15 mL
Polyvinyl Alcohol with Povidone	Eye drops 14 mg-6 mg per mL	15 mL
Prednisolone Acetate	Eye drops 5 mg per mL	5 mL
Prednisolone Acetate with Phenylephrine Hydrochloride	Eye drops 10 mg-1.2 mg per mL	10 mL
Prednisolone Sodium Phosphate	Eye/ear drops 5 mg per mL	5 mL
Prochlorperazine	Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate	5
	Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate	5
Salbutamol Sulfate	Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units	30
	Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units	30
	Oral solution equivalent to 2 mg salbutamol per 5 mL	300 mL
	Pressurised inhalation equivalent to 100 micrograms salbutamol per dose	400 doses
	Pressurised inhalation in breath actuated device equivalent to 100 micrograms salbutamol per dose	400 doses

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Silver Sulfadiazine with Chlorhexidine Gluconate	Cream 10 mg-2 mg per g	50 g
	Cream 10 mg-2 mg per g	100 g
Sodium Citro-Tartrate	Sachets containing oral effervescent powder 3.7 g (Citralite)	25
	Sachets containing oral effervescent powder 4 g (Citravescent Sachets)	25
	Sachets containing oral effervescent powder 4 g (Ural Sachets)	25
Sodium Cromoglycate	Eye drops 20 mg per mL	10 mL
	Pressurised inhalation 1 mg per dose	200 doses
	Pressurised inhalation 5 mg per dose	112 doses
Sterculia with Frangula Bark	Granules 620 mg-80 mg per g	500 g
Sulfacetamide Sodium	Eye drops 100 mg per mL	15 mL
Sulfamethoxazole with Trimethoprim	Paediatric oral suspension 200 mg-40 mg per 5 mL	100 mL
Sulindac	Tablets 100 mg	20
	Tablets 200 mg	10
Surgical Cement	Skin bond adhesive	118 mL
Surgical Cement Solvent	Liquid	237 mL
	Liquid	240 mL
	Liquid	250 mL
Terbutaline Sulfate	Elixir 300 micrograms per mL	300 mL
	Nebuliser solution 10 mg per mL	50 mL
	Powder for oral inhalation in breath actuated device 500 micrograms per dose	200 doses
	Pressurised inhalation 250 micrograms per dose	400 doses
Tetracycline Hydrochloride	Eye ointment 10 mg per g	5 g
Theophylline	Oral solution 80 mg per 15 mL	500 mL
Thioridazine	Oral solution 30 mg per mL	30 mL
Thiotepa	Eye drops set containing 15 mg vial, 2 ampoules sterile water 10 mL, syringe with needle and 15 mL dropper bottle	1 set
Tiaprofenic Acid	Tablets 200 mg	20
	Tablets 300 mg	10
Timolol Maleate	Eye drops equivalent to 2.5 mg timolol per mL	5 mL
	Eye drops equivalent to 5 mg timolol per mL	5 mL
Timolol Maleate with Pilocarpine Hydrochloride	Eye drops 5 mg (timolol)-20 mg per mL	5 mL
	Eye drops 5 mg (timolol)-40 mg per mL	5 mL
Tobramycin	Eye drops 3 mg per mL	5 mL
	Eye ointment 3 mg per g	3.5 g
Triamcinolone Acetonide	Cream 500 micrograms per g	15 g
	Ointment 500 micrograms per g	15 g

Name of pharmaceutical benefit	*Form (strength, type, etc.)*	*Standard Pack*
Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin	Ear cream 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g	5 g
	Ear drops 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g	7.5 mL
	Ear ointment 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g	5 g
Triglycerides Oil, Medium Chain		1 L
Urea	Cream 100 mg per g	100 g
Vidarabine	Eye ointment 30 mg per g	3.5 g
Wool Alcohols	Ointment B.P.	100 g
Zinc Oxide	Ointment, compound	50 g
	Suppositories, compound	12
Zinc Sulfate with Phenylephrine Hydrochloride	Eye drops 2.5 mg-1.2 mg per mL	15 mL

Dated this sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER SECTION 93

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, pursuant to section 93 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1994.

2. The Determination under section 93 of the *National Health Act 1953* made on 15 November 1993 with effect from 1 December 1993 is hereby revoked.

3. The pharmaceutical benefits referred to in this Determination shall be those specified in the Schedule to this Determination.

4. A medical practitioner is authorised for the purpose of section 93 of the *National Health Act 1953* to supply any of the pharmaceutical benefits obtained by the medical practitioner, or by another medical practitioner for whom the first-named medical practitioner is temporarily acting as a locum, in pursuance of this Determination.

5. Subject to this Determination, the maximum quantity or number of units of a pharmaceutical benefit which may be obtained by a medical practitioner in any one month for the purpose of section 93 of the *National Health Act 1953* is the quantity or number specified in the Schedule to this Determination in relation to the pharmaceutical benefit.

6. Where a medical practitioner has obtained a pharmaceutical benefit for the purpose of section 93 of the *National Health Act 1953*, that medical practitioner is not entitled to obtain a further quantity or number of units of that pharmaceutical benefit for that purpose whilst in possession of a quantity or number of units of the pharmaceutical benefit obtained by the medical practitioner equal to or greater than the maximum quantity or number of units allowed for the pharmaceutical benefit by paragraph 5.

THE SCHEDULE

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Maximum quantity*
Adrenaline Acid Tartrate	Injection equivalent to adrenaline 1 in 1,000, 1 mL	5
Aminophylline	Injection 250 mg in 10 mL ampoule	5
Atropine Sulfate	Injection 600 micrograms in 1 mL ampoule	5
Benztropine Mesylate	Injection 2 mg in 2 mL ampoule	5
Chlorpromazine Hydrochloride	Injection 50 mg in 2 mL ampoule	10
OR		
Haloperidol	Injection 5 mg in 1 mL ampoule	10
Diazepam	Injection 10 mg in 2 mL ampoule	5
Dihydroergotamine Mesylate	Injection 1 mg in 1 mL ampoule	5
Diphtheria and Tetanus Vaccine, Adsorbed	Injection 0.5 mL ampoule	10

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Maximum quantity*
Diphtheria and Tetanus Vaccine, Adsorbed, Diluted	Injection 0.5 mL ampoule	10
Ergometrine Maleate	Injection 250 micrograms in 1 mL ampoule	5
Erythromycin	Injection 100 mg in 2 mL ampoule	5
Frusemide Sodium	Injection equivalent to 20 mg frusemide in 2 mL ampoule	5
Glucagon Hydrochloride	Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe	1
Glyceryl Trinitrate	Buccal/sublingual pressurised spray 400 micrograms per dose, 200 doses	1
Hydrocortisone Sodium Succinate	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	2
OR		
Hydrocortisone Sodium Succinate	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	1
OR		
Dexamethasone Sodium Phosphate	Injection equivalent to 4 mg dexamethasone phosphate in 1 mL ampoule	5
Lignocaine Hydrochloride	Injection 100 mg in 5 mL ampoule	4
Metoclopramide Hydrochloride	Injection 10 mg in 2 mL ampoule	10
OR		
Prochlorperazine Edisylate	Injection 12.5 mg in 1 mL ampoule	10
OR		
Prochlorperazine Mesylate	Injection 12.5 mg in 1 mL ampoule	10
Morphine Sulfate	Injection 15 mg in 1 mL ampoule	5
OR		
Morphine Sulfate	Injection 30 mg in 1 mL ampoule	5
Naloxone Hydrochloride	Injection 2 mg in 5 mL disposable injection set	2
Pethidine Hydrochloride	Injection 100 mg in 2 mL ampoule	5
Procaine Penicillin	Injection 1.5 g in disposable syringe	10
OR		
Benzylpenicillin Sodium with any determined brand of sterilised Water for Injections	Injection equivalent to 600 mg benzylpenicillin, vial (with 2 mL ampoule)	10
Promethazine Hydrochloride	Injection 50 mg in 2 mL ampoule	10
Salbutamol Sulfate	Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units, 30	1
Salbutamol Sulfate	Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units, 30	1

Name of pharmaceutical benefit	*Form (strength, type, size, etc.)*	*Maximum quantity*
Terbutaline Sulfate	Injection 100 micrograms in 1 mL ampoule	5
OR		
Terbutaline Sulfate	Injection 500 micrograms in 1 mL ampoule	5
Tetanus Vaccine, Adsorbed	Injection 0.5 mL ampoule	10
Verapamil Hydrochloride	Injection 5 mg in 2 mL ampoule	5

Dated this sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER SUBSECTION 85B (1)

I, DAVID TREVOR GRAHAM, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health and Delegate of the Minister for Human Services and Health, pursuant to subsection 85B (1) of the *National Health Act 1953* (referred to in this Determination as "the Act"), hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1994.

2. The Determination under subsection 85B (1) of the Act made on 14 September 1994 with effect from 1 December 1994 is hereby revoked.

3. Section 85B of the Act applies in relation to each of the brands of the pharmaceutical benefits specified in Part A of the Schedule to this Determination (referred to in this Determination as "the Schedule").

4. For the purposes of paragraph 85B (1) (c) of the Act, the quantity or number of units that is relevant for the purpose of determining an amount referred to in paragraph 85B (1) (d) or 85B (1) (e) of the Act in relation to each brand of a pharmaceutical benefit specified in Part A of the Schedule is the quantity or number of units specified in Part B of the Schedule in relation to the brand of the pharmaceutical benefit.

5. For the purposes of paragraph 85B (1) (d) of the Act, the amount that is, for the purposes of Part VII of the Act, to be taken to be the manufacturer's price for sales to approved pharmacists in relation to each brand of a pharmaceutical benefit specified in Part A of the Schedule is the amount specified in Part C of the Schedule in relation to the brand of the pharmaceutical benefit.

6. For the purposes of paragraph 85B (1) (e) of the Act, the amount that is, for the purposes of Part VII of the Act, to be taken to be the price claimed by the manufacturer as the manufacturer's price for sales to approved pharmacists in relation to each brand of a pharmaceutical benefit specified in Part A of the Schedule is the amount specified in Part D of the Schedule in relation to the brand of the pharmaceutical benefit.

7. The name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed "Brand" in Part A of the Schedule in relation to a pharmaceutical benefit specified in that Part of the Schedule is or are the brand or brands of the pharmaceutical benefit referred to in paragraphs 3, 4, 5 and 6:

Letters	*Manufacturer's Name*
AB	Abbott Australasia Pty Ltd
AG	Allergan Australia Pty Ltd
AP	Astra Pharmaceuticals Pty Ltd
AY	Ayerst Laboratories Pty Ltd, Division of Wyeth Australia Pty Limited
BC	Bristol Laboratories, A Division of Bristol–Myers Squibb Pharmaceuticals Pty Ltd
BO	Boehringer Mannheim Australia Pty Limited
BQ	Bristol–Myers Squibb Pharmaceuticals Pty Ltd
BT	The Boots Company (Australia) Pty Ltd
BW	Wellcome Australia Limited
CG	Ciba-Geigy Australia Limited
CS	Commonwealth Serum Laboratories Limited
FA	Faulding Pharmaceuticals, A Division of F.H. Faulding & Co. Limited
FR	Charles E. Frosst, Division of Merck Sharp & Dohme (Australia) Pty Ltd
GL	Glaxo Australia Pty Ltd
HP	Hoechst Australia Limited
IC	ICI Australia Operations Pty Ltd
JC	Janssen-Cilag Pty Ltd
JP	Janssen Pharmaceutica Pty Ltd
KN	Knoll AG, Germany
LY	Eli Lilly Australia Pty Limited

2

Letters	*Manufacturer's Name*
MB	May & Baker, Division of Rhône-Poulenc Rorer Australia Pty Ltd
MK	Merck Sharp & Dohme (Australia) Pty Ltd
ML	Marion Merrell Dow Australia Pty Ltd
NN	Nelson Laboratories, Division of Laboratories Pharm-a-care Pty Ltd
OR	Organon (Australia) Pty Limited
PF	Pfizer Pty Limited
PS	Pharmacia (Australia) Pty Ltd
PY	Procter & Gamble Pharmaceuticals Australia Pty Ltd
RC	Reckitt & Colman Pharmaceuticals
RL	Roussel Uclaf Australia Pty Limited
RO	Roche Products Pty Ltd
RR	Rorer Consumer, Division of Rhône-Poulenc Rorer Australia Pty Ltd
SC	Schering Pty Ltd, Australian subsidiary of Schering AG, Berlin
SD	Syntex Australia Limited
SE	Servier Laboratories (Aust.) Pty Ltd
SH	Schering-Plough Pty Ltd
SK	SmithKline Beecham (Australia) Pty Ltd
SU	Sauter Laboratories (Aust.) Pty Ltd
SZ	Sandoz Australia Pty Ltd
UP	Upjohn Pty Limited
WY	Wyeth Australia Pty Limited

THE SCHEDULE

	PART A		*PART B*	*PART C*	*PART D*
	PHARMACEUTICAL BENEFIT				
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*	*Relevant quantity or number of units*	*Manufacturer's price for sales*	*Price claimed by manufacturer*
				$	$
Allopurinol	Tablet 100 mg	BW	100	4.22	4.60
	Tablet 300 mg	BW	60	5.54	6.10
Alprazolam	Tablet 1 mg	UP	50	11.00	11.80
Amiloride Hydrochloride	Tablet 5 mg	MK	50	2.33	2.78
Amitriptyline Hydrochloride	Tablet 10 mg	MK	50	1.04	1.58
	Tablet 25 mg	MK	50	1.51	2.06
Amoxycillin Trihydrate	Capsule equivalent to 250 mg amoxycillin	CS	20	3.11	3.45
		SK	20	3.11	3.50
	Capsule equivalent to 500 mg amoxycillin	SK	20	6.12	6.60
		CS	20	6.12	6.62
Amoxyci lin Trihydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL	CS	1	2.70	2.90
		SK	1	2.70	2.91
	Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL	CS	1	3.90	4.20
		SK	1	3.90	4.23

3

PART A			*PART B*	*PART C*	*PART D*
	PHARMACEUTICAL BENEFIT				
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*	*Relevant quantity or number of units*	*Manufacturer's price for sales*	*Price claimed by manufacturer*
				$	$
Ampicillin Trihydrate	Capsule equivalent to 250 mg ampicillin	SK	24	3.60	6.16
	Capsule equivalent to 500 mg ampicillin	SK	24	6.75	8.95
Atenolol	Tablet 50 mg	IC	30	6.50	7.41
Baclofen	Tablet 10 mg	CG	100	33.00	33.86
	Tablet 25 mg	CG	100	71.00	71.86
Betamethasone Dipropionate	Cream equivalent to 500 micrograms betamethasone per g, 15 g	SH	1	1.72	2.44
	Ointment equivalent to 500 micrograms betamethasone per g, 15 g	SH	1	1.72	2.44
	Scalp lotion equivalent to 500 micrograms betamethasone per g, 30 mL	SH	1	4.40	5.12
Bethanechol Chloride	Tablet 10 mg	MK	50	2.66	2.88
Bleomycin Sulfate with any determined brand of sterilised Water for Injections or other solvent	Injection equivalent to 15 units bleomycin activity (with required solvent)	BQ	10	497.55	1,012.00
Carbamazepine	Tablet 200 mg	CG	200	29.36	29.90
Cephalexin	Capsule 250 mg (anhydrous)	GL LY	20 20	3.45 3.45	4.36 4.46
	Capsule 500 mg (anhydrous)	GL LY	20 20	6.20 6.20	7.11 7.21
Cephalexin with Purified Water B.P.	Granules for oral suspension 125 mg per 5 mL, 100 mL	GL LY	1 1	4.11 4.11	5.04 5.12
	Granules for oral suspension 250 mg per 5 mL, 100 mL	GL LY	1 1	6.11 6.11	7.04 7.12
Cimetidine	Tablet 200 mg	SK	120	26.00	26.54
	Tablet 400 mg	SK	60	26.00	26.54
	Tablet 800 mg	SK	30	26.00	26.54
Cisplatin	I.V. injection 10 mg in 10 mL vial	BL	1	12.30	12.50
	I.V. injection 50 mg in 50 mL vial	BL	1	33.00	33.50
Clofibrate	Capsule 500 mg	IC	100	8.70	9.61
Clomiphene Citrate	Tablet 50 mg	ML	5	14.69	29.66

4

Drug or medicinal preparation	*PART A* PHARMACEUTICAL BENEFIT *Form (strength, type, size, etc.)*	*Brand*	*PART B* *Relevant quantity or number of units*	*PART C* *Manufacturer's price for sales*	*PART D* *Price claimed by manufacturer*
				$	$
Clotrimazole	Cream 10 mg per g, 20 g	SH	1	2.00	3.11
		BN	1	2.00	4.44
	Lotion 10 mg per mL, 20 mL	BN	1	2.58	3.49
	Pessaries 100 mg, 6	BN	1	3.62	4.53
	Vaginal cream 50 mg per 5 g, 35 g	BN	1	3.81	4.72
Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin	Ear drops 500 micrograms (dexamethasone)-5 mg-50 micrograms per mL, 8 mL	RL	1	1.74	2.74
Dexamethasone with Framycetin Sulfate and Gramicidin	Ear ointment 500 micrograms-5 mg-50 micrograms per g, 5 g	RL	1	1.54	2.54
Diazepam	Tablet 2 mg	SU	50	1.93	2.20
		RO	50	1.93	2.84
	Tablet 5 mg	SU	50	2.15	2.43
		RO	50	2.15	3.06
Diclofenac Sodium	Tablet 50 mg (enteric coated)	CG	50	5.77	6.68
Disopyramide	Capsule 100 mg	RL	100	16.15	17.30
	Capsule 150 mg	RL	100	23.05	24.20
Dothiepin Hydrochloride	Capsule 25 mg	BT	50	2.46	3.30
	Tablet 75 mg	BT	30	2.74	3.74
Doxepin Hydrochloride	Capsule equivalent to 10 mg doxepin	PF	50	1.63	2.25
	Capsule equivalent to 25 mg doxepin	PF	50	1.91	2.55
Doxycycline Hydrochloride	Capsule equivalent to 50 mg doxycycline (containing enteric coated pellets)	FA	25	4.55	5.06
	Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets)	FA	7	2.55	3.16
		FA	21	7.65	8.92
	Tablet equivalent to 50 mg doxycycline	PF	25	4.55	5.18
	Tablet equivalent to 100 mg doxycycline	PF	7	2.55	3.20
Econazole Nitrate	Cream 10 mg per g, 20 g	SK	1	2.58	3.18
Erythromycin Ethyl Succinate	Granules for oral suspension equivalent to 200 mg erythromycin per 5 mL, 100 mL	AB	1	3.50	4.36
	Tablet equivalent to 400 mg erythromycin	AB	25	3.90	4.65

PART A			*PART B*	*PART C*	*PART D*
	PHARMACEUTICAL BENEFIT				
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*	*Relevant quantity or number of units*	*Manufacturer's price for sales*	*Price claimed by manufacturer*
				$	$
Flucloxacillin Sodium	Capsule equivalent to 250 mg flucloxacillin	CS	24	6.20	6.38
		SK	24	6.20	6.55
	Capsule equivalent to 500 mg flucloxacillin	CS	24	13.00	13.33
		SK	24	13.00	13.40
Frusemide	Tablet 40 mg	HP	100	3.34	3.80
	Tablet 500 mg	HP	50	14.91	18.97
Glibenclamide	Tablet 5 mg	BO	100	4.93	5.40
		HP	100	4.93	5.84
Glipizide	Tablet 5 mg	PS	100	9.00	10.01
Griseofulvin	Tablet 500 mg	IC	28	7.42	9.24
Hydrochlorothiazide with Amiloride Hydrochloride	Tablet 50 mg-5 mg	MK	50	3.74	4.01
Hydrochlorothiazide with Triamterene	Tablet 25 mg-50 mg	SK	100	6.00	8.14
Hydrocortisone Acetate	Cream 10 mg per g, 30 g	UP	1	1.67	2.17
	Cream 10 mg per g, 50 g	UP	1	2.11	2.61
Hydrocortisone with Cinchocaine Hydrochloride	Ointment 5 mg-5 mg per g, 30 g	RL	1	4.62	14.70
	Ointment 5 mg-5 mg per g, 2 g single use tubes, 5	RL	1	1.54	6.65
	Suppositories 5 mg-5 mg, 12	RL	1	4.06	11.05
Idoxuridine	Eye drops 1 mg per mL, 15 mL	AG	1	5.05	5.67
Indapamide Hemihydrate	Tablet 2.5 mg	SE	90	13.80	16.28
Indomethacin	Capsule 25 mg	MK	50	1.75	2.66
Isosorbide Dinitrate	Tablet 10 mg	AY	100	4.00	4.55
Ketoprofen	Capsule 100 mg (sustained release)	MB	50	8.60	10.05
	Capsule 200 mg (sustained release)	MB	28	9.63	10.86
Labetalol Hydrochloride	Tablet 100 mg	GL	100	8.36	9.27
	Tablet 200 mg	GL	100	14.54	15.45
Lactulose	Solution B.P. 3.34 g per 5 mL, 500 mL	JC	1	9.75	11.35
Levonorgestrel with Ethinyloestradiol	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	SC, WY	1	2.22	3.33

	PART A		PART B	PART C	PART D
	PHARMACEUTICAL BENEFIT		Relevant quantity or number of units	Manufacturer's price for sales	Price claimed by manufacturer
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*			
				$	$
	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms and 10 tablets 125 micrograms-30 micrograms	SC, WY	1	2.22	3.33
	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets	SC, WY	1	2.22	3.33
	Tablets 150 micrograms-30 micrograms, 21	SC, WY	1	2.22	3.33
Methotrexate	Tablet 2.5 mg	BL	100	15.07	15.57
Methyldopa	Tablet 250 mg	MK	100	6.00	6.64
Metoclopramide Hydrochloride	Tablet 10 mg	SK	25	1.51	2.71
Metoprolol Tartrate	Tablet 50 mg	CG	100	6.60	6.91
		AP	100	6.60	6.93
	Tablet 100 mg	CG	60	8.10	8.41
		AP	60	8.10	8.50
Metronidazole	Tablet 200 mg	MB	21	1.90	3.55
	Tablet 400 mg	MB	5	1.80	3.27
		MB	21	4.45	5.83
Mianserin Hydrochloride	Tablet 10 mg	OR	50	9.00	10.86
	Tablet 20 mg	OR	50	19.00	21.68
Miconazole Nitrate	Cream 20 mg per g, 40 g	JP	1	3.81	5.11
	Pessaries 100 mg, 7	JP	1	3.62	5.19
Morphine Sulfate	Injection 10 mg in 1 mL ampoule	AP	5	2.75	4.89
	Injection 15 mg in 1 mL ampoule	AP	5	2.80	4.98
Naproxen	Tablet 250 mg	SD	50	4.51	5.50
	Tablet 500 mg	SD	50	8.01	9.00
	Tablet 750 mg (sustained release)	SD	28	7.14	8.13
	Tablet 1 g (sustained release)	SD	28	9.52	10.51
	Tablets 250 mg, 20	SD	1	2.25	2.43
	Tablets 500 mg, 10	SD	1	2.15	2.33
Nitrazepam	Tablet 5 mg	RO	25	1.82	2.73
Norethisterone with Ethinyloestradiol	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	SD	1	2.22	2.78

7

PART A			*PART B*	*PART C*	*PART D*
	PHARMACEUTICAL BENEFIT				
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*	*Relevant quantity or number of units*	*Manufacturer's price for sales*	*Price claimed by manufacturer*
				$	$
	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	SD	1	2.22	2.78
	Pack containing 12 tablets 500 micrograms-35 micrograms 9 tablets 1 mg-35 micrograms and 7 inert tablets	SD	1	2.22	2.78
Oxazepam	Tablet 15 mg	WY	25	1.46	2.37
	Tablet 30 mg	WY	25	1.66	2.57
Pethidine Hydrochloride	Injection 50 mg in 1 mL ampoule	AP	5	2.38	4.49
	Injection 100 mg in 2 mL ampoule	AP	5	2.70	5.21
Phenoxymethylpenicillin Benzathine	Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL, 100 mL	CS	1	2.70	3.06
	Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL, 100 mL	CS	1	3.43	3.93
Pindolol	Tablet 5 mg	SZ	100	6.25	7.16
	Tablet 15 mg	SZ	50	9.00	9.91
Piroxicam	Capsule 10 mg	PF	50	8.11	9.11
	Capsule 20 mg	PF	50	7.74	8.84
Polygeline	Intravenous infusion 17.5 g per 500 mL, with Na^+ 145 mmol per L, K^+ 5.1 mmol per L, Ca^{2+} 6.25 mmol per L and Cl^- 145 mmol per L; 500 mL	HP	1	15.15	17.34
Prazosin Hydrochloride	Tablet equivalent to 1 mg prazosin	PF	100	8.10	9.87
	Tablet equivalent to 2 mg prazosin	PF	100	11.30	13.07
	Tablet equivalent to 5 mg prazosin	PF	100	19.50	21.27
Prochlorperazine Mesylate	Injection 12.5 mg in 1 mL ampoule	MB	10	6.46	7.85
Propranolol Hydrochloride	Tablet 10 mg	IC	100	1.28	3.10
	Tablet 40 mg	IC	100	2.50	4.32
	Tablet 160 mg	IC	50	3.85	5.67
Quinine Bisulfate	Tablet 300 mg	NN RR	50 50	4.85 4.85	5.32 5.35
Quinine Sulfate	Tablet 300 mg	NN RR	50 50	4.85 4.85	5.32 5.35

8

PART A			*PART B*	*PART C*	*PART D*
	PHARMACEUTICAL BENEFIT				
Drug or medicinal preparation	*Form (strength, type, size, etc.)*	*Brand*	*Relevant quantity or number of units*	*Manufacturer's price for sales*	*Price claimed by manufacturer*
				$	$
Salbutamol	Pressurised inhalation 100 micrograms per dose, 200 doses	GL	1	2.25	2.53
Salbutamol Sulfate	Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units, 30	GL	1	11.15	11.44
	Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units, 30	GL	1	11.79	12.07
	Nebuliser solution equivalent to 5 mg salbutamol per mL, 30 mL	GL	1	3.93	4.43
Selegiline Hydrochloride	Tablet 5 mg	RC	100	69.50	105.56
Sodium Valproate	Tablet 200 mg (enteric coated)	RC	100	14.82	15.27
	Tablet 500 mg (enteric coated)	RC	100	29.32	29.77
Sotalol Hydrochloride	Tablet 160 mg	AP	60	25.04	25.95
Sucralfate	Tablet equivalent to 1 g anhydrous sucralfate	BT	120	17.00	18.50
Sulfacetamide Sodium	Eye drops 100 mg per mL, 15 mL	AG	1	3.76	4.30
Sulindac	Tablet 100 mg	FR	50	4.60	5.06
	Tablet 200 mg	FR	50	9.10	9.60
Temazepam	Capsule 10 mg	WY	25	1.82	2.45
	Tablet 10 mg	WY	25	1.82	2.45
Tetracycline Hydrochloride with a buffering agent	Capsule 250 mg	BC	25	2.11	2.70
Tinidazole	Tablet 500 mg	PF	4	2.56	4.32
Trimethoprim	Tablet 300 mg	BW	7	2.55	3.00
Urea	Cream 100 mg per g, 100 g	PY	1	3.37	4.94
Verapamil Hydrochloride	Tablet 40 mg	KN, SC	100	6.16	7.07
	Tablet 80 mg	KN, SC	100	10.94	11.84

Dated this sixteenth day of November 1994.

D. GRAHAM
Assistant Secretary
Pharmaceutical Benefits Branch
Department of Human Services and Health
Delegate of the Minister for Human Services and Health

9403887

NATIONAL FOOD AUTHORITY

FOOD STANDARDS

The following notices are made pursuant to the *National Food Authority Act 1991.*

All correspondence, including requests for further information on the matters detailed below, should be forwarded to the following address quoting the relevant title and reference number:

Standards Liaison Officer
National Food Authority
Box 7186
CANBERRA MAIL CENTRE ACT 2610

Tel: 06-2712219

Written submissions should be received by the Authority no later than the dates advised below. Submissions will be placed on the public register of the Authority unless a claim of commercial confidentiality (either in respect of all or part of the submission) is made and justified.

NOTICE PURSUANT TO SECTION 14

Titanium Dioxide in Deposited Confectionery (A231)

The National Food Authority received an application (A231) on 25 October 1994, from Snow Confectionery Pty Ltd, to amend the Food Standards Code. The applicant seeks to amend Standard K3 to permit the use of titanium dioxide at a rate of 2 g/kg in deposited confectionery.

The Authority has made a preliminary assessment, accepted the application and will make a full assessment. To assist this process, the Authority invites written submissions on matters relevant to the application. **Submissions should be received by the Authority no later than 11 January 1995.**

NOTICE PURSUANT TO SECTION 27

Use of Geographical Indications in relation to Spirits (P123)

The National Food Authority has completed an inquiry into the draft variation to amend the Food Standards Code, prepared after full assessment of Proposal 123, and has recommended that the National Food Standards Council adopt the draft variation, as amended to Standard P3 - Spirits and Liqueurs.

The recommendation, if accepted by the Council, will prohibit the use of geographical indications in relation to spirits where the spirit does not originate in the locality indicated, even where the true origin of the spirit is indicated or the geographical indication is used in translation or accompanied by expressions such as 'kind', 'type', 'style', 'imitation' or the like.

A geographical indication is any indication, whether express or implied, which identifies a spirit as originating in a particular country, locality or region, where a given quality, reputation or other characteristic of the spirit is essentially attributable to its origin in that particular country, locality or region.

The proposed amendment will give effect to Australia's international obligations flowing from the Uruguay Round of GATT trade negotiations.

Further information about the recommendation and the reasons for it, can be obtained by writing to the Authority.

MAXIMUM PERMITTED CONCENTRATION FOR CADMIUM IN FOOD

The National Food Authority has decided to review those parts of Standard A12 - Metals and Contaminants in Food, relevant to the maximum permitted concentration of cadmium in food with a view to preparing a proposal to amend the Food Standards Code. The proposal will consider developing maximum permitted concentrations for cadmium which relate to commodity groupings of foods.

To assist in the process, the Authority invites written submissions on matters relevant to the review. **Submissions should be received by the Authority no later than 28 February 1995.**

9403888

Immigration and Ethnic Affairs

Department of Immigration and Ethnic Affairs
Migration Agents Registration Scheme
Notice under section 114Q(1) of the Migration Act 1958

Notice is hereby given that the persons whose details appear below have applied to be registered as migration agents. Any person may lodge an objection to the registration of any applicant appearing below. Objections must be in writing and received not later than six (6) weeks after the date of this notice. Objections should be addressed to:

The Secretary
Department of Immigration and Ethnic Affairs
PO Box 25
Belconnen ACT 2617

A written statement should be provided which outlines the nature of the objection and clearly identifies the person against whom the objection has been made.

NAME	DATE OF BIRTH	BUSINESS NAME	BUSINESS ADDRESS	PROVIDES FREE SERVICE OR CHARGES FEES?
BOURIS Andrew	8/1/1955	Mallesons Stephen Jaques	Governor Phillip Tower 1 Farrer Place SYDNEY 2000	CHARGES
CAFFREY Donna Jennefer	30/1/1957	Donna Caffrey & Associates	1st Floor 33C Bell Street YARRA GLEN 3775	CHARGES
FURLONG Michael Walter	20/9/1952	Furlong & Associates Solicitors	Suite 705, Level 7 66 Elizabeth Street SYDNEY 2000	CHARGES
GROGAN Peter James	23/11/1964	Marsdens Solicitors	Cnr Queen & Dumaresq Str CAMPBELLTOWN 2560	CHARGES
RAKUS Victor Vincent	10/7/1956	Rakus Solicitors & Attorneys	Level 67, MLC Centre 19 Martin Place SYDNEY 2000	CHARGES
SMITH Christine Louise	27/12/1963	Gardens Ridgeway	Lvl 15, 77 Castlereagh S SYDNEY 2000	CHARGES

for SECRETARY
23 November 1994

9403889

Industrial Relations

Regulation 22

Form R16
Industrial relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

IN the matter of:

ABORIGINAL AND COMMUNITY CONTROLLED HEALTH SERVICES (COMMUNITY HEALTH NURSING STAFF) AWARD 1988

(C No. 80078 of 1994)

DATED 22 March 1989

AND in the matter of the variation of the award

Notice is hereby given:

(a) That on 3 November 1994, the Commission varied the term (or terms) of the abovementioned award referred to in the Schedule below;

(b) that the variation will be a common rule of the Northern Territory with effect from 3 November 1994;

and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the Award may be inspected at the Australian Industrial Registry, 1 Briggs Street, Darwin free of charge.

SCHEDULE
TERMS TO BE VARIED
A0483CRN V012A PRINT L6341

CLAUSE NO.	SUBJECT	SUBSTANCE OF VARIATION
6(a)	Salaries	First Safety Net Adjustment - September 1994
51	Safety Net Adjustment	New Clause

Dated 11 November 1994

LYNDALL SOETENS
DEPUTY INDUSTRIAL REGISTRAR

Regulation 22

Form R16
Industrial relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

IN the matter of:

DOCTORS' NURSES (NORTHERN TERRITORY) AWARD 1980

(C No. 80077 of 1994)

DATED 23 January 1986

AND in the matter of the variation of the award

Notice is hereby given:

(a) That on 3 November 1994, the Commission varied the term (or terms) of the abovementioned award referred to in the Schedule below;

(b) that the variation will be a common rule of the Northern Territory with effect from 3 November 1994;

and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the Award may be inspected at the Australian Industrial Registry, 1 Briggs Street, Darwin free of charge.

SCHEDULE
TERMS TO BE VARIED
D0015CRN V029 A PRINT L6340

CLAUSE NO.	SUBJECT	SUBSTANCE OF VARIATION
6(a)	Classifications and Salaries	First Safety Net Adjustment - September 1994
30	Safety Net Adjustment	New Clause

Dated 11 November 1994

LYNDALL SOETENS
DEPUTY INDUSTRIAL REGISTRAR

Regulation 22

Form R16
Industrial relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

IN the matter of:

HAIRDRESSING AND BEAUTY INDUSTRY (NORTHERN TERRITORY) AWARD 1987

(C No. 23289 of 1994)

DATED 13 November 1987

AND in the matter of the variation of the award

Notice is hereby given:

(a) That on 4 November 1994, the Commission varied the term (or terms) of the abovementioned award referred to in the Schedule below;

(b) that the variation will be a common rule of the Northern Territory with effect from 3 November 1994;

and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the Award may be inspected at the Australian Industrial Registry, 1 Briggs Street, Darwin free of charge.

SCHEDULE
TERMS TO BE VARIED
H0042CRN V024 A PRINT L6317

CLAUSE NO.	SUBJECT	SUBSTANCE OF VARIATION
7(b)	Wage Rates and Classifications	First Safety Net Adjustment - September 1994

Dated 11 November 1994

LYNDALL SOETENS
DEPUTY INDUSTRIAL REGISTRAR

Regulation 22

Form R16
Industrial relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

IN the matter of:

NURSES (NORTHERN TERRITORY) PRIVATE SECTOR AWARD 1994

(C No. 80079 of 1994)

DATED 5 January 1990

AND in the matter of the variation of the award

Notice is hereby given:

(a) That on 3 November 1994, the Commission varied the term (or terms) of the abovementioned award referred to in the Schedule below;

(b) that the variation will be a common rule of the Northern Territory with effect from 3 November 1994;

and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the Award may be inspected at the Australian Industrial Registry, 1 Briggs Street, Darwin free of charge.

SCHEDULE
TERMS TO BE VARIED
N0111CRN V014 A PRINT L6342

CLAUSE NO.	SUBJECT	SUBSTANCE OF VARIATION
8(a)	Salaries	Safety Net Adjustment and Review - September 1994
50	Safety Net Adjustment	New Clause

Dated 11 November 1994

LYNDALL SOETENS
DEPUTY INDUSTRIAL REGISTRAR

9403890

Industry, Science and Technology

AUSTRALIAN CUSTOMS SERVICE

COMMONWEALTH OF AUSTRALIA

CUSTOMS ACT 1901

APPOINTMENT UNDER SECTION 17 (b)
APPOINTMENT NOTICE NUMBER VS/9405

I, John Gerard Ryan, Delegate of the Comptroller-General for the Australian Customs Service, in pursuance of paragraph (b) of Section 17 of the Customs Act 1901, hereby appoint the place identified in the following schedule as a place for the examination of goods on landing.

MANAGER
BORDER MANAGEMENT
VICTORIA
11 November, 1994

THE SCHEDULE

PLACE NAME	LOCATION
Brian Miller Removals and Storage Pty Ltd trading as Gronows Removals.	That part of the building which is indicated by the hatching on scale drawing VS/9411 held by the Senior Inspector, Sea Cargo, and which is situated on land at present known as No 283, Inkerman Street, St. Kilda, Victoria, 3182. File No V94/2482 refers.

9403891

COMMONWEALTH OF AUSTRALIA
CUSTOMS ACT 1901

NOTICE OF RATES OF EXCHANGE - s161J CUSTOMS ACT 1901

I, REIN PRAKS, delegate of the Comptroller-General of Customs, hereby specify, pursuant to s161J of the Customs Act 1901, that the amounts set out in Columns 3 to 9 hereunder are the ruling rates of exchange, on the dates specified, for the purposes of ascertaining the value of imported goods under the provisions of Division 2 of Part VIII of the Customs Act 1901.

SCHEDULE (Foreign Currency = AUS $1)

Column 1	Column 2 Currency	Column 3 02/11/94	Column 4 03/11/94	Column 5 04/11/94	Column 6 05/11/94	Column 7 06/11/94	Column 8 07/11/94	Column 9 08/11/94
Austria	Schillings	7.8165	7.8071	7.9108	7.9108	7.9108	7.9703	8.0178
Belgium/Lux	Francs	22.7400	23.1200	23.1600	23.1600	23.1600	23.4100	23.4500
Brazil	Reals	.6300	.6300	.6300	.6300	.6300	.6300	.6300
Canada	Dollars	1.0039	1.0064	1.0081	1.0081	1.0081	1.0150	1.0212
China	Yuan	6.3002	6.3181	6.3160	6.3160	6.3160	6.3697	6.4054
Denmark	Kroner	4.3255	4.3993	4.4114	4.4114	4.4114	4.4395	4.4686
EC	ECU	.5806	.5877	.5912	.5912	.5912	.5957	.5975
Fiji	Dollar	1.0535	1.0567	1.0586	1.0586	1.0586	1.0661	1.0721
Finland	Markka	3.4038	3.4561	3.4597	3.4597	3.4597	3.4890	3.5204
France	Francs	3.7864	3.8532	3.8605	3.8605	3.8605	3.8851	3.9108
Germany	Deutschmark	1.1050	1.1242	1.1254	1.1254	1.1254	1.1329	1.1402
Greece	Drachmae	170.6200	173.4800	173.5800	173.5800	173.5800	174.7700	175.8300
Hong Kong	Dollars	5.7195	5.7359	5.7359	5.7359	5.7359	5.7854	5.8169
India	Rupees	23.2445	23.3163	23.3013	23.3013	23.3013	23.5066	23.6508
Indonesia	Rupiah	1615.9000	1620.4000	1620.7000	1620.7000	1620.7000	1634.7000	1643.9000
Ireland	Pounds	.4575	.4641	.4641	.4641	.4641	.4685	.4725
Israel	Shekel	2.2173	2.2420	2.2336	2.2336	2.2336	2.2474	2.2620
Italy	Lire	1135.9700	1155.5100	1156.7700	1156.7700	1156.7700	1162.6000	1169.4700
Japan	Yen	71.4400	72.3500	72.4700	72.4700	72.4700	72.8500	73.2200
Korea	Won	590.5200	592.1900	592.0400	592.0400	592.0400	596.6000	599.9500
Malaysia	Dollar	1.8931	1.8987	1.8997	1.8997	1.8997	1.9176	1.9269
Netherlands	Guilder	1.2389	1.2598	1.2616	1.2616	1.2616	1.2701	1.2780
New Zealand	Dollar	1.2014	1.2045	1.2049	1.2049	1.2049	1.2071	1.2112
Norway	Kroner	4.8240	4.9020	4.9144	4.9144	4.9144	4.9441	4.9785
Pakistan	Rupee	22.4600	22.5200	22.5200	22.5200	22.5200	22.7100	22.8400
Papua NG	Kina	.8403	.8402	.8498	.8498	.8498	.8626	.8692
Philippines	Peso	18.4200	18.4800	18.3700	18.3700	18.3700	18.3800	18.1600
Portugal	Escudo	113.3500	114.8300	115.1000	115.1000	115.1000	115.8700	116.2700
Singapore	Dollar	1.0855	1.0902	1.0900	1.0900	1.0900	1.0996	1.1037
Solomon Is.	Dollar	2.4649	2.4670	2.4679	2.4679	2.4679	2.4892	2.5024
South Africa	Rand	2.5877	2.5956	2.6025	2.6025	2.6025	2.6314	2.6397
Spain	Peseta	92.1800	93.6000	93.7500	93.7500	93.7500	94.3800	94.9600
Sri Lanka	Rupee	35.2500	35.3500	35.3800	35.3800	35.3800	35.7100	35.9100
Sweden	Krona	5.3068	5.3869	5.4563	5.4563	5.4563	5.4821	5.5236
Switzerland	Franc	.9210	.9382	.9405	.9405	.9405	.9475	.9541
Taiwan	Dollar	19.2500	19.3000	19.3100	19.3100	19.3100	19.4800	19.6000
Thailand	Baht	18.4200	18.4800	18.4900	18.4900	18.4900	18.6500	18.7400
UK	Pounds	.4525	.4573	.4586	.4586	.4586	.4629	.4660
USA	Dollar	.7402	.7423	.7421	.7421	.7421	.7485	.7527

REIN PRAKS
Delegate of the
Comptroller-General of Customs
CANBERRA A.C.T.
9/11/94

9403892

COMMONWEALTH OF AUSTRALIA
CUSTOMS ACT 1901

NOTICE OF RATES OF EXCHANGE - s161J CUSTOMS ACT 1901

I, REIN PRAKS, delegate of the Comptroller-General of Customs, hereby specify, pursuant to s161J of the Customs Act 1901, that the amounts set out in Columns 3 to 9 hereunder are the ruling rates of exchange, on the dates specified, for the purposes of ascertaining the value of imported goods under the provisions of Division 2 of Part VIII of the Customs Act 1901.

SCHEDULE (Foreign Currency = AUS $1)

Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9
	Currency	09/11/94	10/11/94	11/11/94	12/11/94	13/11/94	14/11/94	15/11/94
Austria	Schillings	7.9758	8.1055	8.1030	8.1030	8.1030	8.1005	8.1654
Belgium/Lux	Francs	23.3600	23.7000	23.7600	23.7600	23.7600	23.7000	23.8600
Brazil	Reals	.6200	.6200	.6300	.6300	.6300	.6300	.6258
Canada	Dollars	1.0200	1.0224	1.0244	1.0244	1.0244	1.0205	1.0204
China	Yuan	6.4011	6.4155	6.4128	6.4128	6.4128	6.3942	6.3890
Denmark	Kroner	4.4428	4.5111	4.5033	4.5033	4.5033	4.5044	4.5306
EC	ECU	.5958	.6043	.6059	.6059	.6059	.6059	.6086
Fiji	Dollar	1.0671	1.0687	1.0709	1.0709	1.0709	1.0684	1.0713
Finland	Markka	3.4915	3.5361	3.5127	3.5127	3.5127	3.4849	3.5073
France	Francs	3.8943	3.9575	3.9616	3.9616	3.9616	3.9675	3.9868
Germany	Deutschmark	1.1334	1.1516	1.1519	1.1519	1.1519	1.1539	1.1596
Greece	Drachmae	174.9600	177.4900	177.6400	177.6400	177.6400	177.2200	178.6600
Hong Kong	Dollars	5.8131	5.8269	5.8271	5.8271	5.8271	5.8109	5.8064
India	Rupees	23.6307	23.6888	23.6992	23.6992	23.6992	23.6115	23.5755
Indonesia	Rupiah	1643.6000	1647.5000	1648.2000	1648.2000	1648.2000	1643.7000	1642.3000
Ireland	Pounds	.4714	.4773	.4790	.4790	.4790	.4798	.4823
Israel	Shekel	2.2505	2.2732	2.2648	2.2648	2.2648	2.2568	2.2525
Italy	Lire	1164.7200	1183.3400	1181.9100	1181.9100	1181.9100	1182.5500	1188.7100
Japan	Yen	72.9000	73.6800	73.6500	73.6500	73.6500	73.5500	73.8300
Korea	Won	599.5500	600.9900	600.9900	600.9900	600.9900	599.2400	598.6100
Malaysia	Dollar	1.9226	1.9290	1.9286	1.9286	1.9286	1.9238	1.9247
Netherlands	Guilder	1.2703	1.2908	1.2921	1.2921	1.2921	1.2942	1.3000
New Zealand	Dollar	1.2079	1.2070	1.2134	1.2134	1.2134	1.2118	1.2111
Norway	Kroner	4.9512	5.0304	5.0448	5.0448	5.0448	5.0335	5.0682
Pakistan	Rupee	22.8200	22.8800	22.8800	22.8800	22.8800	22.8100	22.7900
Papua NG	Kina	.8726	.8812	.8878	.8878	.8878	.8796	.8681
Philippines	Peso	17.7100	17.9000	18.2200	18.2200	18.2200	18.0600	18.2200
Portugal	Escudo	115.7400	117.6700	117.4700	117.4700	117.4700	117.1900	118.2500
Singapore	Dollar	1.1016	1.1062	1.1080	1.1080	1.1080	1.1065	1.1063
Solomon Is.	Dollar	2.5007	2.5083	2.5083	2.5083	2.5083	2.5013	2.4993
South Africa	Rand	2.6319	2.6492	2.6537	2.6537	2.6537	2.6467	2.6466
Spain	Peseta	94.4900	95.9600	95.0300	95.0300	95.0300	95.7900	96.5100
Sri Lanka	Rupee	35.8700	35.9600	35.9600	35.9600	35.9600	35.8600	35.8500
Sweden	Krona	5.4778	5.5323	5.4851	5.4851	5.4851	5.4065	5.4767
Switzerland	Franc	.9475	.9659	.9663	.9663	.9663	.9679	.9735
Taiwan	Dollar	19.6000	19.6500	19.6700	19.6700	19.6700	19.6500	19.6700
Thailand	Baht	18.7300	18.7800	18.8000	18.8000	18.8000	18.7600	18.7600
UK	Pounds	.4640	.4696	.4708	.4708	.4708	.4716	.4723
USA	Dollar	.7522	.7540	.7540	.7540	.7540	.7519	.7513

REIN PRAKS
Delegate of the
Comptroller-General of Customs
CANBERRA A.C.T.
16/11/94

9403893

Primary Industries and Energy

Commonwealth of Australia

Pasture Seed Levy Act 1989

Pasture Seed Levy Declaration No. 1 of 1994

I, ROBERT LINDSAY COLLINS, Minister for Primary Industries and Energy, after considering the recommendation of the Grains Council of Australia, make the following declaration under subsection 9 (1) of the *Pasture Seed Levy Act 1989.*

Dated 7 Nov 1994.

Minister for Primary Industries and Energy

Citation

1. This declaration may be cited as the Pasture Seed Levy Declaration No. 1 of 1994.

Commencement

2. This declaration commences on 1 January 1995.

Interpretation

3. In this declaration:

"the Act" means the *Pasture Seed Levy Act 1989.*

Pasture Seed Levy Declaration No. 1 of 1994

Schedule to the Act

4. The Schedule to the Act is taken to be amended by omitting all the words, figures and symbols after the heading and substituting:

"1	Medicago littoralis	Strand medic	Harbinger	$10.00/tonne
			Harbinger AR	$10.00/tonne
2	Medicago murex	Murex medic	Zodiac	$10.00/tonne
3	Medicago polymorpha	Burr medic	Circle Valley	$10.00/tonne
			Santiago	$10.00/tonne
			Serena	$10.00/tonne
4	Medicago rugosa	Gama medic	Paragosa	$10.00/tonne
			Paraponto	$10.00/tonne
			Sapo	$10.00/tonne
5	Medicago sativa	Lucerne	Alfanafa/Sirosal	$12.50/tonne
			Amador	$12.50/tonne
			Aquarius	$12.50/tonne
			Aurora	$12.50/tonne
			Cimarron	$12.50/tonne
			CUF 101	$12.50/tonne
			Eureka	$12.50/tonne
			Falkiner	$12.50/tonne
			Hunterfield	$12.50/tonne
			Hunter River	$12.50/tonne
			L34	$12.50/tonne
			L52	$12.50/tonne
			L69	$12.50/tonne
			L99	$12.50/tonne
			Matador	$12.50/tonne

Pasture Seed Levy Declaration No. 1 of 1994

SCHEDULE—continued

			Maxidor II	$12.50/tonne
			Nova	$12.50/tonne
			Pioneer 577	$12.50/tonne
			Pioneer 581	$12.50/tonne
			Pioneer 5929	$12.50/tonne
			Prime	$12.50/tonne
			P581	$12.50/tonne
			Quadrella	$12.50/tonne
			Sceptre	$12.50/tonne
			Sequel	$12.50/tonne
			Sheffield	$12.50/tonne
			Siriver	$12.50/tonne
			Springfield	$12.50/tonne
			Trifecta	$12.50/tonne
			Validor	$12.50/tonne
			Wakefield	$12.50/tonne
			WL 318	$12.50/tonne
			WL 320	$12.50/tonne
			WL 415	$12.50/tonne
			WL 514	$12.50/tonne
			WL 515	$12.50/tonne
			WL 516	$12.50/tonne
			WL 605	$12.50/tonne
			WL Southern Special	$12.50/tonne
6	Medicago scutellata	Snail medic	Kelson	$10.00/tonne
			Sair	$10.00/tonne
			Sava	$10.00/tonne
7	Medicago sphaerocarpos	Sphere medic	Orion	$10.00/tonne
8	Medicago tornata	Disc medic	Rivoli	$10.00/tonne
			Tornafield	$10.00/tonne

Pasture Seed Levy Declaration No. 1 of 1994

SCHEDULE—continued

9	Medicago truncatula	Barrel medic	Ascot	$10.00/tonne
			Caliph	$10.00/tonne
			Cyprus	$10.00/tonne
			Jemalong	$10.00/tonne
			Mogul	$10.00/tonne
			Parabinga	$10.00/tonne
			Paraggio	$10.00/tonne
			Sephi	$10.00/tonne
10	Ornithopus compressus	Yellow serradella	Avila	$10.00/tonne
			Elgara	$10.00/tonne
			Madeira	$10.00/tonne
			Paros	$10.00/tonne
			Pitman	$10.00/tonne
			Tauro	$10.00/tonne
			Uriserra	$10.00/tonne
11	Trifolium alexandrium	Berseem clover	Akenaton	$10.00/tonne
			Alex	$10.00/tonne
			Attila	$10.00/tonne
			Big Bee	$10.00/tonne
			Multi-cut	$10.00/tonne
			Sacromonte	$10.00/tonne
12	Trifolium balansae	Balansa clover	Paradana	$10.00/tonne
13	Trifolium fragiferum	Strawberry clover	O'Connors	$10.00/tonne
			Palestine	$10.00/tonne
14	Trifolium hirtum	Rose clover	Hykon	$10.00/tonne
			Kondinin	$10.00/tonne
15	Trifolium pratense	Red clover	Astred	$10.00/tonne
			Redquin	$10.00/tonne
16	Trifolium repens	White clover	Alice	$10.00/tonne
			Dusi	$10.00/tonne
			Haifa	$10.00/tonne
			Irrigation	$10.00/tonne
			Karina	$10.00/tonne
			Menna	$10.00/tonne
			Tamar	$10.00/tonne

Pasture Seed Levy Declaration No. 1 of 1994

SCHEDULE—continued

17	Trifolium resupinatum	Persian clover	Accadia	$10.00/tonne
			Archibald	$10.00/tonne
			Felix	$10.00/tonne
			Kyambro	$10.00/tonne
			Lupers	$10.00/tonne
18	Trifolium semipilosum	Kenya white clover	Safari	$10.00/tonne
19	Trifolium subterraneum	Subterranean clover	Bacchus Marsh	$10.00/tonne
			Clare	$10.00/tonne
			Daliak	$10.00/tonne
			Dalkeith	$10.00/tonne
			Denmark	$10.00/tonne
			Dinninup	$10.00/tonne
			Enfield	$10.00/tonne
			Esperance	$10.00/tonne
			Geraldton	$10.00/tonne
			Gosse	$10.00/tonne
			Goulburn	$10.00/tonne
			Green Range	$10.00/tonne
			Junee	$10.00/tonne
			Karridale	$10.00/tonne
			Larisa	$10.00/tonne
			Leura	$10.00/tonne
			Meteora	$10.00/tonne
			Mt Barker	$10.00/tonne
			Northam	$10.00/tonne
			Nuba	$10.00/tonne
			Nungarin	$10.00/tonne
			Rosedale	$10.00/tonne
			Seaton Park (reselected)	$10.00/tonne
			Tallarook	$10.00/tonne
			Trikkala	$10.00/tonne
			Woogenellup	$10.00/tonne".

COMMONWEALTH OF AUSTRALIA

DRIED SULTANA PRODUCTION UNDERWRITING ACT 1982

REDUCTION FACTOR FOR DRIED SULTANAS FOR THE 1992 SEASON

Pursuant to sub-section 9C(1) of the Dried Sultana Production Underwriting Act 1982 I, ROBERT LINDSAY COLLINS, Minister of State for Primary Industries and Energy, HEREBY determine that the reduction factor for dried sultanas in respect of the prescribed later season that commenced on 1 January 1992 is 0.9557988.

Dated this 24 day of Oct. 1994

ROBERT LINDSAY COLLINS
Minister for Primary Industries and Energy

COMMONWEALTH OF AUSTRALIA

DRIED SULTANA PRODUCTION UNDERWRITING ACT 1982

AVERAGE EXPORT RETURN RATE FOR DRIED SULTANAS FOR THE 1992 SEASON

Pursuant to sub-section 9A(1) of the Dried Sultana Production Underwriting Act 1982 I, ROBERT LINDSAY COLLINS, Minister of State for Primary Industries and Energy, HEREBY determine that the amount of $1695.39 per tonne is to be the average export return rate for dried sultanas in respect of the prescribed later season that commenced on 1 January 1992.

Dated this 24 day of Oct. 1994

ROBERT LINDSAY COLLINS
Minister for Primary Industries and Energy

COMMONWEALTH OF AUSTRALIA

DRIED SULTANA PRODUCTION UNDERWRITING ACT 1982

DETERMINATION UNDER SECTION 9D

Pursuant to and in accordance with sub-section 9D(2) of the Dried Sultana Production Underwriting Act 1982 I, ROBERT LINDSAY COLLINS, Minister of State for Primary Industries and Energy, HEREBY determine that the amount of $1,447.57 per tonne is to be the guaranteed minimum export return rate for dried sultanas in respect of the prescribed later season that commenced on 1 January 1993

Dated this 24 day of OCT 1994

ROBERT LINDSAY COLLINS
Minister for Primary Industries and Energy

9403895

Prime Minister

ABORIGINAL AND TORRES STRAIT ISLANDER COMMISSION ACT 1989

NOTIFICATION OF THE MAKING OF AMENDMENTS TO REGIONAL COUNCIL DELEGATIONS

Notification is hereby given that pursuant to section 45A(7) of the *Aboriginal and Torres Strait Islander Commission Act 1989,* amendments have been made to the Commission's "Schedule of Regional Council Delegations".

Copies of the Schedule of Regional Council Delegations including the Commission's Written Directions are available on request at each office of the Commission free of charge. In Canberra, copies may be obtained from Budgets and Procedures Branch, 7th Floor, MLC Building, Woden Plaza, Phillip ACT 2606.

L. O'Donoghue

Chairperson
Aboriginal and Torres Strait Islander Commission

// November 1994

9403896

Transport

Civil Aviation Authority
AUSTRALIA

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE CIVIL AVIATION REGULATIONS

Notice is hereby given that the following amendment to Civil Aviation Orders Part 105 will become effective on 23 November 1994.

AD/R44/1 - COOLING FAN

Copies of the above Orders are available for inspection and may be purchased over the counter from the:

Civil Aviation Authority
Publications Centre
607 Swanston Street
CARLTON SOUTH VIC 3053

or by mail from:

Civil Aviation Authority
Publications Centre
PO Box 1986
CARLTON SOUTH VIC 3053

9403897

Treasurer

Declaration No. 32 under the Prices Surveillance Act 1983
COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
VARIATION OF DECLARATION NO. 32

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby vary declaration No. 32 of 28 May 1987 published in the Commonwealth of Australia Gazette No. GN 6 of 10 June 1987 by:

(1) deleting the word "and" from the end of sub sub paragraph (2)(a)(iii);

(2) inserting "; and" at the end of sub sub paragraph (2)(a)(iv); and

(3) adding a new sub sub paragraph (2)(a)(v) to read:

"(v) steel mill products produced by the Rod and Bar Products Division of the Broken Hill Proprietary Company Limited."

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

Declaration No. 58 under the *Prices Surveillance Act 1983*
COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
VARIATION OF DECLARATION NO 58

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby vary declaration No. 58 of 15 September 1989 published in the Commonwealth of Australia Gazette No. GN 38 of 4 October 1989 by:

(1) omitting "and" from the end of sub paragraph (2)(b);

(2) omitting the full stop at the end of sub paragraph (2)(c) and substituting "; and"; and

(3) inserting a new sub paragraph (2)(d) to read:

"(d) this declaration will cease to have effect after three years from the date of this variation.".

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

Declaration No. 79 under the *Prices Surveillance Act 1983*
COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
VARIATION OF DECLARATION NO. 79

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby vary declaration No. 79 of 28 August 1992 published in the Commonwealth of Australia Gazette No. GN 37 of 16 September 1992 by:

(1) omitting sub paragraph (2)(b) and substituting:

"(b) Carlton and United Breweries Limited and Lion Nathan Australia Limited to be, in relation to those goods, declared persons for the purposes of the Act; and"; and

(2) omitting sub paragraph (2)(c) and substituting:

"(c) this declaration will cease to have effect after three years from the date of this variation.".

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
REVOCATION (NO. 11)

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby revoke declaration No. 69 of 25 September 1991 relating to biscuits and Arnott's Biscuits Limited, published in the Commonwealth of Australia Gazette No. GN 39 of 9 October 1991.

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
REVOCATION (NO. 12)

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby revoke declaration No. 77 of 15 July 1992 relating to instant coffee and Nestlé Australia Ltd published in the Commonwealth of Australia Gazette No. GN 30 of 29 July 1992.

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
REVOCATION (NO. 13)

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby revoke declaration No. 78 of 23 July 1992 relating to tampons and Johnson and Johnson Pacific Pty Ltd published in the Commonwealth of Australia Gazette No. GN 31 of 5 August 1992.

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

COMMONWEALTH OF AUSTRALIA
Prices Surveillance Act 1983
REVOCATION (NO. 14)

I, GEORGE GEAR, Assistant Treasurer, in pursuance of section 21 of the *Prices Surveillance Act 1983*, hereby revoke declaration No. 50 of 13 February 1989 relating to packet tea and tea bags, and Unifoods Pty Ltd published in the Commonwealth of Australia Gazette No. GN 9 of 8 March 1989.

Dated this 18th day of November 1994.

GEORGE GEAR
ASSISTANT TREASURER

Superannuation Industry (Supervision) Act 1993

TEMPORARY MODIFICATION DECLARATION No 7

I, Frederick George Herbert Pooley, Insurance and Superannuation Commissioner, pursuant to subsection 333(1) of the *Superannuation Industry (Supervision) Act 1993* (the "Act"), DECLARE that:

1. Section 18 of the Act is to have effect, in relation to superannuation funds, and their trustees, as if it were modified by inserting after subsection 18(1) the following:

" (1A) Despite subsection (1), a superannuation fund is not a public offer superannuation fund if:

(a) it is an excluded superannuation fund; and

(b) at least one of the following subparagraphs applies to each member of the fund (different subparagraphs may apply to different members):
(i) the member is a trustee of the fund;
(ii) the member is an associate of a trustee of the fund;
(iii) the member is a relative of a trustee of the fund;
(iv) the member is at least one of the following in relation to a trustee of the fund that is a body corporate ("the body corporate"):
(A) a responsible officer of the body corporate;
(B) a relative or an associate of a responsible officer of the body corporate;
(C) a responsible officer of another body corporate that is related to the body corporate;
(D) a relative or an associate of a responsible officer of another body corporate that is related to the body corporate;
(E) a person who holds a controlling interest in the body corporate;
(F) a person who holds a controlling interest in another body corporate that is related to the body corporate;
(v) the member is a standard employer-sponsored member;
(vi) the member is a member of a prescribed class; and

(c) at least one of the following subparagraphs applies to each trustee of the fund (different subparagraphs may apply to different trustees):
  (i) the trustee is an associate of a member of the fund;
  (ii) the trustee is a relative of a member of the fund;
  (iii) if the trustee is a body corporate ("the body corporate") - at least one of the following sub-subparagraphs applies to the body corporate:
    (A) a responsible officer of the body corporate is a member of the fund;
    (B) a responsible officer of the body corporate is a relative or an associate of a member of the fund;
    (C) a responsible officer of another body corporate that is related to the body corporate is a member of the fund;
    (D) a responsible officer of another body corporate that is related to the body corporate is a relative or an associate of a member of the fund;
    (E) a member of the fund holds a controlling interest in the body corporate;
    (F) a member of the fund holds a controlling interest in another body corporate that is related to the body corporate;
  (iv) the trustee is:
    (A) an employer-sponsor; or
    (B) a former employer-sponsor;
  of a member of the fund; and

(d) the trustee is not entitled under the governing rules of the fund to receive, and does not receive, any remuneration from:
  (i) the fund; or
  (ii) any person;
  in relation to the performance of the trustee's duties, or the provision of any other services, in relation to the fund; and

(e) no declaration under subsection (6) (which allows for funds to be declared to be public offer superannuation funds) is in force in relation to the fund.

(1B) In this section:

(a) "**relative**", in relation to a person, means any of the following:
  (i) the parent, grandparent, brother, sister, uncle, aunt, great-uncle, great-aunt, nephew, niece, first cousin, second cousin, son, daughter, grandson or granddaughter of the person or of his or her spouse (including a person who stands in one of these relationships as a result of the adoption of that person or of another person); and
  (ii) the spouse of the person or of any other person specified in subparagraph (i);

(b) "**controlling interest**", in relation to a body corporate, means:

(i) an interest in the body corporate that enables the person holding the interest to:

(A) control the composition of the board of directors of the body corporate; or

(B) cast, or control the casting of, more than half of the maximum number of votes that could be cast at a general meeting of the body corporate; or

(C) control more than half of the issued share capital of the body corporate (excluding any part of that issued share capital that carries no right to participate beyond a specified amount in a distribution of either profits or capital); or

(ii) an interest in another body corporate that constitutes, under subparagraph (i), a controlling interest in that other body corporate, where that other body corporate is:

(A) a body corporate that, under subparagraph (i), has a controlling interest in the first-mentioned body corporate; or

(B) a body corporate that has a controlling interest of that kind by another application, or other applications, of this subparagraph.

(1C) When determining the meaning of "associate" in subparagraph (1A)(c)(i), the following additional assumption must be made for the purposes of subsection 12(2), namely that paragraph 13(c) of the Corporations Law had not been enacted. "

2. Regulation 3.01 of the *Superannuation Industry (Supervision) Regulations* is to have effect, in relation to superannuation funds, and their trustees, as if it were modified by adding "and subparagraph 18(1A)(b)(vi)" after "sub-subparagraph 18(1)(a)(ii)(B)"

This declaration:

i. is taken to have commenced to have effect on 1 December 1993;

ii. has no effect after 30 June 1996.

Dated 17 November 1994

F G H Pooley
Commissioner

Superannuation Industry (Supervision) Act 1993

EXPLANATORY MEMORANDUM

ACCOMPANYING

TEMPORARY MODIFICATION DECLARATION No 7

THE DECISION TO EXEMPT CERTAIN EXCLUDED SUPERANNUATION FUNDS FROM BEING PUBLIC OFFER SUPERANNUATION FUNDS

1. "Excluded superannuation fund" is defined in section 10 of the *Superannuation Industry (Supervision) Act 1993* (the "Act" or the "SIS Act") as a superannuation fund with less than 5 members. Excluded superannuation funds are usually either family ("mum and dad") funds or very small workplace funds. They are excluded from many of the substantive requirements that the Act imposes on other funds.

2. If all the members of an excluded superannuation fund are standard employer-sponsored members, it will not be a public offer superannuation fund. However, many excluded funds that are operated for or on behalf of a family or small business will have some non-standard employer-sponsored members, either because some of the members will be partners or unpaid directors of the business rather than employees, or because, if they are employees, they will not be employer-sponsored pursuant to an arrangement between the employer-sponsor and the trustee of the fund, but pursuant to an arrangement directly between themselves and the trustee.

3. The Commissioner considers that if all the non-standard employer-sponsored members of an excluded superannuation fund are not "arm's length" members but are either trustees of the fund, relatives or associates of a trustee, or have a relationship with at least one of the trustees of a kind specified in the temporary modification declaration, and each trustee is not an "arm's length" trustee but is either a relative, associate or employer-sponsor of at least one member of the fund, or has a relationship with at least one member of the fund of a kind specified in the temporary modification declaration, and does not receive any remuneration, then the fund should not be treated as a public offer

superannuation fund. To subject such funds to the requirements applying to public offer funds that are outlined in paragraph 8 below, just because one or more of their members happen not to be standard employer-sponsored members, would be disproportionately expensive for such funds and, given their small size and the close relationship between the members and the trustee, unnecessary. In practice, the members of such funds will be in a position vis-a-vis the trustee to either participate in the running of the fund or to make known their views in relation thereto, and to have or obtain relevant information about the fund from the trustee before they take up a superannuation interest in it.

DEFINITIONS RELEVANT TO PUBLIC OFFER SUPERANNUATION FUNDS

4. Section 18(1) of the SIS Act, when read together with regulation 3.01 of the *Superannuation Industry (Supervision) Regulations*, defines "public offer superannuation fund" as (basically) a regulated superannuation fund which is:
   - not a standard employer-sponsored fund; or
   - a standard employer-sponsored fund which has at least one member who:
     - is not a standard employer-sponsored member; and
     - is not a former standard employer-sponsored member who, since ceasing to be a standard employer-sponsored member, either has not made any contributions to the fund, or has made some contributions to the fund during the first 2 years after ceasing to be such a member, but no contributions after that.

5. Section 18(2) permits the trustee of a standard employer-sponsored fund to elect that the fund be treated as a public offer superannuation fund. Section 18(6) enables the Commissioner to declare a superannuation fund to be a public offer superannuation fund, while section 18(7) enables the Commissioner to declare a superannuation fund not to be a public offer superannuation fund.

6. "Standard employer-sponsored fund" is defined in section 16(4) as a superannuation fund which has at least one standard employer-sponsor. "Standard employer-sponsor" is defined in section 16(2) as an employer who contributes to a fund in respect of a member wholly or partly pursuant to an arrangement between the employer and the trustee of the fund.

7. "Public offer entity" is defined in section 10 as a public offer superannuation fund, an approved deposit fund which is not an excluded approved deposit fund, or a pooled superannuation trust.

THE ACT MAKES SPECIAL PROVISION FOR PUBLIC OFFER ENTITIES

8. The SIS Act and regulations treat public offer entities differently from other superannuation entities in a number of respects:
   - Part 9, which sets out equal representation rules applying to standard employer-sponsored funds, stipulates that standard employer-sponsored funds which are public offer superannuation funds must have an independent trustee and must comply with the requirements in the regulations relating to policy committees (sections 91(3), 92(3) and 93(3)). Part 9, as recently modified by modification declaration number 2, does not apply to excluded superannuation funds.
   - Part 19 applies to public offer entities and regulates the offering or issuing of interests in public offer entities by, among other things: prohibiting the offering or issuing of superannuation interests in the entities unless the trustee is an approved trustee (ie a corporate trustee approved by the Commissioner pursuant to section 26(1)); requiring documents containing specified information about the entity and its financial condition and investment performance to be given to a person before superannuation interests are issued to him or her (except if the person will be a standard employer-sponsored member if the interest is issued to him or her); requiring documents containing such information about the entity to be given to a person before the person is permitted to become a standard employer-sponsor of the entity; regulating the price at which superannuation interests can be issued or redeemed; requiring application money for superannuation interests to be held on trust; and allowing for a cooling off period after the issuing of superannuation interests.
   - Part 20 prohibits insider trading in relation to superannuation interests in public offer entities.
   - The regulations specify more rigorous time limits for the obtaining of auditors' certificates and the lodgment of annual returns, although these more rigorous time limits do not apply to excluded funds (regulations 8.03 and 11.02).

EXPLANATION OF SOME OF THE TERMS AND PROVISIONS OF THE TEMPORARY MODIFICATION DECLARATION

9. "Associate" (which appears in subparagraphs 18(1A)(b) and (c)) is defined in section 12 by reference to the Corporations Law. In brief, an associate of a person is someone who is in partnership with the person, or who is a trustee of a trust under which the person benefits, or who is a director of a company of which the person is also a director, or who acts or proposes to act with or is or proposes to be associated with the person in respect of a particular matter to which the statutory provision in which reference is made to "associate" relates. An associate of a body corporate includes a director or secretary of the body, a related body corporate (within the

meaning of the Corporations Law), and a director or secretary of a related body corporate.

10. Subsection 18(1C) provides that when determining the meaning of "associate" in subparagraph 18(1A)(c)(i), the additional assumption needs to be made, for the purposes of subsection 12(2) of the SIS Act, that paragraph 13(c) of the Corporations Law had not been enacted. Section 13 of the Corporations Law is one of the provisions defining the meaning of "associate" which section 12 of the SIS Act relies on to define "associate" for the purposes of the SIS Act. Paragraph 13(c) of the Corporations Law provides that a reference to an "associate" of a person includes a reference to a trustee of a trust under which the person benefits. This part of the Corporations Law definition of "associate" is not appropriate for subparagraph 18(1A)(c)(i), which stipulates that each trustee of the fund must be an associate of a member of the fund (if that trustee does not have some other relationship with a member that is specified in paragraph 18(1A)(c)), because each trustee will, by the very fact of being a trustee, meet the criterion in paragraph 13(c). The requirement that each trustee be an associate of a member would be meaningless, as every trustee would automatically fulfil the requirement.

11. The "prescribed class" referred to in subparagraph 18(1A)(b)(vi) is prescribed in regulation 3.01 of the *Superannuation Industry (Supervision) Regulations*. The precribed class consists of former standard employer-sponsored members who, since ceasing to be standard employer-sponsored members, either have not made any contributions to the fund, or have not made any contributions to the fund after 2 years after ceasing to be standard employer-sponsored members.

12. Paragraphs 18(1A)(b) and (c) contain references to bodies corporate which are "related to" other bodies corporate. Section 20 of the SIS Act provides that the question whether bodies corporate are related to each other is to be determined in the same way that that question would be determined under the Corporations Law. Section 50 of the Corporations Law provides that where a body corporate is a holding company of another body corporate, or a subsidiary of another body corporate, or a subsidiary of a holding company of another body corporate, it is related to the other body corporate. "Holding company", in relation to a body corporate, is defined in section 9 of the Corporations Law to mean a body corporate of which the first-mentioned body corporate is a subsidiary by virtue of Division 6 of Part 1.2 of the Corporations Law.

13. "Responsible officer", in relation to a body corporate, is defined in section 10 of the SIS Act as meaning a director, secretary or executive officer of the body. "Executive officer", in relation to a body corporate, is defined in section 10 as meaning a person, by whatever name called and whether or not a director of the body, who is concerned, or takes part, in the management of the body.

14. The effect of paragraph 18(1A)(d) is that no trustee of the fund may receive, or be entitled under the rules of the fund to receive, whether directly or indirectly, and whether during the current year of income or any future year of income, any remuneration from either the fund, any member or beneficiary of the fund or any other person, in respect of any services performed by the trustee in respect of the fund or other acts of the trustee in relation to the fund, whether as trustee or in any other capacity. "Remuneration" includes any payment or recompense for services performed or for time spent, and any payment in the nature of commission. The paragraph does not preclude the trustee from being reimbursed for or indemnified in respect of disbursements actually made or incurred in favour of the fund.

15. It should be noted that even if an excluded fund meets the conditions in subsection 18(1A), so that, by virtue of that subsection, it is not a public offer superannuation fund, the Commissioner may, in appropriate circumstances, exercise the power in subsection 18(6) to declare it to be a public offer superannuation fund.

16. A standard employer-sponsored fund which meets the conditions in subsection 18(1A) may elect under subsection 18(2) to be treated as a public offer superannuation fund.

DURATION OF THE DECLARATION

17. By force of section 333(2), temporary modification declaration number 7 will have no effect after 30 June 1996.

17 November 1994

(Published by authority of the Insurance and Superannuation Commissioner)

9403899

Veterans' Affairs

COMMONWEALTH OF AUSTRALIA

Veterans' Entitlements Act 1986

NOTICE UNDER SUBSECTION 68(3)

I, CONCETTO ANTONIO SCIACCA, Minister of State for Veterans' Affairs, under paragraph 68(3)(b) of the *Veterans' Entitlements Act 1986* (the Act), designate the Force specified in Column 1 of the Schedule to be a Peacekeeping Force for the purposes of Part IV of the Act as and from the date specified in Column 2 of the Schedule.

SCHEDULE

Column 1	Column 2
Peacekeeping Force	Date specified pursuant to paragraph 68(3)(b) of the Act
Australian Defence Force Support to a Pacific Peacekeeping Force for a Bougainville Peace Conference	21 September 1994

Dated 9th November 1994

CONCETTO ANTONIO SCIACCA
Minister of State for Veterans' Affairs

9403900

rma
Repatriation
Medical Authority

Veterans' Entitlements Act 1986

NOTIFICATION OF INSTRUMENTS UNDER SECTION 196B

Notice is hereby given that the undermentioned instruments have been made under section 196B of the *Veterans' Entitlements Act 1986*. Copies of the instrument can be obtained from:

- the Repatriation Medical Authority, GPO Box 1014, Brisbane Qld 4001; or
- the Department of Veterans' Affairs, MLC Tower, Woden ACT; or
- the Department of Veterans' Affairs, PO Box 21, Woden ACT 2606.

Number of Instrument	Description of Instrument
62 of 1994	Amendment of Statement of Principles, Instrument No.1 of 1994, under subsection 196B(2) concerning malignant neoplasm of the lung and death from malignant neoplasm of the lung
63 of 1994	Amendment of Statement of Principles, Instrument No.25 of 1994, under subsection 196B(2) concerning sensorineural hearing loss and death from sensorineural hearing loss
64 of 1994	Amendment of Statement of Principles, Instrument No.26 of 1994, under subsection 196B(3) concerning sensorineural hearing loss and death from sensorineural hearing loss
65 of 1994	Amendment of Statement of Principles, Instrument No.17 of 1994, under subsection 196B(2) concerning chronic airflow limitation and death from chronic airflow limitation
66 of 1994	Amendment of Statement of Principles, Instrument No.18 of 1994, under subsection 196B(3) concerning chronic airflow limitation and death from chronic airflow limitation
67 of 1994	Statement of Principles under subsection 196B(2) concerning diverticular disease of the colon and death from diverticular disease of the colon
68 of 1994	Statement of Principles under subsection 196B(3) concerning diverticular disease of the colon and death from diverticular disease of the colon
69 of 1994	Statement of Principles under subsection 196B(2) concerning chloracne and death from chloracne
70 of 1994	Statement of Principles under subsection 196B(3) concerning chloracne and death from chloracne
71 of 1994	Statement of Principles under subsection 196B(2) concerning porphyria cutanea tarda and death from porphyria cutanea tarda
72 of 1994	Statement of Principles under subsection 196B(3) concerning porphyria cutanea tarda and death from porphyria cutanea tarda
73 of 1994	Statement of Principles under subsection 196B(2) concerning haemorrhoids and death from haemorrhoids
74 of 1994	Statement of Principles under subsection 196B(3) concerning haemorrhoids and death from haemorrhoids

9403901

Produced by the Australian Government Publishing Service

Commonwealth of Australia Gazette

No. S 397, Monday, 14 November 1994

Published by the Australian Government Publishing Service, Canberra

SPECIAL

ADVERTISEMENT

Form 529

Section 509
Rule 107

Corporations Law

NOTICE OF FINAL MEETING

JOHN BOVELL HOLDINGS PTY LTD (IN LIQUIDATION)

ACN 009 118 996

NOTICE IS HEREBY GIVEN that a final meeting of the members of John Bovell Holdings Pty Ltd (In Liquidation) will be held at the offices of Taylor Woodings, 4th Floor, 679 Murray Street, West Perth on Tuesday 13th December 1994, commencing at 10.30am.

AGENDA

1. To consider and if thought fit, adopt the Liquidator's Report showing how the winding up has been conducted and the property of the company disposed of.

2. To consider and if thought fit, approve the Liquidator's remuneration.

3. To discuss and if thought fit, approve the Liquidator's intention to destroy the Company's books and records at the expiry of three months after the meeting.

4. To discuss and if thought fit, approve the Liquidator's resignation.

5. To discuss any general business which may be raised.

Dated this 10th day of November 1994.

A.L.J. WOODINGS
Liquidator

TAYLOR WOODINGS, Chartered Accountants, 679 Murray Street, WEST PERTH, WA 6005.
Telephone: (09) 321 8533

Produced by the Australian Government Publishing Service
70978 Cat. No. 94 1469 0
ISSN 1032-2345

9 780644 372060

Commonwealth of Australia Gazette

No. S 398, Tuesday, 15 November 1994

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTICE OF APPLICATION UNDER SECTION 459P OF THE CORPORATIONS LAW

(Order 71, subrule 37(9))

IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY

Notice of application relating to: CHALLOW PTY LIMITED

AUSTRALIAN COMPANY NUMBER: 001 789 804

Milonia Pty Limited (In Liquidation) (Receiver & Manager Appointed) [ACN 001 683 754] will apply to the Federal Court of Australia at 9.15am on 18th November 1994, at Law Courts Building, Queens Square Sydney, NSW in Proceedings No G3539 of 1994 for an order that Challow Pty Limited [ACN 001 789 804] ("Company") be wound up.

The applicant's address for service is SOWDEN McINNES AKERMAN, Solicitors, Level 13, 179 Elizabeth Street, Sydney NSW 2000, DX 293 SYDNEY.

Any contributory, member or creditor of the Company may appear at the hearing in person or by counsel or by a solicitor to support or oppose the making of an order to wind up the company.

Any person intending to appear at the directions hearing must file a notice of appearance in accordance with Form 79 and an affidavit verifying any grounds of opposition to the winding up application in accordance with Form 93B and must serve the notice of appearance and affidavit on the applicant at its address for service shown above, not later than 2 days before the day appointed for the hearing.

Produced by the Australian Government Publishing Service
70979 Cat. No. 94 1471 0
ISSN 1032-2345

9 780644 372053

Commonwealth of Australia Gazette

No. S 399, Tuesday, 15 November 1994

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTICE OF APPLICATION RELATING TO CORNING AUSTRALIA PTY LIMITED ACN 003 708 183

Corning Australia Pty Limited ("the plaintiff") will apply to the Supreme Court of New South Wales at 11.00am on 24 November 1994 at Law Courts Building, Queens Square, Sydney for an order confirming a special resolution of the plaintiff whereby the share premium account of the plaintiff is reduced from its present amount of $3,453,384 to an amount of $1,453,384 by paying to each shareholder the sum of $2.00 per share held by the shareholder at the date of the special resolution, being a total payment of $2,000,000 standing to the credit of the share premium account of the plaintiff.

Any person intending to appear at the hearing must file a notice of appearance in the prescribed form and serve that notice on the plaintiff at its address for service shown below not later than 21 November 1994.

Bruce John Ramsay
Solicitor for the Plaintiff
C/- Freehill, Hollingdale & Page
Solicitors
Level 38, MLC Centre
19-29 Martin Place
SYDNEY NSW 2000
TEL: 225 5000
DX: 361, Sydney
REF: BJR:DAC:PAV:27D

Produced by the Australian Government Publishing Service
70980 Cat. No. 94 1472 2
ISSN 1032-2345

9 780644 372152

Commonwealth of Australia Gazette

No. S 400, Tuesday, 15 November 1994

SPECIAL

Published by the Australian Government Publishing Service, Canberra

FORM 93

NOTICE OF APPLICATION UNDER SECTION 459P OF THE CORPORATIONS LAW

Order 71, Sub Rules 36(8) and 37(9)

IN THE FEDERAL COURT OF AUSTRALIA
MELBOURNE DISTRICT REGISTRY

Notice of Application relating to:

L.R. PARISH & SON PROPRIETARY LIMITED
AUSTRALIAN COMPANY NO 004 178 787

PATRICK LUMBER COMPANY will apply to the Federal Court of Australia at 2.15 pm on Monday 5 December 1994 at 450 Little Bourke Street, Melbourne in the State of Victoria in Proceedings No. VG3483 of 1994 for an Order that L.R. Parish & Son Proprietary Limited ("Company") be wound up.

The Applicant's address for service is care of Meerkin & Apel, Solicitors, 46 Caroline Street, South Yarra, 3141 (Ref: GK:AM:932158).

Any contributory, member or creditor of the Company may appear at the hearing in person or by counsel or by a solicitor to support or oppose the making of an Order to wind up the Company.

Any person intending to appear at the directions hearing must file a notice of Appearance in accordance with Form 79 and an affidavit verifying any grounds of opposition to the winding up application in accordance with Form 93A and must serve the notice of appearance and affidavit on the applicant at its address for service shown above, no later than 2 days before the day appointed for hearing.

Produced by the Australian Government Publishing Service
71069 Cat. No. 94 1470 9
ISSN 1032-2345

9 780644 371964

Commonwealth of Australia **Gazette**

No. S 401, Tuesday, 15 November 1994

SPECIAL

Published by the Australian Government Publishing Service, Canberra

MINISTER FOR THE ENVIRONMENT, SPORT AND TERRITORIES

Departmental No. 15

Executive Council Meeting No. 34

..... 19

Minute Paper for the Executive Council

SUBJECT

World Heritage Properties Conservation Act 1983

Proclamations under subsection 6 (3)

Recommended for the approval of His Excellency the Governor-General in Council that, by Proclamations in the attached form, under subsection 6 (3) of the World Heritage Properties Conservation Act 1983, he declare certain property to be property to which section 9 of that Act applies.

Minister for the Environment, Sport and Territories

Approved in Council

Governor-General 15/11/94

Filed in the Records of the Council

Secretary to the Executive Council

71070 Cat. No. 94 1476 X
ISSN 1032-2345

9 780644 363761

Commonwealth of Australia Gazette
No. S 401, 15 November 1994

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 6 (3) of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 9 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), and proceeding in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 25″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 16′ 54″ South and Longitude 146° 03′ 29″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 17′ 48″ South and Longitude 146° 04′ 10″ intersection of Latitude 18° 18′ 12″ South and the Mean Low Water Mark of the coastline of the Australian mainland (approximate Longitude 146° 03′ 48″ East), and then in a generally north-westerly

direction along the line of Mean Low Water Mark to the point of commencement.

L.S.

Signed and sealed with the Great Seal of Australia on

15-11-94

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

Commonwealth of Australia Gazette
No. S 401, 15 November 1994

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 6 (3) of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 9 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), running in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 5″ East then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18°16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 16′ 42″ South and the Mean Low Water Mark of the coastline of the Australian mainland in the vicinity of Oyster

Point, and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on

15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

Commonwealth of Australia Gazette
No. S 401, 15 November 1994

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 6 (3) of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 9 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), running then in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18°16′ 54″South and Longitude 146° 03′ 29″ East, then in a south-westerly direction in a straight line to the

point of intersection of Latitude 18° 17′ 18″South and the Mean Low Water Mark of the coastline of the Australian mainland (approximate Longitude 146° 03′ 06″), and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on 15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 6 (3) of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 9 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 21″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), and proceeding in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 25″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18" East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 16′ 42″ South and the Mean Low Water Mark of the coastline of the Australian mainland in the vicinity of

Oyster Point, and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on

15-11-94

Governor-General

L.S.

By His Excellency's Command,

Minister for the Environment, Sport and Territories

MINISTER FOR THE ENVIRONMENT, SPORT AND TERRITORIES

Departmental No. 16

Executive Council Meeting
No 34

..... 19

Minute Paper for the Executive Council

SUBJECT

World Heritage Properties Conservation Act 1983

Proclamations under section 7

Recommended for the approval of His Excellency the Governor-General in Council that, by Proclamations in the attached form, under section 7 of the World Heritage Properties Conservation Act 1983, he declare certain property to be property to which section 10 of that Act applies.

Minister for the Environment,
Sport and Territories

Approved in Council

Governor-General 15-11-94

Filed in the Records
of the Council

Secretary to the Executive Council

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under section 7 of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 10 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), running in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 25″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 16′ 42″ South and the Mean Low Water Mark of the coastline of the Australian mainland in the vicinity of Oyster

Point, and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on
15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under section 7 of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 10 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), running then in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 54″ South and Longitude 146° 03′ 29″ East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 17′ 18″ South and the Mean Low Water Mark of the coastline of the Australian mainland (approximate Longitude

146° 03′ 06″), and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on 15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under section 7 of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 10 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), and proceeding in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 25″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 05″ South and Longitude 146° 02′ 44″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18° 16′ 18″ South and Longitude 146° 03′ 18″ East, then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 16′ 54″ South and Longitude 146° 03′ 29″ East, then in a south-easterly direction in a straight line to the point of intersection of Latitude 18°17′ 48″ South and Longitude 146° 04′ 10″ East, then in a south-westerly direction in a straight line to the point of

intersection of Latitude 18° 18′ 12″ South and the Mean Low Water Mark of the coastline of the Australian mainland (approximate Longitude 146° 03′ 48″ East), and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on 15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

World Heritage Properties Conservation Act 1983

PROCLAMATION

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under section 7 of the *World Heritage Properties Conservation Act 1983*, being satisfied that the property described in the Schedule is likely to be damaged, declare that property to be property to which section 10 of that Act applies.

SCHEDULE

All that area bounded by a line commencing at the point of intersection of the meridian of Longitude 146° 02′ 02″ East and the Mean Low Water Mark of the coastline of the Australian mainland near the township of Cardwell (approximate Latitude 18° 16′ 20″ South), then running in a north-easterly direction in a straight line to the point of intersection of Latitude 18° 15′ 55″ South and Longitude 146° 02′ 25″ East, then in a north-easterly direction in a straight line to the point of intersection of the parallel of Latitude 18° 14′ 54″ South and the Mean Low Water Mark of the coastline of Hinchinbrook Island in the vicinity of Hecate Point, and then in a generally south-easterly direction along the line of Mean Low Water Mark of the western coastline of Hinchinbrook Island to the point of intersection with the parallel of Latitute 18° 16′ 29″ South (approximate Longitue 146° 05′ 26″), then in a south-westerly direction in a straight line to the point of intersection of Latitude 18° 17′ 48″ South and Longitude 146° 04′ 10″ East, then in a south-

westerly direction in a straight line to the point of intersection of Latitude 18° 18′ 12″ South and the Mean Low Water Mark of the coastline of the Australian mainland (approximate Longitude 146° 03′ 48″ East), and then in a generally north-westerly direction along the line of Mean Low Water Mark to the point of commencement.

Signed and sealed with the Great Seal of Australia on 15-11-94

L.S.

Governor-General

By His Excellency's Command,

Minister for the Environment, Sport and Territories

Produced by the Australian Government Publishing Service

Commonwealth of Australia **Gazette**

No. S 402, Wednesday, 16 November 1994

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

The following Statutory Rules have been made and copies may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City, ACT.

Act under which the Statutory Rules were made	Description of the Statutory Rules	Year and number of the Statutory Rules
Migration Act 1958	Migration Regulations (Amendment)	1994 No. 376
Migration Act 1958 and *Migration Reform Act 1992*	Migration Reform (Transitional Provisions) Regulations (Amendment)	1994 No. 377
Customs Act 1901	Customs (Prohibited Imports) Regulations (Amendment)	1994 No. 378
Customs Act 1901	Customs (Prohibited Exports) Regulations (Amendment)	1994 No. 379
Export Finance and Insurance Corporation Act 1991	Export Finance and Insurance Corporation Regulations (Amendment)	1994 No. 380
States Grants (Primary and Secondary Education Assistance) Act 1992	States Grants (Primary and Secondary Education Assistance) Regulations (Amendment)	1994 No. 381
Air Navigation Act 1920	Air Navigation (Aerodrome Curfew) Regulations (Amendment)	1994 No. 383
Air Navigation Act 1920	Air Navigation Regulations (Amendment)	1994 No. 384
Banks (Shareholdings) Act 1972	Banks (Shareholdings) Regulations (Amendment)	1994 No. 385

Produced by the Australian Government Publishing Service
71071 Cat. No. 94 1474 6
ISSN 1032-2345

9 780644 371940

Commonwealth of Australia Gazette

No. S 403, Thursday, 17 November 1994

Published by the Australian Government Publishing Service, Canberra

SPECIAL

Civil Aviation Authority AUSTRALIA

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE CIVIL AVIATION REGULATIONS

Notice is hereby given that on 16 November 1994 amendments were made to the following Civil Aviation Orders:

Part 20, section 20. 9.

The commencement date for these amendments is 17 November 1994.

Copies of the orders are available for inspection at, and may be purchased over the counter from:

Civil Aviation Authority
(Publications Centre)
607 Swanston Street
CARLTON VICTORIA

Copies of the orders may be purchased by mail from:

Civil Aviation Authority
(Publications Centre)
GPO Box 1986
CARLTON SOUTH VIC 3053

Produced by the Australian Government Publishing Service
71072 Cat. No. 94 1475 8
ISSN 1032-2345

9 780644 372046

Commonwealth of Australia Gazette

No. S 404, Thursday, 17 November 1994

SPECIAL

Published by the Australian Government Publishing Service, Canberra

NOTICE OF APPLICATION UNDER SECTION 195 OF THE CORPORATIONS LAW

(Order 71, subrule 14(15))

IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY

NOTICE OF APPLICATION RELATING TO ADVENT LIMITED

AUSTRALIAN COMPANY NUMBER: 006 509 708

In Proceedings No. VG3518 of 1994 Advent Limited ("the Company") will apply to the Federal Court of Australia at 10.15am on 25 November 1994 at 450 Little Bourke Street, Melbourne, Victoria for an order confirming a resolution of the Company to reduce its issued share capital from $15,701,060 to $7,783,334 and its share premium account by the cancellation of:

1. Paid up capital of $0.25 on each fully paid redeemable preference share ("Fully Paid RPS") and ordinary share ("Existing Ordinary Share") held by a member at 5.00pm on 14 November, 1994 ("the Record Date") in amounts wholly divisible by four, without a cash return;

2. The whole of the paid up capital on each Fully Paid RPS, Existing Ordinary Share and partly paid redeemable preference share ("Partly Paid RPS") held by a member on the Record Date in amounts not wholly divisible by four, and the return of $2.24 for each Fully Paid RPS and Partly Paid RPS and $0.74 for each Existing Ordinary Share so cancelled;

3. Paid up capital of $0.35 on each Partly Paid RPS held by a member on the Record Date, extinguishment of the liability to pay up the upaid capital due on each such share and the release by the Company of the obligation of the member to pay up any further amount of unpaid premium due on those shares; and

4. $8,000,000 of the amount standing to the credit of the Company's Share Premium Account.

Any creditor of the Company who has not consented to the proposed reduction of capital and whose debt or claim has not been discharged or secured in full may appear at the hearing and oppose the application, unless the Company has indicated that it is willing to appropriate the amount of that debt or claim in such a manner as the Court directs.

Any person intending to appear at the hearing of the application must file a notice of appearance in Form 79 together with any affidavit on which he or she intends to rely at the hearing and serve that notice of appearance and affidavit on the Company at its address for service shown below not later than 2 days before the date appointed for the hearing.

The Company's address for service is C/- Gledhill Burridge & Cathro, Level 23, 459 Collins Street, Melbourne, Victoria, 3000.

GLEDHILL BURRIDGE & CATHRO
Solicitors for the Company

Produced by the Australian Government Publishing Service
71073 Cat. No. 94 1482 7
ISSN 1032-2345

9 780644 372145